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Respiratory syncytial virus: burden of disease
Respiratory syncytial virus (RSV) is the single most important cause of viral bronchiolitis in 
infants and young children and the leading cause of infant hospitalization in the world.1 It 
has been estimated that in 2005, 33.8 million children suffered from RSV-associated acute 
lower respiratory infection (ALRI). Out of these, at least 3.4 million children developed severe 
ALRI, requiring hospitalization. In 2005, an estimated 66,000-199,000 children died of RSV-
associated ALRI, 99% of whom in developing countries.2 In the USA, RSV causes 85,000-144,000 
hospitalizations of children per year and accounts for 20-25% of pneumonia cases and up to 
70% of bronchiolitis cases recorded in hospitals.1-4 Nearly all children have been infected with 
RSV by the age of 2 years.5 Infection at young age, however, does not provide life-long protection 
against RSV and reinfections occur later in life. In healthy adults, RSV infection manifests itself 
with common-cold-like symptoms.6 
The elderly and immunocompromised people are also at high risk of developing RSV-associated 
disease.7,8 In the USA, approximately 180,000 people over 64 years of age are hospitalized with 
an RSV infection and RSV is estimated to be responsible for the death of 14,000 elderly in the 
USA per year. Hospitalization due to RSV infections also has a significant economic impact with 
annual costs exceeding $1 billion in the USA alone.7 
The total worldwide burden of RSV disease amounts up to 64 million infections and 160,000 
deaths per year. This, together with the significant economic burden, makes RSV one of the 
most important remaining vaccine targets.9 There is, unfortunately, no such RSV vaccine on the 
market today. 
Biology of RSV
Genes, proteins and function
RSV, together with for instance Measles, Mumps and Sendai virus, belongs to the family 
Paramyxoviridae, which consists of enveloped viruses with a negative-sense, single-stranded 
RNA genome. RSV belongs to the subfamily Pneumovirinae and, together with Para-Influenza 
Virus (PIV), it constitutes the genus Pneumovirus There are two main serotypes of RSV:  RSV A 
and RSV B.10 
The RSV genome is 15,222 base pairs long and codes for 11 viral proteins (Figure 1.1). The genome 
is transcribed from the 3’ end to the 5’ end with only a fraction of the polymerase moving on to 
the next gene, resulting in a gradient of transcription reflecting the required relative abundance 
of the encoded proteins.10 
The non-structural NS1 and NS2 proteins are located at the 3’ end of the genome and are 
therefore the most abundantly transcribed RSV proteins. RSV NS proteins play an important 
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role in immune evasion mechanisms: they inhibit virus-induced type-I interferon responses of 
the host through inhibition of RIG-I, IRF-3 and proteosomal degradation of Stat2.11-13 
The nucleocapsid proteins nucleoprotein (N) and phosphoprotein (P) are encoded downstream 
of the NS proteins and are essential for transcriptional activity.10 The matrix (M) protein is located 
underneath the lipid bilayer of the assembled virus particle and is important in inhibition of the 
polymerase prior to virus assembly.10 The small hydrophobic protein (SH) forms an ion channel 
that spans the viral membrane. Its function in RSV infection or replication is still unknown.10,14 
RSV attachment and fusion glycoproteins G and F are encoded downstream of SH. These RSV 
proteins induce virus-neutralizing antibodies upon infection of the host which makes them 
excellent RSV vaccine targets.10 The F protein shows a relative conserved sequence among 
different strains, while sequences of G exhibit more variation. Differences in G protein sequences 
are also the main determinants of the RSV A/B serotype division.10 The G protein mediates 
binding of the virus to the host cell membrane through binding to cell-surface proteoglycans. 
Despite the role of G protein in attachment of RSV to host cells, it is not absolutely required for 
RSV infection of in vitro cultured cells.15 Virus lacking the G protein grows to high titers in culture 
but is attenuated in its replicative capacity upon infection of cells lining the respiratory tract.16 
Furthermore, a proportion of the G protein that is synthesized upon infection is produced in 
soluble form (sG). This sG has been shown to affect a proper immune response to RSV infection or 
vaccination.17 sG has also been shown to inhibit type-I IFN induction through Toll-Like Receptors 
(TLRs), such as TLR3 and TLR4,18 underlining the role of this protein in immune evasion. 
The F protein is absolutely required for RSV infection: it mediates fusion of the viral membrane 
with the host cell membrane, facilitating deposition of the RSV genome into the host cell.10 
A recent study has suggested nucleolin to function as the cellular receptor for RSV-F.19 F is 
produced as a 67 kDa precursor (F0) which undergoes proteolytic cleavage into F1 and F2. These 
two subunits form the mature pre-fusion F which, in the membrane, forms a homotrimer.20 
During fusion, this homotrimer undergoes a conformational change leading to insertion of 
the fusion peptide in to the membrane, facilitating membrane fusion. RSV F fusion occurs at 
the plasma membrane and is pH-independent.21 The precise trigger for RSV fusion, however, is 
still unknown. When, during infection, F is expressed on the cell surface of infected cells it also 
facilitates cell-cell fusion leading to the formation of syncytia.10
The M2 protein is encoded downstream of F and has two open reading frames resulting in the 
transcription of M2-1 and M2-2.20 M2-1 functions as a transcription elongation factor.22and M2-2 
is involved in virus transcription regulation.23 
The long gene (L) is located at the 5’ end of the genome and is therefore the least abundant RSV 
protein. The L gene codes for the polymerase, which facilitates replication of the viral RNA and 
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is also implicated in capping, methylation and polyadenylation.24
Infection, replication and virus assembly
RSV transmission occurs though contaminated nasal secretions via large respiratory droplets 
by either close contact with an infected individual, or a contaminated surface. Aereosolized 
secretions appear to be less important in RSV transmission.25 Upon entry in the respiratory 
tract, RSV infects the airway epithelium.10 As indicated above, this involves attachment of the 
G protein to cell-surface proteoglycans followed by binding of the F protein to its receptor 
nucleolin, leading to membrane fusion which delivers the viral ribonucleoprotin (RNP) in to the 
target cell cytosol.19,26 Inside the cell, the viral genome is transcribed by the polymerase complex 
(L, N, P, M2-1) and subsequently translated by cellular ribosomes. When viral proteins start 
to accumulate in the cell, the virus switches from transcription to virus genome replication.27 
The viral glycoproteins travel through the Golgi complex to the membrane. The glycoproteins, 
matrix protein and the viral RNP assemble at lipid rafts and new virus particles subsequently 
bud of from the cell membrane.28 Another mechanism of infection is by F-mediated cell-cell 
fusion which effectively delivers viral RNP to neighboring uninfected cells.29 Cell to cell spread 
of RSV in vivo is the most efficient replication mechanism for the virus leading to infection of 
neighboring cells while evading detection by the immune system.30
Attachment (G)
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Figure 1.1. RSV virus particle and genome. Schematic representation of an RSV virus particle (above) and the RSV 
single stranded negative-sense genome (below)
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Pathogenesis of RSV infection
Upon entry of RSV in the respiratory mucosa, the virus replicates in the nasopharyngeal 
epithelium in the upper respiratory tract and will subsequently move to the lower respiratory 
tract after one to three days.25,31,32 In the lower respiratory tract, RSV causes bronchitis, 
bronchiolitis and pneumonia.1 RSV pathology is caused by viral, immunological and host-
genetic factors.1 RSV F-mediated fusion of infected cells with non-infected cells leads to the 
formation of large masses of cells with multiple nuclei, i.e. syncytia.33 These necrotic clumps 
of cells induce mucus secretion in the airways leading to airway obstruction. The formation 
of syncytia is followed by peribronchial infiltration of lymphocytes, neutrophils, eosinophils, 
plasma cells and macrophages contributing to immunologically-mediated pathology.33 
A wide range of single nucleotide polymorphisms (SNP) in host immune response genes have 
been correlated with disease severity.1,34 SNP in genes of the innate immune response such 
as transcriptional regulator Jun, IFN-α, nitric oxide synthase and vitamin D receptor show the 
strongest correlation with disease severity.35,36
In more severe disease, the infection progresses to the lower respiratory tract, leading to 
pneumonia with interstitial infiltration, alveolar filling and eventually, in the worst cases, the 
death of the patient.31 In most cases, however, recovery begins within several days after the start 
of the symptoms and symptoms disappear after 7 to 10 days.25 The airway epithelium is fully 
restored in four to eight weeks after initiation of the infection.31
Immune response to RSV infection
The immune response against RSV infection is a double-edged sword: On the one hand, it is 
required for clearance of the virus; on the other hand, it also contributes to immunopathology, 
as described above. The innate, humoral and cellular arms of the immune response all play a 
vital role in protection against RSV infection.
Innate response
The first line of the host’s defense against an RSV infection is the innate immune response. Innate 
immunity against RSV serves to prevent viral replication and spread of the virus, while, at the 
same time, priming the adaptive immune system for an adequate response. The innate immune 
system contributes to protection with its own antiviral mechanisms, such as the production of 
type-I IFN and activation of NK cells.37,38 The most important role however, of innate immunity 
is to prime the adaptive immune system in such a way that it adapts its responses to effectively 
clear the virus and establish an adequate protection against reinfection.39 
Adaptive immune responses against infections are tailored to protect the host in an efficient 
and pathogen specific manner. Infection with an extracellular parasite for instance, can be 
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eliminated by antibodies while the clearance of intracellular virus infection require cytotoxic 
T-cells.40 The establishment of an immune response in one of these directions is governed by 
CD4+ T-helper cells. These can differentiate from naïve, Th0 cells in to either Th2 cells which give 
rise to an immune response suited for protection against extracellular pathogens or Th1 cells 
will induce an immune response suited for protection against intracellular pathogens such as 
viruses.40.
To establish an effective immune response against RSV, it is important that a Th1-response is 
induced. While some events during RSV infection give rise to such a Th1-type response, RSV 
has evolved mechanisms that skew immunity towards a less effective Th2-type response.41 
A number of viral proteins have direct effects on the host’s cytokine and T cell response, as 
indicated below.
 When RSV binds to host cells, the F protein is recognized by TLR4 expressed on the cell membrane 
which induces the production of IL-1β IL-6, IL-8 and TNF-α.42 Mice deficient in TLR4 showed 
impaired natural killer (NK) cell activity, reduced IL-12 expression and reduced capability to 
clear the virus.43 Polymorphisms in TLR4 have been shown to influence the severity of disease in 
children, indicating that TLR4-mediated detection of RSV also plays a role in protection against 
RSV in humans.44 Besides the induction of the cytokines mentioned above, RSV infections also 
induce secretion of cytokines and collectins such as ICAM-1, IL-8 and RANTES (Regulation upon 
Activation Normal T cell-Expressed and Secreted) that initiate neutrophil, CD4+ and eosinophil 
chemotaxis.45-47 
Replication of RSV leads to the production of double stranded RNA which activates RIG-like 
helicases RIG-I and MDA-5.48 Activation of RIG-I normally leads to activation of the transcription 
factor IRF-3 and, consequently, to production of type-1 IFNs like IFN-β.48 During RSV infection 
however, this pathway is inhibited by the RSV non-structural NS proteins.13 
RSV G and sG proteins also influence the innate immune response as well as adaptive T cell 
responses, stimulating, for example, Th2-skewing of the cellular immune response.41 RSV G 
contains a domain that mimics the CX3C domain of fractalkine (FKN), a chemokine known to 
attract neutrophils and eosinophils. Furthermore, a T cell antigen domain in RSV G (aa181-192) 
induces release of high amounts of the Th2 cytokines IL-4, which inhibits the differentiation 
to Th1 cells.41 It further induces IgE subclass antibodies involved in hypersensitivity reactions. 
Other induced cytokines involve IL-5, an activator of eosinophils, IL-10 and IL-13. The inhibition 
of Th1 cell-produced cytokines such as IFN-γ, mediated by these cytokines diminishes viral 
clearance and correlates with disease severity.49
It is clear that RSV infection induces multiple factors that drive both Th1 and Th2 responses. 
Activation of TLR4 by RSV F and RIG-I by dsRNA produced during replication triggers factors 
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that enhance Th1-type responses suitable for effective inhibition of viral replication On the 
other hand, the NS proteins inhibit RIG-I signaling and sG induces Th2 cytokines that favor 
the formation of IgE and chemo-attraction of neutrophils and eosinophils, thus diverting the 
immune response a phenotype less suited for inhibition of viral replication and to the resolution 
of disease. The balance between these mechanisms determines to a considerable extent the 
severity of RSV-induced illness. 
Cellular response
After establishment of an infection, the cellular branch of the adaptive immune response 
is important to control the infection.49 Patients with impaired T cell immunity showed more 
severe disease and increased virus shedding.50 CD8+ Cytotoxic T lymphocyte (CTL) responses 
are elicited against NS2, N, M, M2, F and SH proteins with responses against F, N and M2 being 
the most prominent.51 CD4+ T-helper cells express a wide range of cytokines, including IL-2 and 
IFN-γ, contributing to the efficacy of the CTL response. Studies in BALB/c mice have shown that 
early expression of IFN-γ is especially important for priming of an adequate CTL response.52 
Humoral response
CTL are instrumental in clearing virus after infection, however, they have limited effect in 
protecting against infection. Antibodies on the other hand are able to provide protection against 
reinfection. Passively acquired maternal RSV-specific antibodies protect newborns against 
infection during the first couple of weeks of life, but levels of these antibodies wane rapidly.53 
High levels of maternally-acquired antibodies correlate with absence of severe bronchiolitis 
upon RSV infection.54 The monoclonal anti-F antibody Paluvizumab is administered to children 
from high-risk-groups such as preterm infants and children with congenital heart disease and 
protects against lower respiratory tract illness.55 After primary infection, transduced and locally 
produced IgA predominantly protects the upper respiratory tract against reinfection.56 In the 
lower respiratory tract, high-affinity virus-neutralizing IgG antibodies have been demonstrated 
to provide protection.56 The G protein-mediated induction of high levels of IL-4 also causes B 
cells to undergo class-switching to produce IgE which has been associated with more severe 
disease and wheezing.57,58 In general, the levels of induced antibodies wane rapidly and quickly 
fall below a protective threshold level. During reinfection, levels of neutralizing antibodies 
rise faster than during primary infection which contributes to a milder course of disease after 
secondary infection.56 An RSV reinfection in adults induces a rise in antibody levels, which within 
2 years recede back to levels that are not sufficient to confer protection.59 For protection of the 
elderly, RSV vaccination should result in long-lasting protective levels of neutralizing antibodies. 
It is unlikely that an immunization strategy induces neutralizing antibodies at levels that last 
longer than those induced after natural infection. This would probably require vaccination to be 
given on a yearly basis.59
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Treatment of RSV infection
As mentioned above, the monoclonal antibody Palivizumab is registered for prophylactic 
administration to children in high-risk groups.60,61 Palivizumab is also sometimes used as a 
treatment to stop progression of upper respiratory tract infection to the lower respiratory 
tract, however the efficacy and cost-effectiveness of this treatment are debatable.62 Apart from 
Palivizumab, aerolized Ribavirin is also registered for treatment of RSV in children. Its efficacy 
in children is controversial in children as not all the randomized controlled trials conducted 
to evaluate this treatment have demonstrated a significant effect.63 The evidence for efficacy 
of Ribavirin to reduce RSV replication in adults is not assessed in clinical trials and merely 
anecdotal.64 Currently, RSV treatment in adults consists of symptomatic relief and includes 
administration of fluids, supplemental oxygen and bronchodilators in the most severe cases.65 
Because of the limited efficacy of treatment available for RSV-infected patients, a vaccine that 
could provide protection against infection would significantly lower the burden of RSV disease. 
Early vaccination strategies against RSV
Formalin-inactivated vaccine
After the success of the killed polio vaccine66 and the recognition that RSV posed a serious threat 
for infants, a formalin-inactivated RSV vaccine was developed and evaluated in children.67 A 
prior small-scale trial had shown increases in immunogenicity without any adverse effects. This 
warranted further study and four clinical trials were conducted, which ran between 1965 and 
1967 in the United States.67-70 Two of these trials were held on military bases, Fort Ord in California 
and Lowry airforce base in Colarado, one in a center for homeless children in Washington DC and 
one in children from the community around Washington DC. The FI-RSV vaccine was developed 
by Pfizer and consisted of a concentrated formalin-inactivated alum-absorbed RSV preparation. 
The Bennett RSV strain was used to generate the vaccine: it was first propagated four times on 
primary human embryonic kidney cells and subsequently ten times on vervet monkey kidney 
cells.68 In 3 trials, children of 6 months of age and older were vaccinated. The trial in children 
from the Washington community also included children below 6 months of age. 
Reports from all four trials indicated that vaccination with FI-RSV did induce serum antibody 
levels, as measured by complement-fixation techniques, with a four-fold increase in antibody 
levels in almost 90% of the vaccinees. The rise in antibody levels was highest in the oldest 
children.69 The outcome of virus neutralization titer determination differed between trials and 
age groups. In the youngest children, only a small increase in virus neutralization titers was 
found,68 while in older groups larger increases in neutralization titers were found. Approximately 
50% of the non-vaccinated children also had high levels of neutralizing antibodies due to 
previous infections. Up to 72% of the vaccinated children above the age of one year showed high 
neutralizing antibody titers.67 The presence of neutralizing antibodies in both the vaccinated and 
in the non-vaccinated group correlated with reduced virus shedding after RSV infection, but not 
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with the onset of pneumonia.67 Strikingly, 69%-80% percent of vaccinated children developed 
pneumonia after infection compared to only 9% of the non-vaccinated children. Hospitalization 
rates were 4-fold higher in vaccinated children compared to those in non-vaccinated children.
In the trial which included the youngest infants, 91% of the children had RSV antibody CF titers 
but only 43% showed an increase in virus-neutralizing titers.68 From the children vaccinated 
with FI-RSV, 65% were reported to having subsequently acquired an RSV infection: 80% of 
these children required hospitalization. Another group included in this study was vaccinated 
against parainfluenza. Of these children, 53% acquired an RSV infection but only 5% of the 
infected children required hospitalization. Of the 18 hospitalized children, 2 died as a result 
of complications following infection. Postmortem analysis of the lungs of these two children 
showed that they suffered from extensive bronchopneumonia. Microscopic analysis of lung 
samples showed the presence of peribronchial monocytic infiltration with some excess in 
eosinophils. At least 104 TCID50 RSV could be recovered from the lungs of the deceased children.
68 
At the time, knowledge about immunological mechanisms that contributed to this phenomenon 
was scarce, although parallels were observed between FI-RSV-mediated enhanced disease and 
a-typical measles cause by a killed measles vaccine formulation.70,71 
Enhanced respiratory disease
Following the disastrous outcome of the four FI-RSV clinical trials, the emphasis in the RSV 
field moved to elucidating the underlying mechanisms responsible for the development of 
enhanced respiratory disease (ERD). The first analysis performed on the clinical trial samples 
showed that, although antibody titers determined by ELISA against the F and G protein were 
high, these antibodies had lower neutralizing capacity compared to those induced by live virus 
infection.72,73 Not only did these antibodies fail to protect from infection, they possibly have also 
contributed to ERD by the formation of immune complexes, which fix chemotactic complement 
factors that attract, for instance, neutrophils.74,75 Later studies in mice showed that the failure 
of the antibodies to neutralize the virus was primarily due to poor affinity maturation, which in 
turn was caused by the lack of adequate TLR signaling by FI-RSV.76
Besides the induction of poorly neutralizing antibodies, studies in mice and cotton rats have 
also shown that FI-RSV skews the adaptive immune response to a Th2-phenotype.77,78 Anti-
IL-4 treatment of mice at the time of FI-RSV vaccination led to decreased clinical symptoms.79 
Furthermore, it was shown that FI-RSV vaccination in cotton rats followed by infection with live 
virus stimulated a wide range of Th2-associated cytokines as well as several Th1-type cytokines. 
Addition of the TLR4 ligand monophosphoryl lipid A (MPLA) during vaccination reduced the 
cytokine expression levels and inhibited lung pathology in cotton rats.78
The exact mechanism by which FI-RSV leads to the induction of ERD after infection is unknown 
and most likely multifactorial. Antigen alteration by formalin,80 the presence of cell culture 
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proteins81 and the use of alum as an adjuvant82,83 all have been shown to contribute to ERD. As 
successful RSV vaccine should therefore induce high levels of RSV-neutralizing antibodies and 
should not skew the immune response excessively a Th2-phenotype.84 
Current RSV vaccine strategies under development
A wide range of approaches including the use of live attenuated RSV, subunit or purified viral 
proteins, chimeric viruses and vector-based vaccines, have been or still are under development 
as candidate RSV vaccination strategies. Several of these have been tested in clinical trials, but 
so far, none of them has met the required safety and efficacy criteria. To illustrate a number 
of the difficulties associated with RSV vaccine development, several of these approaches are 
discussed below.
Live attenuated vaccines
The most extensively evaluated approach to vaccination against RSV is the use of live 
attenuated virus vaccines and this is the only strategy so far that has recently been tested in 
seronegative children, 1-2 months of age. With attenuated RSV vaccines, however, the balance 
between immunogenicity and attenuation appears to be difficult to establish.84 A number of live 
attenuated vaccines have been evaluated in clinical trials from cpRSV in 1968 to ts-1 and ts-2 in 
the early eighties.85 The first live attenuated vaccine to be tested in children was cpts 248/99586 
and cpts 248/404 was the first to be evaluated in 1- to 2-month-old infants. Immunization with 
this vaccine caused high incidence of nasal congestion and was considered to be insufficiently 
attenuated for use in the youngest children.87 To further attenuate the vaccine the SH gene was 
deleted and an additional mutation was introduced (rA2cpts248/404/1030/𝛥SH). This virus did 
not lead to nasal congestion in infants and induced a measurable immune response in 44% 
of the vaccinees. These responses however did not correlate with protection in this study and 
more studies are required to show protective efficacy of this vaccine.88 
During immunization with attenuated vaccines, low levels of virus replication occur leading 
to selection for viruses with a higher replicative potential, possibly reversing the attenuating 
mutations. Virus recovery from the children who received A2cpts248/404/1030/𝛥SH showed 
that 1 of the 5 mutations were lost.88 These revertants however did not show increased virulence 
compared to the vaccine strains. Clinical trials in larger populations will have to demonstrate 
whether the virus retains sufficient numbers of attenuating mutations and will not revert back 
to a pathogenic virus.
Subunit or purified protein vaccines
Purified protein vaccines are relatively straightforward to produce and are efficacious in, for 
instance, HepB and HPV vaccination strategies. A purified RSV F protein (PFP-2 and PFP-3) 
adjuvanted with alum has been evaluated in pregnant women, healthy adults over 60 years 
of age and children with cystic fibrosis (CF).89-91 In the case of pregnant women, the vaccine 
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induced a greater than 4-fold increase in virus-neutralizing antibodies only in 10% of the 
vaccines.90 Antibodies against F in newborns and breast milk from vaccinated mothers, however, 
were significantly increased. In elderly, this vaccine induced a greater than 4-fold increase 
in neutralizing antibodies in 61% of the vaccinees. In children with CF, the vaccine induced a 
greater than 4-fold rise in neutralizing antibodies in 67% of the vaccinees. Group sizes in these 
trials were insufficient to show a significant reduction in RSV infection in the vaccinated groups.92
Another approach using a vaccine consisting of purified F, G and M proteins induced a greater than 
4-fold rise in neutralizing antibodies in 58% percent of vaccinated individuals over 65 years of 
age. A possible explanation for the good immunogenicity of these purified protein preparations 
could be that they form virus like particles. This was previously shown with Newcastle disease 
virus (NDV), another paramyxovirus.93 
A G protein fragment fused to an albumin binding region (BBG2NA) produced in E. coli showed 
promising results in preclinical studies, but induced only moderate increases in virus-neutralizing 
antibodies in healthy adults.94,95 Studies in rhesus macaques demonstrated the inability of this 
vaccine to induce protection against virus infection and also showed undesired induction of 
detectable eosinophils and expression of Th2-cytokine IL-13 in the lungs.96
Furthermore, several other vaccine approaches are currently being evaluated in preclinical 
and early-clinical trials.97,98 To date, no purified protein vaccine has been tested in seronegative 
children. In order for a candidate vaccine to proceed to clinical trials in seronegative children, 
it should first be well established that these vaccines induce a robust neutralizing antibody 
response and skew the T-cell response away from a Th2-phenotype.84 In order to achieve this, 
a non-replicating RSV vaccine could benefit from the use of an immunomodulating adjuvant. 
Chimeric live virus
Other approaches for RSV vaccination include the use of chimeric viruses which have the ability 
to replicate but do not cause disease. These viruses express RSV genes and immune response 
are mounted against RSV gene products upon infection. A chimeric virus consisting of Bovine 
PIV3 expressing RSV F and hPIV F (MEDI-534) is so far the only chimeric vaccine approach tested 
in the clinic. In a preclinical evaluation in African green monkeys, this vaccine induced protection 
against infection with wild-type RSV, even though the levels of neutralizing antibodies induced 
were low.99 In clinical tests, the vaccine proved to be well tolerated and safe. However, the 
capacity of the vaccine to induce neutralizing antibodies was limited in humans as well.100,101 In a 
study in seronegative children between 6 and 24 months of age, the vaccine showed acceptable 
safety and a greater than 4-fold increase in neutralizing antibody levels was demonstrated in 
half of the children.102 A phase 1/2a study evaluating protection against infection is currently 
underway.102 
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Virus replicon particles (VRP) derived from the Alphavirus Venezuelan Equine Encephalitis virus 
(VEE) expressing RSV F (VRP-RSV.F) have been evaluated in mice and cotton rats. These studies 
demonstrated induction of mucosal IgA, which would be beneficial in protection against RSV 
infection.103Furthermore, the VEE replicon vaccine has proven to be immunogenic and to refrain 
from skewing to a Th2-type immune response.103 As yet, this approach has not been tested in a 
clinical setting. 
Vaccine considerations
The number and diversity of vaccine approaches currently being tested in preclinical and clinical 
stages demonstrate the high demand for an RSV vaccine. Unfortunately, all the approaches 
currently being tested have revealed major drawbacks and the ideal RSV vaccine is yet to be found. 
The use of attenuated viruses is difficult because of the delicate balance between attenuation 
and immunogenicity. Both attenuated RSV and live chimeric vaccines require careful storage 
and transportation and have a limited shelf life. This is especially challenging in the developing 
world, where RSV causes the highest mortality rates. Furthermore, purified protein approaches 
have only shown limited immunogenicity in clinical trials and some tendency to skew towards a 
Th2-type response in animal models. This urges for different approaches that more specifically 
address these issues, as discussed below. 
Virosome technology
Another vaccine approach that might prove useful to protect against RSV, involves the use 
of virosomes. Virosomes consist of reconstituted viral envelopes that contain the surface 
glycoproteins of the virus but lack the viral nucleocapsid. The first virosomes were developed in 
1975 on the basis of influenza virus.104 Influenza proteins hemaglutinin (HA) and neuraminidase 
(NA) were purified and inserted into unilamellar liposomes made from phosphatidycholine (PC) 
and phosphatidylethanolamine (PE).104 Subsequently, proteins from HIV, EBV, Senbis virus and 
Rabies virus have been used in a similar approach to generate virosomes.105 
The HA in influenza virosomes mediates receptor-mediated endocytosis similar to that induced 
by live influenza. Because the HA also retained its membrane fusion capacity, virosome 
encapsulated protein antigens have been shown to be delivered into the cytoplasm of antigen 
presenting cells, where proteasomal degradation of antigen occurs and antigen-derived 
peptides can be transported to the ER for loading on MHC class I molecules thus priming for 
CTL induction.106 Influenza virosomes have also been shown to enhance immune responses 
towards “third party” antigens107 leading to the use of influenza virosomes as carriers for other 
viral antigens such a Hepatitis A.108,109 
In addition to using liposomes for insertion of influenza HA and NA proteins, virosomes can 
also be produced by solubilization of the viral membrane by the detergent octaethyleneglycol 
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mono(n-dodecyl)ether (C12E8), nucleocapsid removal and subsequent reconstitution of 
the solubilized viral membrane by addition of detergent-binding beads.110 C12E8-mediated 
solubilization of membranes and removal of the detergent by beads is a laborious process. 
Dialysis would be a preferred method for detergent removal and viral membrane reconstitution. 
However, C12E8 has a low critical micelle concentration (cmc) making dialysis inefficient.
111 
The short-chain phospholipid 1,2-dicaproyl-sn-glycero-3-phosphocholine (DCPC) can also 
solubilize virus membranes without affecting the membrane proteins. Removal of DCPC by 
dialysis is possible because of its relatively high cmc.111 So far, the DCPC approach has been 
used only for production of influenza virosomes. RSV, however, is a similar enveloped virus and 
therefore solubilization and reconstitution of RSV membranes using DCPC could represent a 
viable approach for making a virosomal RSV vaccine. Through removal of the nucleocapsid, RSV 
virosomes lack the viral genome and, thus, are non-replicating virus-like particles. 
1. Purified RSV as starting 
material
2. Add DCPC to solubilize 
the membrane
3. Spin down the nucleocapsid
4. Solubilized membrane 
and membrane proteins
5. Addition of lipophilic adjuvant 6. Removal of DCPC by 
dialysis yields virosomes
Figure 1.2. Virosome production. 
Schematic representation of the pro-
duction of RSV virosomes with TLR 
ligands as adjuvants. Purified RSV is 
solubilized with DCPC. The nucleo-
capsid is removed by ultracentrifuga-
tion. The lipophilic adjuvant is added 
to the supernatant and the DCPC is 
removed by dialyses, reconstituting 
the viral envelopes containing the 
membrane glycoproteins and inseter-
ted TLR ligand
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TLR ligands as vaccine adjuvants
General, TLR ligands in vaccines
A promising approach to modulate the immune response induced by vaccination is the addition 
or inclusion of Toll-Like Receptor (TLR) ligands.112 TLRs are a very conserved component of the 
innate immune system. They belong to the family of pattern-recognition receptors (PRRs) that 
recognize pathogen-associated molecular patterns (PAMPs). Unique components of bacteria 
or viruses are recognized by TLRs expressed on the surface or in endosomes of a wide variety 
of cells.113 TLRs are instrumental in directing the adaptive immune response towards a Th1 or 
Th2-type response.114 Activation of TLRs and their down-stream signaling pathways through 
adapter molecules MyD88 and TRIF induces the production of inflammatory cytokines and 
type-I interferons which in turn directs the differentiation of naïve Th0 cells to Th1 or Th2-type 
CD4+ T-helper cells. 40 
TLR ligands have (unintentionally) been a part of a wide variety of human vaccines starting 
with the rabies virus vaccine introduced in 1886, which contained singl-stranded RNA.115 It took 
until the 1990s for TLR to be recognized as the molecules responsible for the recognition of 
PAMPs from pathogens and in 2005 the first vaccine with an intentionally added TLR ligand was 
approved for use in humans.115 The ability of certain TLR ligands to skew the immune response 
to a Th1-type response and, at the same time, to stimulate processes like antibody production 
make them an excellent potential additional component of an RSV vaccine.76 The production 
process of the reconstituted virosomes allows incorporation of lipophilic adjuvants, for instance 
lipophilic TLR ligands, into the membrane during the reconstitution. The association of the 
antigen (virosomal proteins) with the adjuvant (TLR ligand) fully mimics natural pathogens 
and allows instant activation of antigen-presenting cells, such as dendritic cells that take up 
the antigen. This leads to a more efficient response.116 Furthermore, lipophilic TLR ligands 
benefit from incorporation into lipid membranes as this more closely represents their native 
conformation. Two lipophilic TLR ligands that are of particular interest for inclusion into a 
virosomal RSV vaccine are lipopeptide TLR2 ligand N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-
propyl]-[R]-cysteinyl-[S]-seryl-[S]-(lysyl)3-lysine (Pam3CSK4) and the LPS-derived TLR4 ligand 
monophosphoryl lipid A (MPLA). 
Pam3CSK4
Lipoproteins are found in the membrane of Gram-negative bacteria, Gram-positive bacteria and 
mycoplasma.117 In the 1970s it was observed that lipoproteins stimulate B-cell growth.118 Later 
it was shown that they also activate the transcription factor NFκB and cytokine production.119,120 
Synthetic analogues of the N-terminus of lipopeptide of the E. coli lipoproteins have been 
shown to be as active as the natural lipoprotein.121,122 The synthetic lipopeptide Pam3CSK4 was 
shown to more effectively induce CTL when compared to other adjuvants.123 Similar to a large 
number of known TLR ligands, the notion that Pam3CSK4 signaling occurs through TLR2 was 
only discovered after it was long known that this molecule had beneficial adjuvant effects.124 
PhD thesis_0.1.indd   23 10-10-12   11:23

































The lipophilic properties and immunomodulating properties of Pam3CSK4 make it a suitable 
candidate as an adjuvant for use in a virosomal RSV vaccine, as it could boost the formation of 
(neutralizing) antibodies and modulate T helper type responses.
MPLA
Another lipophilic TLR ligand possibly suited for use in a RSV virosomal vaccine is the 
detoxified LPS derivative MPLA. The first molecule that was recognized as a TLR ligand was 
lipopolysaccharide (LPS), which signals through TLR4.125 Extreme toxicity however, prevented 
LPS to be useful in human vaccines. In the 1980s Edgar Ribi and colleagues modified the LPS 
of Salmonella Minnesota, leading to the discovery of a compound that lacks the toxicity of LPS 
but retained the its immunomodulating activity.126 This led to the development of MPLA as an 
adjuvant component currently used in two licensed human vaccines.127 MPLA has been shown 
to stimulate the immune response against the antigens with which it is co-administered and 
has an acceptable safety profile in humans.127,128 Furthermore MPLA has been shown to suppress 
symptoms of RSV ERD when co-administered with FI-RSV to cotton rats,78,129 suggesting that the 
immunomodulatory function of MPLA is beneficial in RSV vaccination. 
Animal models for RSV vaccine evaluation
In order to elucidate RSV infection mechanism and evaluate candidate vaccines, animal models 
are indispensible. Unfortunately infection with human RSV infection is strictly confined to 
humans and none of the available animal models fully replicate all aspects of human disease.130 
Non-human primates (NHP) have been used for assessment of the level of attenuation of 
live-attenuated vaccines, even though they do not undergo severe RSV infection.131 African 
Green Monkeys are the most RSV-permissive NHP and have also been used as a model of FI-
RSV-induced ERD.132,133 Due to costs and logistical problems associated with NHP as an animal 
model, this species is less suited for use in early stage preclinical vaccine evaluation.134 
RSV was initially discovered as a chimpanzee coryza agent135 and also infects other non-human 
primates such as African green monkeys.136 The economical, ethical and emotional burden of 
working with chimpanzees is extremely high. Furthermore, there are no inbred strains and the 
experimental sample size is typically small.134 Therefore non-human primates are not the most 
suitable animal model when it come to early preclinical vaccine evaluation. 
Bovine RSV is very much related to human RSV and infects cattle. There are several advantages 
to using cattle as an RSV infection model, such as similarities in infection with humans and 
the possibility to perform respiratory function analysis in these animals. However, their size, 
associated costs and the lack of available reagents for immunological studies makes this species 
less suited for preclinical RSV vaccine evaluation.130,134
Rodent models such as the Th2-biased BALB/C mouse137,137,138 and the cotton rat (Sigmodon 
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hispidus)129,139,140 have been used extensively to model RSV disease, ERD, and vaccine 
immunogenicity and efficacy. The major advantages of using mice over cotton rats include the 
availability of knock-out strains and the availability of a large array of reagents for immunological 
assessment.134 Advantages of the cotton rat include the increased permissiveness and the 
more faithful replication of ERD-associated lung pathology after immunization with FI-RSV 
and subsequent infection.141 These two animal models are therefore, highly suitable for use 
in preclinical evaluation of RSV vaccines such as, for instance, an adjuvanted virosomal RSV 
vaccine.
Aim and outline of the study described in this thesis
This thesis describes the development and preclinical evaluation of a novel virosomal RSV 
vaccine supplemented with specific TLR-ligands. In Chapter 2 the feasibility of the production 
of reconstituted RSV membranes using DCPC is investigated. Also, the incorporation of the 
TLR2 ligand Pam3CSK4 in virosomal membranes is studied and the immunogenicity, protective 
efficacy and safety of the virosomal formulation is evaluated in mice and in cotton rats. To 
investigate the potency of a more widely used TLR4 ligand with potentially stronger Th1-
skewing properties, virosomes with incorporated MPLA are tested in Chapter 3. TLR-signaling 
properties of the virosomes are evaluated in vitro together with their ability to induce a 
protective and safe Th1-skewed anti-viral immune response in vivo in mice. Chapter 4 describes 
the immunogenicity, protective capacity and safety of RSV-MPLA virosomes in cotton rats. 
Here emphasis lies on analysis of local cytokine production in RSV-infected lungs of vaccine-
primed animals and analysis of histopathological events in the lung following infection of 
cotton rats. In Chapter 5, the capacity of the RSV-MPLA virosomal vaccine to induce protective 
immune responses are investigated in an approach using mucosal immunization, i.e. intranasal 
immunization, of mice and cotton rats. Chapter 6 describes the capacity of RSV virosomes, with 
or without MPLA adjuvant, to induce protective immunity in an aged immune system. Here, 
aged cotton rats are used as an animal model. Additionally, the capacity of the virosomal RSV 
vaccine to boost pre-existing immunity in the aged cotton rats is explored. Finally, the results 
are summarized and discussed in Chapter 7. This chapter also presents a future perspective on 
the use of an adjuvant supplemented virosomal RSV vaccine. 
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Respiratory syncytial virus (RSV) causes severe respiratory disease in children and the elderly. 
There is no registered RSV vaccine. Early experimental non-replicating vaccines have been 
found to exacerbate RSV symptoms upon infection causing enhanced respiratory disease. 
Here we show that immunization of mice with reconstituted virosomes produced from 
RSV envelopes and containing the lipopeptide adjuvant (Pam3CSK4), induces high-titer 
virus-neutralizing antibodies, and the secretion of IFN-γ through both MHC-I and MHC-II 
presentation of antigen, with a balanced Th1/Th2 profile. Immunization with RSV-Pam3CSK4 
virosomes provides sterilizing immunity to virus challenge in mice and cotton rats, while not 
producing symptoms of enhanced disease. Therefore, these virosomes represent a promising 
candidate inactivated RSV vaccine formulation.
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According to the WHO, respiratory syncytial virus (RSV) causes 64 million infections annually, 
with an estimated mortality of 160,000,142 contributing as much as influenza to death from 
respiratory disease in the elderly,143 and leading to the hospitalization of 18,000-75,000 children 
in the USA alone. However, in contrast to influenza, there is no registered vaccine for RSV. Both 
replicating and non-replicating vaccine formulations are currently being developed. So far, 
attempts to produce vaccines that are based on replicating attenuated or recombinant virus 
have resulted in overattenuation or in vaccines that are not sufficiently tolerated.  Development 
of non-replicating vaccines has been complicated by the disastrous outcome of a clinical trial 
with a formaldehyde-inactivated, alum-adjuvanted virus vaccine (FI-RSV) in the 1960’s. Natural 
RSV infection in children vaccinated with FI-RSV, that were seronegative prior to vaccination, 
resulted in enhanced disease symptoms, and two of the children died.68 Although sera from the 
vaccinees contained antibodies to the viral F and G membrane proteins, these antibodies did 
not neutralize the virus. In mice vaccinated with FI-RSV, it has further been demonstrated that 
enhanced disease was characterized by a response skewed towards Th2 cells,77 associated with 
lung eosinophilia and alveolitis. Recent findings have identified crucial factors in the induction 
of an effective immune response against RSV without priming for enhanced disease. As had 
long been thought, formaldehyde modification of epitopes in the virus contributes to the 
production of non-neutralizing antibodies76 and formaldehyde treatment of vaccines should 
therefore be avoided. However, some non-formaldehyde-treated non-replicating vaccines are 
also able to elicit symptoms of enhanced disease.76,144 More importantly, it was demonstrated 
that a lack of antibody affinity maturation, caused by poor Toll-like receptor (TLR) stimulation 
by FI-RSV, or other types of non-replicating vaccines, results in the production of low-avidity 
antibodies and primes for enhanced disease.76 The addition of a mixture of TLR-adjuvants to 
non-formaldehyde-treated non-replicating vaccines induced virus-neutralizing antibodies and 
prevented enhanced disease.76 These findings are in line with observations suggesting that 
addition of monophosphoryl lipid A, a ligand for TLR-4, to FI-RSV attenuates the symptoms of 
enhanced disease.78 Priming of mice with live virus prior to FI-RSV vaccination, resulting in overt 
TLR stimulation, led to a Th1-skewed immune response and prevented the development of 
enhanced disease.77 These new insights suggest that a non-replicating RSV vaccine that does 
not prime for enhanced disease can be made provided it is properly adjuvanted. 
Physical association between adjuvant and antigen may ensure activation of antigen-presenting 
cells (APCs) with TLR activation of that same cell. Virosomes are non-replicating vaccines 
composed of the reconstituted membrane of enveloped viruses.106 Virosome vaccines currently 
in use, or being developed as vaccines are mostly based on influenza virus106 and are used as 
a vaccine for influenza virus. They may additionally carry antigens from other pathogens.108 
When properly reconstituted, influenza-based virosome vaccines retain the receptor binding 
and membrane fusion activities of influenza virus enabling the virosomes to enter APCs by 
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receptor-mediated endocytosis. Virosome-endosome fusion then follows and the antigen is 
delivered to the cytoplasm of the cell.145 The antigen delivered by virosomes is then degraded 
by cytosolic proteasomes and the products are transported, through TAP, to the ER where they 
form complexes with MHC-I molecules. This leads to class I MHC-restricted Ag presentation 
and a cellular immune response, which includes cytotoxic T cell responses. Since APCs take 
up particles more efficiently than non-particulate antigen, the virosomes augment the immune 
response to the antigen. To further enhance the adjuvant effect of virosomes, TLR-agonists 
can be incorporated in their membrane activating the immune response by cells that take up 
the virosomes.146,147 Influenza virosomes containing the F protein of RSV, and adjuvanted with 
the E. coli heat-labile toxin (HLT), have previously been tested as an experimental RSV vaccine 
formulation. However, the immune response to these virosomes was characterized by > 20:1 
ratio of IgG1 to IgG2a, representing Th2- and Th1-signature isotype antibodies respectively, 
indicating that the immune response was biased toward a Th2-type response and afforded the 
vaccinated animals only a one log protection against a virus challenge.148 
Here we have produced virosomes directly from the RSV envelope using a reconstitution method 
that does not involve detergent but, instead, the short-chain phospholipid 1,2 dihexanoyl-
sn-glycero-3-phosphocholine (DCPC).111 The virosomes were adjuvanted with the synthetic 
lipopeptide adjuvant Pam3CSK4 that is recognized by TLR-2.149 It is demonstrated that these 
virosomes induce a protective immune response to the virus with a balanced Th1/Th2 profile, 
without the immunological correlates of enhanced disease.
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Reconstitution of RSV envelopes and incorporation of lipopeptide
For the preparation of RSV-derived virosomes, we solubilized RSV with the short-chain 
phospholipid DCPC and subsequently reconstituted viral envelopes, using a method developed 
for influenza virus.111 This method, after the solubilization step, involves centrifugation to 
remove the viral nucleocapsid and dialysis of the supernatant to remove the DCPC, resulting 
in the formation of virosomes. Solubilization of BPL-inactivated RSV, strain A2, using 100 mM 
DCPC disrupted the viral membrane. After solubilization and ultracentrifugation the viral 
membrane glycoproteins, F and G, were found in the supernatant and not in the pellet (periodic 
acid-Schiff stained SDS-PAGE gels, not shown). The supernatant contained about 30% of the 
total viral protein. The viral supernatant was mixed with additional dissolved lipids in DCPC. 
Subsequent dialysis of the DCPC from the lipid/supernatant mixture resulted in particles 
migrating as a single peak of protein and lipid at a density of about 1.12 g/ml, indicating that 
virosomes were formed (Figure 2.1A). Adding the lipopeptide Pam3CSK4 to the supernatant 
along with the lipids also resulted in a similar peak of virosomes (Figure 2.1B). Two different 
lipid mixtures were found to support particle formation. First a mixture of phosphatidylcholine 
(PC), egg phosphatidylethanolamine (PE), sphingomyelin (SM) and cholesterol at a molar ratio 
of 2:1:3.5:3.5 (Figure 2.1A), which had previously been found crucial for the proper reconstitution 
of another paramyxovirus, Sendai virus.150 Second a mixture of PC and PE, at a molar ratio of 
2:1 (not shown). The ratio of lipid to protein in the supernatant/lipid mixture could be varied, 
yielding virosomes with different protein/lipid ratios. 
Negative stain electron microscopy of the virosomes showed vesicles of 70-130 nm in diameter, 
with the viral glycoproteins forming a fuzzy white ring of spikes around the vesicles (Figure 2.2A). 
The virosomes were shown to contain the viral membrane proteins F and G and to some extent 
protein M. The viral proteins N and P were not present, indicating the effective removal of viral 
nucleocapsid components (Figure 2.2B). The lipopeptide adjuvant was present within the peak 
Figure 2.1. Equilibrium density sucrose gradient analyses of dialyzed viral supernatant samples. A) With added PC/PE/
SM/Chol, supernatant protein/lipid ratio 1 mg/0.3 µmol.   B) With added PC/PE/SM/Chol and Pam3CSK4 protein/ lipo-
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fraction of the virosomes on the sucrose gradients, and was therefore most likely incorporated 
in the virosomes (Figure 2.2B). 
Immunization of mice with RSV virosomes
Female BALB/c mice were immunized once or twice, at a 2-week interval, by i.m. injections of 
viral protein with 5 µg per injection, using virosomes with or without the Pam3CSK4 adjuvant. 
Blood samples were taken 2 weeks after injection. A single injection with RSV virosomes induced 
a (10 log) titer of 2.8 ± 0.3, whereas a single injection with virosomes containing the adjuvant 
resulted in a significantly higher (p < 0.001) titer of 3.9 ± 0.1 (Figure 2.3A). A second injection 
raised these titers to 3.6 ± 0.3 and 4.7 ± 0.3, respectively (p < 0.001). On Western blots, sera 
from immunized mice recognized viral F and G proteins (not shown). To assess the Th1/Th2 
skewing of the response, the amounts of IgG1 and IgG2a isotypes were determined, IgG2a being 
a hallmark Th1 isotype. After two vaccinations the virosomes without adjuvant induced very 
little IgG2a while vaccination with RSV-Pam3CSK4 virosomes led to a more balanced response 
(Figure 2.3B). Upon subsequent challenge with live RSV virus this pattern did not change (not 
shown).
The virus-neutralizing capacity of these antibodies was then tested ex vivo. High titers of 
neutralizing antibodies could be demonstrated, with the adjuvanted virosomes inducing five-
fold (p < 0.01) higher titers than the virosomes without adjuvant (Figure 2.3C). To test for virus 
neutralization by the vaccinated animals in vivo, mice were vaccinated twice with virosomes 
with or without Pam3CSK4 as above and challenged with live virus. All vaccinated animals 
cleared the virus completely after 4 days (Figure 2.3D). 
Figure 2.2. Electron microscopy and virosomes proteins. A) Electron micrograph of virosomes. Bar is 200 nm . B) 
Silver-stained SDS-PAGE gel of virosomes (lane 1) and virus (lane 2) under non-reducing conditions (protein G does not 
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We subsequently analyzed secretion of IFN-γ and IL-5 by spleen cells isolated from these 
virosome-vaccinated mice challenged with live virus. Spleen cells were stimulated ex vivo with 
inactivated virus, which results mostly in the presentation of viral antigen via MHC-II molecules 
and the secretion of IFN-γ, which is characteristic of a Th1 response, while IL-5 secretion 
is indicative of a Th2 response. In response to the challenge, unvaccinated mice produced 
some IFN-γ 4 days after challenge and secretion was not significantly enhanced as a result of 
vaccination with virosomes without Pam3CSK4. However, virosomes with the adjuvant induced 
3 times more IFN-γ producing cells (p < 0.001; Figure 2.4A). In contrast, the IL-5 secretion that 
was seen after challenge in unvaccinated mice doubled if the mice had been vaccinated with 



















































































Virus neutralization Virus titers in lungs
IgG Isotypes
Figure 2.3. Humoral immune response and protection in mice. A) Mice were vaccinated with virosomes with or with-
out Pam3CSK4, either by a single injection with 5 µg of vaccine (lane 1), or two vaccinations at a two week interval (lane 
2). B) IgG isotypes in serum were determined for mice which were vaccinated twice at a two week interval, two weeks 
after the second vaccination by means of ELISA and quantified using a standard curve (bars represent the mean + SEM, 
** p<0.001 in Mann-Whitney U test, n=6). C) Serum samples were taken two weeks after the last immunization,   Dilutions 
of the samples were mixed with 100 TCID50 of virus, incubated for one hour, after which a TCID50 assay was performed 
using the mixture. Titers are the reciprocal dilutions giving 50% inhibition of infectivity (bars represent mean + SEM). 
D) Mice were challenged two weeks after they received their second vaccination with 2.2 x 106 TCID50 RSV virus. Four 
days after challenge, virus titers were determined in 50 µl of minced lung tissue with TCID50.  (* p<0.01, ** P<0.001 in 
Mann-Whitney U test, n=6)
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2.4B). In conclusion, virosomes with or without adjuvant induce sterilizing immunity in mice 
but the inclusion of the Pam3CSK4 adjuvant leads to a significant increase in virus-specific, 
neutralizing antibody titer, significantly promotes the secretion of IFN-γ from RSV-specific 








































IFN-γ in spleen IL-5 in spleen
Figure 2.4. Cellular immune response. A) ELISPOT IFN-γ secretion from spleen cells stimulated in vitro with inacti-
vated virus. B) IL-5 secretion (ELISA) from spleen cell cultures stimulated in vitro with inactivated virus (Bars represent 
mean + SEM, * p<0.01, ** P<0.001 in Mann-Whitney U test, n=6)
Since enhanced disease correlates with an immune response that is skewed towards Th2, 
our data suggest that the protection against live virus challenge afforded by the adjuvanted 
virosomes might have occurred without induction of responses associated with enhanced 
disease. To exanimate this directly the lungs of mice vaccinated with adjuvanted virosomes 
and subsequently challenged with live virus were examined by histopathological analysis 
of Giemsa stained lung slices, and compared to those of non-vaccinated mice that had been 
challenged. None of the mice showed signs of enhanced disease, such as alveolitis, infiltrates 
rich in eosinophiles, or bronchitis (Figure 2.5). 
Immunization of cotton rats
BALB/c mice are relatively sensitive to RSV, inherently biased to a Th2 response, and the 
role of T-cells in BALB/c pathology induced by RSV has been well characterized.151 Therefore, 
the balanced nature of the immune response and the lack of enhanced disease induced by 
adjuvanted virosomes in mice were encouraging. However, enhanced disease is best studied 
in cotton rats, since in these animals the lung histopathology can be reproduced that was seen 
in children after vaccination with the “lot 100” formaldehyde/alum vaccine and subsequent 
infection with RSV.140 To produce an FI-RSV vaccine similar to the “lot 100” vaccine, a preparation 
of RSV A2 virus was inactivated with formaldehyde and precipitated with aluminum hydroxide, 
according to the protocol for the production of the vaccine as reported by Prince et al.140 Cotton 
rats were then vaccinated twice at an interval of 2 weeks with this FI-RSV vaccine preparation or 
virosomes containing Pam3CSK4. Both vaccine preparations protected the cotton rats against 
an infectious virus challenge 2 weeks after the last vaccination (p < 0.001; Figure 2.6A). This 
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protective effect of the FI-RSV vaccine in cotton rats is clearly different from the situation in 
humans, and has been reported before.152 During the challenge, cotton rats vaccinated with 
virosomes containing the adjuvant gained more weight than the non-vaccinated group, 
indicating the challenge had a bigger burden on the non-vaccinated cotton rats (p < 0.01; Figure 
2.6B). Five days after challenge, the lungs of FI-RSV vaccinated cotton rats showed massive 
peribronchiolar and perivascular infiltrates containing lymphocytes, eosinophiles and mast 
cells or macrophages, and clear signs of alveolitis characterized predominantly by intra- and 
peri-alveolar eosinophiles (Figure 2.7). In contrast, no signs of aveolitis and fewer or no mast 
cells and macrophages were present in the lungs of unvaccinated and virosome-vaccinated 
cotton rats after virus challenge. There were limited cell infiltrates containing predominantly 
lymphocytes. In conclusion, lipopeptide-containing RSV virosomes induce protective immunity 
in mice and cotton rats, without priming for enhanced disease upon a live virus challenge.
Virosomes containing Pam3CSK4 were also prepared from a B-strain of RSV, and the results of 
vaccination and the effect of Pam3CSK4 were similar (results not shown). 
A B
C
Figure 2.5. Low magnification Giemsa stained micrographs of mouse lungs. A): Mice were vaccinated and challenged 
as in Figure 2.3, and the lungs were examined 4 days after challenge. (B): Age-matched non-vaccinated, non-challenged 
mouse.
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A BVirus titers in lungs Cotton rat weight
Figure 2.6. Weights and virus titers after vaccination and challenge of cotton rats. Cotton rats were vaccinated 
twice either with virosomes containing Pam3CSK4 adjuvant, as described in Fig 2.3, or with FI-RSV as described, and 
challenged with 2.2 x 106 TCID50 infectious virus intranasally, three weeks after the last vaccination. A) the cotton rats 
were weighed before and after the challenge. The relative increase in weight was plotted for individual mice. B) Four 
days after the challenge, lungs were removed and TCID50 virus titers determined in 50 µl samples of minced lung tissue 
supernatant. (* p<0.01 in Mann-Whitney U test, n=6)
No Vaccine RSV-Pam3CSK4 Virosomes FI RSV
Figure 2.7. Giemsa stained micrographs of cotton rat lungs. Upper row; low magnification, lower row; higher mag-
nification focusing on the alveoli. Cotton rats were vaccinated twice either with virosomes containing Pam3CSK4 adju-
vant, as described in Fig 2.3, and challenged with 2.2 x 106 TCID50 infectious virus intranasally, three weeks after the last 
vaccination. Notice the peribronchiolar en perivascular infiltrates in the FI-RSV vaccinated animals, the absence of these 
infiltrates in the other animals, and the clear alveolitis in the FI-RSV vaccinated animals.
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Until recently, it would appear that immunization with RSV proteins or peptides inevitably 
primes for enhanced disease upon live virus challenge, whereas infection with RSV, either 
natural or attenuated, or by recombinant viruses expressing RSV proteins, does not lead to 
enhanced disease upon viral (re)infection. Various hypotheses have been advanced to explain 
the phenomenon. Most recently, it was demonstrated that a lack of antibody affinity maturation, 
caused by poor Toll-like receptor (TLR) stimulation by FI-RSV, resulted in the production of 
low-avidity antibodies to protective epitopes, resulting in a lack of protection.76 This is in line 
with previous observations showing that the symptoms of enhanced disease caused by FI-RSV 
could be attenuated by co-injecting a TLR-4 adjuvant with the vaccine.78 These data suggest 
that adjuvanted inactivated vaccines might avoid priming for enhanced disease, provided the 
immune system is stimulated appropriately. 
Here, a vaccine was tested that combines two adjuvanting principles; the presence of multiple 
antigens in one particle, the virosome, consisting of the reconstituted envelope of RSV and in 
addition, the presence within its membrane, of Pam3CSK4, an adjuvant recognized by TLR-
2. Immunization of mice with these virosomes induced high-titer neutralizing antibodies to 
the virus, the secretion of IFN-γ and a balanced Th1/Th2 profile in mice. Immunization with 
adjuvanted RSV virosomes also provides sterilizing immunity to virus challenge in mice and 
cotton rats, without producing symptoms of enhanced disease. Therefore, these virosomes 
represent a promising, inactivated, candidate RSV vaccine. 
Previously, virosomes consisting of reconstituted influenza virus envelopes, containing the 
purified F protein of RSV and reconstituted using the detergent octaethylene-glycol-mono-N-
dodecylether with E. coli HLT added as an adjuvant have been tested as an RSV vaccine. It was 
found that these virosomes offered little protection against a live virus challenge, and induced 
an immune response dominated by IgG1, indicative of a Th2 bias.148 In our present study, 
virosomes consisting of reconstituted RSV membranes, without adjuvant, induced sterilizing 
immunity to RSV challenge, suggesting that the presence of the RSV protein G along with F in 
the virosomal membrane, the reconstitution by means of the short-chain phospholipid DCPC, or 
the absence of influenza proteins in the virosomes improves the outcome. In this respect, it has 
been shown that concomitant vaccination of elderly people with a preparation of the RSV F, G 
and M proteins and trivalent influenza vaccine had no effect on influenza immunity,153 indicating 
that, in humans, RSV proteins do not affect responses to influenza proteins. Conversely, it 
might be deduced that the presence of influenza proteins per se does not affect the response 
to RSV antigens. However, the presence of influenza proteins in the membrane of these hybrid 
virosomes,148 could interfere with the oligomerization of RSV F protein which is required for 
induction of highly neutralizing antibodies,154 possibly explaining the superior activity of our 
virosomes lacking influenza proteins. Also the presence of protein G, in addition to F may have 
played a role despite the fact that protein F contributes more to RSV immunity than protein G.155 
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Finally, the use of a short-chain phospholipid (DCPC) rather than a detergent and the method 
applied to remove the DCPC from may have contributed to the favorable outcome of our 
experiments. Reconstitution of membrane proteins with enzymatic activity using short-chain 
phospholipids, preserved the activity of the proteins better than detergents.156,157 Furthermore, 
the currently used method preserves the fusion activity of the influenza hemagglutinin protein 
after reconstitution very well.111 This data suggests that our method of reconstitution optimally 
preserves protein conformation and, consequently, contributes to optimal induction of 
protective antibodies.  
Comparing the activity of the DCPC-reconstituted virosomes, with or without Pam3CSK4 
adjuvant, it was found that both types of virosomes induced sterilizing immunity to virus 
challenge in mice. However, the adjuvanted virosomes induced significantly higher antibody 
titers, more effective neutralizing antibodies and more IFN-γ production, while not inducing 
the secretion of more IL-5 from MHC-II presented antigen, suggesting that the adjuvant had a 
beneficial effect on the Th1/Th2 ratio. 
Therefore, the inclusion of the adjuvant in the virosomal membrane merits consideration in 
future clinical trials. The choice of adjuvants for any human vaccine remains empirical because 
so far, very few adjuvants have been allowed in vaccines. Aluminum phosphate did not enhance 
the immune response to a preparation of RSV F, G, and M protein in clinical trials.158 The 
lipopeptide Pam3CSK4 is synthetic and has an excellent safety profile in animals. Its inclusion in 
the virosomal membranes means that minimal concentrations can be used. Other hydrophobic 
adjuvants, such as monophosphoryl lipid A, a component of other human vaccines, may 
also be included in the virosomal membrane, and could improve the safety profile and/or 
immunogenicity of virosomal RSV vaccines even further.
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RSV strains A2 (American Type Culture Collection, ATCC) and strain B1 (National Collection 
of Pathogenic Viruses, UK) were grown in roller bottles on Hep-2 cells (ATCC), purified by a 
combination of differential and rate zonal ultracentrifugation on sucrose gradients and stored 
frozen in 17.4% glycerol, 145 mM NaCl, 2.5 mM HEPES, 0.1 mM MgCl2, 0.1 mM CaCl2, pH 7.4 
(adopted from Gupta et al159). After rapid thawing, aliquots of the virus were inactivated with 
0.025% beta-propiolactone (BPL) (Acros Organics, Amsterdam, The Netherlands), for 16 h at 4°C 
with gentle shaking, followed by 2 hr of incubation at 37°C to inactivate the BPL. The virus was 
then pelleted by ultracentrifugation for 20 min at 90000 g, the supernatant removed and the 
pellets were suspended in sterile buffer containing 5 mM Hepes, 145 mM NaCl, 1 mM EDTA, pH 
7.4 (HNE) at 4°C. For reconstitution with DCPC, an equal volume of sterile 200 mM DCPC in HNE 
was added. The sample was mixed by pipetting and incubated for 45 min at 4˚C. To remove the 
viral nucleocapsids the sample was spun in sterile tabletop ultracentrifuge eppendorf tubes at 
90,000 x g for 30 min at 4°C. The supernatant was filtered through a 0.22 µm filter, the volume was 
measured and the protein concentration was determined by the Bio-Rad Bradford protein assay 
(Bio-Rad, Veenendaal, The Netherlands). For the addition of lipids, a lipid mix was prepared 
from stock solutions of egg phosphatidylcholine (PC), egg phosphatidylethanolamine (PE), with 
or without brain sphingomyelin (SM) and cholesterol (Chol) (all lipids from Avanti Polar Lipids, 
Alabaster, AL, USA) in chloroform/methanol 2:1. The molar ratios for PC/PE/SM/Chol and PC/PE 
mixtures were 2/1/3.5/3.5 and 2/1, respectively. The mixture was evaporated to dryness on the 
wall of a glass tube and traces of the solvents were removed at a high vacuum. The lipopeptide 
adjuvant, N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-(lysyl)3-
lysine (Pam3CSK4, EMC Microcollections GmbH, Tübingen, Germany, lyophilized from the HCl 
solution), was dissolved in 100 mM DCPC in HNE, the pH was adjusted to 7.4 with NaOH, and 
the solution filtered through an 0.22 µm filter. To prepare virosomes, the viral DCPC supernatant 
was combined with the thin film of lipids (0.8 µmol per mg protein unless indicated otherwise), 
and the lipopeptide solution was added in the case of the adjuvanted virosomes (1 mg of 
lipopeptide per mg of viral protein). The mixture was incubated for 15 min on ice, then filtered 
through a 0.22 µm filter for sterilization, and DCPC was subsequently removed by dialysis of the 
mixture against 2 L of HNE buffer pH 7.4 in a sterile slide-a-lyzer (10 kD cut-off; Thermo Scientific, 
Etten-Leur, The Netherlands) for 48 h. The buffers were changed 4 times. This resulted in the 
formation of virosomes. 
All virosome preparations were found to be sterile after plating on blood/agar plates and 
incubation for 2 days at 37°C. Virosome formations were analyzed by equilibrium density 
gradient centrifugation on 10-60% sucrose gradient in HNE buffer, spun for 85 hr in a Beckmann 
SW55 Ti rotor at 50,000 rpm, and samples from the gradient were analyzed for protein using 
a Bio-Rad Bradford protein assay (Bio-Rad, Veenendaal, The Netherlands), phospholipid 
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phosphate as described before160 and density (by refractometry). Samples were prepared for 
electron microscopy by application to freshly carbon-coated copper grids, followed by 1% 
uranyl acetate stain, and air-drying.
FI-RSV was generated as described before.140 Briefly, African green monkey kidney cells (ATCC) 
were infected with RSV until CPE was visible in >80% of the cells. The medium was harvested and 
clarified by low-speed centrifugation (1000 x g, 10 min, 4˚C) and filtered through a 5 µm filter. 
The filtrate was formalin inactivated for 3 days with stirring and subsequently ultracentrifuged 
to harvest the inactivated virus. The vaccine was concentrated 25 times and absorbed to 4mg/
ml aluminum hydroxide. The compounded material was concentrated 4 times and taken up in 
medium with 200 units/ml of each neomycin, streptomycin and polymyxin B, and a 1:40,000 
final dilution of benzethonium chloride. This yielded a 100 times concentrated vaccine with 
16mg/ml alum.
Animals
Animal experiments were evaluated and approved by The Institutional Animal Care and Use 
Committee of the University of Groningen according to the guidelines provided by Dutch 
Animal Protection Act. Female specified pathogen-free mice (BALB/c OlaHds, 8-12-week-old) 
were supplied by Harlan, The Netherlands and kept in individually ventilated cages. Female 
cotton rats (COT/NCrL, 8-12-week-old) were supplied by Charles River, Germany, and housed 
conventionally. Intramuscular vaccinations were given on days 0 and 14, under isoflurane 
anesthesia. In challenge experiments, mice and cotton rats were challenged 2 or 3 weeks after 
their second vaccination, respectively. For the virus challenge, virus stocks as described above 
were dialyzed against HNE for 2 h to remove glycerol, animals were anesthetized with 3-4.5% 
isoflurane/O2/N2O, and given 5 x 10 µl of virus (2.2 x 10
6 TCID50) in the nose, at 90s intervals. The 
cotton rats were weighed before and at the end of the challenge to assess disease severity. At 
euthanasia, lungs were inflated with PBS, one-half was tied off and removed for virus titration, 
while the other half was fixed overnight in formaldehyde (4% in PBS), keeping lungs inflated 
under 20-25 cm water column pressure. The material was embedded in paraffin and 1-2 µm 
thick lung slices were processed for Giemsa staining. Groups of 6 mice and 6 cotton rats were 
used unless indicated otherwise.
Immunological assays
For ELISA analysis, serum was harvested, deep frozen, and stored in polypropylene tubes at 
<-10°C. ELISA plates (Greiner Bio-one, 655092) were coated with RSV at 0.5 µg protein/well in 
coating buffer (0.05 M carbonate-bicarbonate pH 9.6-9.8) overnight at 37oC. Plates were washed 
3 times with coating buffer and blocked with a 2.5% solution of Protifar Plus (Nutricia, The 
Netherlands) in coating buffer for 45 min at 37°C, then washed twice with coating buffer and 3 
times with PBS containing 0.05% Tween20 (Merck 8.22184.1000) (PBST). Serial two-fold dilutions 
of serum samples were applied to the plates and incubated for 90 min. Plates were washed 3 
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times with PBST and incubated with a 1:5000 dilution of the appropriate antibody (horseradish-
peroxidase-coupled goat anti-mouse IgG, IgG1 or IgG2a; Southern Biotech 1030-05, 1070-05, 
or 1080-05, respectively) for 60 min at 37°C. Subsequently, the plates were washed 3 times 
with PBST and 3 times with PBS, drained and filled with staining solution, 20 mg o-phenylene-
diamine-dihydrochloride (OPD, Kodak, 1078054), in 50 mM phosphate buffer pH 5.6 with 0.02% 
µl H2O2 for 30 min, after which the reaction was stopped by adding 50 µl 2 M H2SO4 per well. The 
absorption of the solution at 492 nm was determined, and the ELISA titer was defined as the 
reciprocal of the highest dilution that gave an absorption of 0.2 at 495 nm. For quantification of 
the IgG1 and IgG2a levels a calibration curve was used. Calibration curves were made as follows. 
ELISA plates were coated with goat anti-mouse-IgG (heavy and light chains, human absorbed, 
Southern Biotech, 1031-01) 100 ng/well in coating buffer overnight at 37˚C. After washing and 
blocking of ELISA plates as described above, a stock solution of mouse IgG1 isotype control 
(Southern Biotech, 1070-01) and mouse IgG2a isotype control (Southern Biotech, 0103-01) was 
prepared, dilutions were applied to the plates and incubated for 90 min at 37°C, after which the 
plates were stained as described above.  
For ELISPOT assays, ELISA plates were coated with rat anti-mouse IFN-γ (Pharmingen 551216), 
0.25 µg per well in PBS for 1 h at 37°C, washed three times with PBST, and incubated with 
blocking buffer (PBS containing 0.4% BSA). To produce single-cell suspensions, mouse spleens 
were squashed between sterilized microscope slides and filtered through sterile gauze (150 µm 
diameter). Cells were collected by centrifugation at 800 x g for 5 min and washed with IDMD 
medium. Subsequently, erythrocytes were lysed by incubation with hypotonic medium (0.83% 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2) for 5 min on ice. The cells were washed with IMDM, and 
brought to appropriate concentrations. To stimulate the mouse spleen cells, 100 ng/well of BPL-
inactivated RSV was added. Blanc control wells received no inactivated virus. Plates prepared as 
described above were further filled with different concentrations of spleen cells and incubated 
overnight at 37˚C. The medium was then aspirated and the cells were lysed with water. Next, 
wells were washed with PBST, and then 0.0625 µg/well of biotin-coupled rat anti-mouse IFN-γ 
Ab (Pharmingen 554410) was added. Plates were incubated for 1 h at 37°C, washed with PBST 
and incubated with streptavidin-conjugated alkaline phosphatase (Pharmingen 554065). Wells 
were overlaid with agarose-containing substrate solution and kept in the refrigerator until spots 
could be counted. The plates were scored manually and blinded. The blank control values were 
subtracted from the counts. The values were corrected for background spots by subtracting the 
values of naïve spleen cells, which received inactivated virus stimulation only.  
For IL-5 measurements, spleen cells were treated in the same way as for the BPL-inactivated 
virus restimulated ELISPOT described above. IL-5 secreted to the medium by the cells was 
determined using an ELISA kit from R & D Biosystems (kit DY405).
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Virus titration and neutralization in vitro
To determine the infectious titer of virus, TCID50 titers were determined. In brief, 15,000 Hep-
2 cells/well in DMEM containing 2% FCS were seeded in 96-well plates. The next day, wells 
were incubated with serial dilutions of the virus-containing samples, in triplicate. Plates were 
incubated for 6 days at 37ºC in a 5% CO2 atmosphere. After incubation, cells were washed twice 
with PBS, fixed with 1% glutaraldehyde in PBS, stained with Giemsa, and then TCID50 titers were 
determined. To measure neutralizing antibody titers, serum samples were decomplemented at 
56°C for 30 min, serially diluted, mixed with 100 TCID50 of infectious virus, and incubated with 
Hep-2 for 6 days cells as described above.
Statistical analysis
All statistical analyses were performed with Graphad Prism 5.00 for Mac OSX, (GraphPad 
Software, San Diego California USA, www.graphpad.com
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Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young 
children and is also a significant problem in elderly and immuno-compromised adults. 
To date there is no efficacious and safe RSV vaccine, partially because of the outcome of 
a clinical trial in the 1960s with a formalin-inactivated RSV vaccine (FI-RSV). This vaccine 
caused enhanced respiratory disease upon exposure to the live virus, leading to increased 
morbidity and the death of two children. Subsequent analyses of this incident showed 
that FI-RSV induces a Th2-skewed immune response together with poorly neutralizing 
antibodies. As a new approach, we used reconstituted RSV viral envelopes, i.e. virosomes, 
with incorporated monophosphoryl lipid A (MPLA) adjuvant to enhance immunogenicity and 
to skew the immune response towards a Th1-phenotype. 
Incorporation of MPLA stimulated the overall immunogenicity of the virosomes compared to 
non-adjuvanted virosomes in mice. Intramuscular administration of the vaccine led to the 
induction of RSV-specific IgG2a levels similar to those induced by inoculation of the animals 
with live RSV. These antibodies were able to neutralize RSV in vitro. Furthermore, MPLA-
adjuvanted RSV virosomes induced high amounts of IFN-γ and low amounts of IL-5 in both 
spleens and lungs of immunized and subsequently challenged animals, compared to levels 
of these cytokines in animals vaccinated with FI-RSV, indicating a Th1-skewed response. 
Mice vaccinated with RSV-MPLA virosomes were protected from live RSV challenge, clearing 
the inoculated virus without showing signs of lung pathology. Taken together, these data 
demonstrate that RSV-MPLA virosomes represent a safe and efficacious vaccine candidate, 
which warrants further evaluation.
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Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young 
children and is also a significant problem in elderly and immuno-compromised adults. 
According to the WHO, annually 64 million people are infected with RSV, and 160,000 people die 
from the infection around the world.142 It is estimated that, each year, RSV leads to 3.4 million 
hospitalizations of children.2 By the age of two, nearly all children have been infected with 
RSV. However, natural infection does not evoke long-lasting immunity, which causes people 
to undergo multiple RSV infections throughout their lives. In healthy adults, RSV infection will 
manifest itself like a common cold, which is generally cleared within two weeks. When, at old 
age, the immune system weakens, RSV infections become more severe, leading to, for example, 
approximately 10,000 deaths in nursing homes in the US each year.3,161 Current treatment of 
RSV infection in high-risk infants consists of prophylactic administration of the monoclonal 
antibody Palivizumab.55 However, the high costs of monoclonal antibody therapy and the 
limited duration of efficacy of this treatment warrant the development of an RSV vaccine.162,163 
In elderly, treatment is mainly supportive and consists of administration of fluids, oxygen and 
antipyretics.164 Aerosolized Ribavirin is registered for use in some infant groups however, no 
significant effect has been reported in the elderly.164
Even though the need for an RSV vaccine has been recognized for over 60 years, there is 
currently no licensed RSV vaccine available. This is, in part, due to the disastrous outcome 
of a clinical trial in the 1960s, which evaluated a formalin-inactivated, alum-adjuvanted, RSV 
(FI-RSV) vaccine candidate.67-70 In this trial, children who received the vaccine developed RSV-
specific antibodies, but these proved to be poorly virus-neutralizing.72,73 Instead of preventing 
infection, vaccination resulted in enhanced respiratory disease (ERD) upon infection with the 
live virus, leading to a 16-fold increase in hospitalization and even to the death of two children 
in the vaccinated group.165 After this trial, many studies have been performed to elucidate the 
mechanisms causing ERD upon vaccination with FI-RSV and subsequent exposure to live virus. 
Studies in mice, for example, showed that a Th2-like immune response accompanied by influx 
of eosinophils into the lungs plays a major role in ERD.166 Another study in mice has shown that, 
although FI-RSV does elicit RSV-specific antibodies, these have a limited affinity for neutralizing 
epitopes on the RSV fusion protein due to lack of affinity maturation.76 Therefore, a future RSV 
vaccine should induce a Th1-skewed response together with high levels of strongly neutralizing 
antibodies. 
A promising approach towards the development of vaccines that both skew the immune response 
to a Th1-type reaction and induce high-affinity antibodies is to include Toll-Like Receptor (TLR) 
ligands in the vaccine.167 TLRs recognize Pathogen-Associated Molecular Patterns (PAMPs) from 
bacteria and viruses and subsequently signal through adaptor molecules such as MyD88 and 
TRIF to induce the production of inflammatory cytokines and type-I interferons.114 Activation 
of TLR4, for example, leads to production of high amounts of IL12 and IFNɑ resulting in a Th1-
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skewed immune response.40 Importantly, a recent study showed that a UV-inactivated RSV virus, 
which by itself induces poorly neutralizing antibodies, will give rise to high-affinity and strongly 
neutralizing antibodies when supplemented with TLR ligands.76 Using a similar approach, we 
recently showed that the incorporation of the TLR2 ligand P3CSK4 in an experimental virosomal 
RSV vaccine promotes the capacity of the vaccine to induce Th1-type cellular responses together 
with the induction of protective antibodies in mice and cotton rats.168 Thus, the combination of 
an RSV vaccine, such as RSV virosomes, with a TLR ligand improves both the immunogenicity 
and the safety of the vaccine. 
Another promising TLR ligand candidate to be used as an adjuvant in an RSV vaccine is the 
TLR4 ligand monophosphoryl lipid A (MPLA).169 MPLA is a detoxified derivative of bacterial 
lipopolysaccharide (LPS).170 Like LPS, MPLA also signals through TLR4. However, where TLR4 
activation by LPS induces signaling through adaptor molecule MyD88, activation by MPLA leads 
to TRIF-mediated signaling, resulting in enhanced type I IFN production and reduced production 
of inflammatory cytokines compared to MyD88-mediated signaling.76,171,172 MPLA stimulates the 
production of IFNγ by antigen-specific CD4+ T-cells indicating a Th1-skewed response.127,169 
While the TLR2 ligand Pam3CSK4, which we used in our previous study,168 has been associated 
with a balanced Th1/Th2-type immune response, MPLA is thus known to induce a significantly 
Th1-skewed immune response.173 Furthermore, an MPLA derivative with similar immune-
potentiating properties as native MPLA has been evaluated in extensive clinical trials and has 
shown good efficacy combined with an acceptable safety profile for use in humans when co-
administered with a variety of antigens.128 For these reasons, MPLA is the only TLR ligand which 
is currently being used as an adjuvant in a number of licensed vaccines.115,174 Importantly, the 
addition of MPLA to FI-RSV suppressed the expression of RSV ERD associated cytokines in the 
lungs of cotton rats.78 Furthermore, it has been shown that addition of MPLA to FI-RSV promotes 
the immunogenicity of the vaccine and ameliorates lung pathology after challenge.129 Thus, 
the favorable Th1-inducing properties of MPLA, compared to Pam3CSK4, combined with the 
available data on the inhibitory effects of this TLR ligand on the development of RSV ERD and 
its acceptable safety profile in humans, led us to explore MPLA as a possible adjuvant in our RSV 
virosomal vaccine.  
We exploited the lipophilic properties of MPLA to incorporate it in the virosomal membrane 
during the reconstitution process. These virosomes were analyzed for their immunostimulating 
properties and immunogenicity both in vitro and in vivo and for their capacity to induce 
protection against infection with live RSV. Our data show that incorporation of MPLA in RSV 
virosomes increases their immunostimulatory capacity in vitro, as evidenced by increased 
human TLR4-mediated NF-κB activation and upregulation of costimulatory molecules in 
mouse dendritic cells. In vivo, incorporation of MPLA in RSV virosomes stimulated RSV-specific 
IgG antibody levels, with increased IgG2a antibody production and increased levels of virus 
neutralizing antibodies compared to non-adjuvanted RSV virosomes. Also, RSV-MPLA virosomes 
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primed for Th1-type responses as evidenced by high IFN-γ levels and low IL-5 levels, not only 
in ex vivo cultures of splenocytes from immunized mice stimulated with RSV antigen, but also 
in the lungs of immunized mice upon challenge with live RSV. Finally, mice vaccinated with 
RSV-MPLA virosomes were protected from challenge with live RSV without symptoms of ERD, 
as demonstrated by the absence of lung pathology and a lack of eosinophil infiltration into the 
lungs. 
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Characterization of RSV-MPLA virosomes
The formation of virosomes was analyzed by equilibrium density-gradient centrifugation. 
Protein and phosphate were found to co-migrate for RSV virosome preparations with and 
without MPLA, indicating successful reconstitution of the viral envelopes (Figure 3.1A, 3.1B). For 
RSV-MPLA virosomes, the apparent absence of phosphate outside the virosome peak indicated 
that MPLA was primarily associated with the virosomal membranes.
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Figure 3.1. In vitro analysis of RSV and RSV-MPLA virosomes. A,B) RSV virosomes and RSV-MPLA virosomes were spun 
on an equilibrium density sucrose gradient. Subsequently, density, protein concentration, and phosphate concentra-
tions of each fraction was determined. C,D) Fractions from A and B were analyzed for their TLR4-signaling ability using 
Hek-Blue TLR4 cells. To assess non-TLR specific activation of cells, control cells (Null2 cells) were incubated with the 
same virosome fractions. As a control for activation both Hek blue TLR4 and Hek blue null2 cells were stimulated with 
100 ng/ml TNF-ɑ. Bars represent TLR activation relative to that of the TNF- ɑ control. E) Upregulation of DCs costimula-
tory molecules CD40, CD86, CD80. Unfractionated virosome preparations were used to stimulate ex vivo cultured mouse 
DCs overnight. Cells were stained for expression of costimulatory molecules using specific monoclonal antibodies and 
analyzed by FACS. Bars represent the percentage of positive cells. 
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In vitro analysis of RSV-MPLA virosomes
To assess the immune-potentiating capacity of the RSV-MPLA virosomes, fractions from the 
sucrose gradient were tested for their TLR4-activating activity in HEK-Blue TLR4 cells, after 
dialysis to remove the sucrose. The fractions containing the non-adjuvanted virosomes induced 
a TLR4-mediated NF-κB activation which was slightly higher than the activation induced by 
TNF-ɑ (Figure 3.1C). This activation is probably due to TLR signaling of the RSV F protein.42 
Incorporation of MPLA into the virosomes strongly stimulated TLR4 signaling by the virosomes. 
The fraction at the top of the gradient also induced activation of TLR4, indicating that not all the 
added MPLA had been inserted in to the viral envelopes (Figure 3.1D). Since a large proportion 
of the MPLA was associated with the virosomal fraction, as judged by phosphate analysis 
and TLR4-activating capacity of the fractions of the gradient, subsequent experiments were 
performed with non-fractionated virosomes. 
Next, virosomes were tested for their capacity to up-regulate costimulatory molecules in mouse 
DCs. Non-adjuvanted virosomes induced the upregulation of DC maturation markers CD40, CD80 
and CD86. Incorporation of MPLA in to these virosomes significantly stimulated the induction of 
CD40 and CD80 expression compared to the induction by RSV virosomes (Figure 3.1E).
In vivo immunogenicity
To analyze the immunogenicity of the virosomes in vivo, BALB/c mice were vaccinated twice 
with RSV virosomes or RSV-MPLA virosomes at a 2-week interval. For comparison, mice 
were inoculated with live RSV (to induce a Th1-skewed immune response) or vaccinated 
twice with FI-RSV (to induce a Th2-skewed immune response). Two weeks after the first and 
second vaccination, blood was drawn and serum IgG titers were determined. After the priming 
immunization, RSV virosomes induced a mean IgG titer of 2.5 Log GMT. Incorporation of MPLA 
in to the virosomes resulted in significantly increased IgG levels after both priming and booster 
immunizations, not only compared to the levels induced by non-adjuvanted RSV virosomes but 
also to the levels induced by FI-RSV and live virus  (Figure 3.2A). 
Next, RSV-specific IgG1 and IgG2a subtype levels were determined. RSV-MPLA virosomes 
induced significantly higher levels of IgG2a compared to non-adjuvanted virosomes, reaching 
similar levels of RSV-specific IgG2a as seen after live virus inoculation (Figure 3.2B). In parallel 
with the increased RSV-specific IgG2a responses, increases in RSV-specific IgG1 levels were also 
noted. Non-adjuvanted RSV virosomes and FI-RSV mainly induced IgG1, indicative of a Th2-
type response. Live virus inoculations induced low levels of IgG1 and similar levels of IgG2a, 
compared to those induced by RSV-MPLA virosomes (Figure 3.2B).
To further characterize the humoral immune response, we determined IgE levels in sera and 
IgA levels in BAL of immunized mice.  IgE was exclusively induced by immunization with FI-RSV, 
but not by immunization with virosomes or live virus (Figure 3.2C).  IgA in BAL was detectable 
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in mice immunized with FI-RSV (4.6±0.1 Log2 GMT) and live virus (5.6±0.6 Log2 GMT), but not in 
mice immunized with virosomes. For assessment of the functional capacity of the antibodies, 
we performed a microneutralization assay. Non-adjuvanted RSV virosomes induced similar 
neutralizing antibody titers to FI-RSV. Incorporation of MPLA in to the virosomes significantly 



























































































Figure 3.2. RSV specific IgG in mice after vaccination with RSV virosomes and RSV-MPLA virosomes. Mice were 
vaccinated twice with RSV virosomes, RSV-MPLA virosomes or controls (HNE, live virus and FI-RSV). Each injection con-
tained 5 µg of protein. A) RSV-specific IgG titers in serum 14 days after prime and 14 days after booster vaccination. B) 
RSV-specific IgG1 and IgG2a subtype levels in serum 14 days after booster vaccination. C) IgE levels were determined 
at 14 days after booster vaccination. D) RSV neutralizing antibody titers in serum obtained 5 days after challenge. Bars 
represent the GMT (panels A and C), mean concentration of RSV-specific IgG1/2a (panel B) or mean neutralization titer 
(panel D) of 6 mice per group. Error bars represent the SEM. Statistical differences were calculated using the Mann-Whit-
ney-U test. * p<0.05, ** p<0.01, *** p<0.001.  Statistical differences in IgE levels were calculated with an ANOVA with Bon-
ferroni correction for multiple testing *** p<0.001. The data shown are a representative of two individual experiments
To investigate which concentration of MPLA is needed for optimal adjuvant activity, we added 
different amounts of MPLA to the viral protein in solution before reconstitution. Apart from the 1:1 
protein:MPLA ratio, we also produced virosomes with 1:0.2, 1:0.04 and 1:0.008 protein to MPLA 
ratios. Using a similar immunization regimen and antigen dose as before, mice were vaccinated, 
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and RSV-specific serum IgG and subtype responses were determined. The reduction in total 
RSV-specific serum IgG induced by the vaccine was proportional to the decline in the amount of 
MPLA in the virosomes (Figure 3.3A). The IgG2a/IgG1 subtype ratio remained similar when the 
amount of MPLA was reduced from 1 to 0.2 mg/mg protein but decreased when the amount of 
MPLA was reduced further (Figure 3.3B). This decrease was primarily due to a reduction in RSV-
specific IgG2a levels, while the level of RSV-specific IgG1 did not increase significantly with lower 
amounts of virosome-incorporated MPLA (Figure 3.3C, 3.3D). Because there was no significant 
difference between the IgG subtypes induced by 1:1 and 1:0.2 protein to MPLA ratio virosomes 
and there are other benefits to be expected from higher MPLA concentrations (i.e. cellular 
immune response and reduction in lung pathology) we chose  to perform the next experiments 
with 1:1 protein:MPLA virosomes. 



























































RSV specific IgG1 RSV specific IgG2a
IgG isotype ratio
Figure 3.3. Influence of MPLA to virosome protein ratios on RSV specific IgG titers. Mice were vaccinated twice with 
RSV-MPLA virosomes (5 µg of protein) with different amounts of incorporated MPLA. 14 days after the second vaccina-
tion RSV-specific IgG titers in serum were determined. (A) RSV-specific IgG titers. (B) Ratio’s of RSV-specific IgG2a/IgG1 
concentrations determined 14 days after booster vaccination. (C) RSV-specific IgG1 concentrations. (D) RSV specific Ig-
G2a concentrations. Bars represent the GMT (panel A), mean ratio (panel B) or mean concentration of IgG1/2a of 6 mice 
per group. Error bars represent the SEM. Statistical differences were calculated using the Mann-Whitney-U test. * p<0.05, 
** p<0.01, *** p<0.001. The data shown are a representative of two individual experiments.
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To analyze if virosome-incorporated MPLA skews the immune response to a favorable Th1 
phenotype, levels of the hallmark Th1 cytokine IFN-γ and Th2 cytokine IL-5 were determined 
in splenocyte cultures of mice, ex vivo stimulated with RSV.  Supernatants of splenocytes 
cultures from mice immunized with RSV-MPLA virosomes or infected with live virus produced 
significantly increased levels of IFN-γ compared to those from mice immunized with RSV 
virosomes alone or FI-RSV (Figure 3.4A) Restimulated splenocytes from non-vaccinated mice 
produced considerable levels of IFN-γ, which may be explained by activation of innate immunity 
(i.e. NK cell activation) as a result of a high viral load occurring in infected  naïve animals. Levels 
of IL-5 were significantly increased in splenocyte cultures from mice immunized with FI-RSV 












































































Figure 4. IFN-γ and IL-5 concentrations in RSV-stimulated splenocyte cultures and lung tissue homogenates. Mice 
were vaccinated twice with RSV virosomes, RSV-MPLA virosomes and control vaccines as in Figure 3.2, and subsequently 
challenged with live RSV. Four days after challenge, IFN-γ and IL-5 responses were determined. A) IFN-γ concentrations 
in splenocyte cultures restimulated with BPL-inactivated RSV for three days. B) IL-5 concentrations in splenocyte cul-
tures, restimulated with BPL-inactivated RSV for three days. C) IFN-γ concentrations in homogenated lung tissue, four 
days after challenge. D) IL-5 concentrations in homogenated lung tissue, four days after challenge. Bars represent the 
mean cytokine concentration of 6 mice per group and error bars represent the SEM. Statistical differences were calculat-
ed using a Mann-Whitney-U test. * p<0.05, ** p<0.01, *** p<0.001. The data shown are a representative of two individual 
experiments.
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Next, secretion of these cytokines was measured locally, i.e. in lung homogenates, 4 days after 
viral challenge. In line with the above data, mice immunized with RSV-MPLA virosomes showed 
significantly increased IFN-γ levels in their lungs upon live virus challenge when compared to 
levels measured in the lungs of mice immunized with non-adjuvanted virosomes, FI-RSV or live 
virus immunization (Figure 3.4C). Also, IL-5 levels were significantly increased in the lungs of 
FI-RSV immunized mice when compared to the levels measured in the lungs of mice immunized 
with (adjuvanted) RSV virosomes or live virus (Figure 3.4D).
Virus clearance after challenge
To analyze vaccination-induced virus clearance after challenge, mice were immunized twice 
with HNE buffer, FI-RSV, live virus, RSV virosomes or RSV-MPLA virosomes. Two weeks after the 
second vaccination mice were challenged with 106 TCID50 live RSV. Four days later, viral titers 
were determined in the lungs of the animals. In the HNE vaccinated group, virus was recovered 
from the lungs of all mice (Figure 3.5). In three out of the six mice immunized with RSV virosomes, 
virus could not be detected. In the other mice, virus was detected albeit at a significant lower 
level than in non-immunized mice. In contrast, in all mice immunized with RSV-MPLA virosomes, 




















Figure 3.5. Protection against live virus challenge and 
infiltration of eosinophils. Mice were vaccinated as de-
scribed in figure 3.2 and challenged with live virus 14 days 
after the booster vaccination. Four days after challenge, 
lungs were removed and the viral titer was determined and 
expressed as TCID50. RSV TCID50 titers from the lungs of 
challenged animals. Statistical differences were calculated 
using the Mann-Whitney-U test. * p<0.05. The data shown 
are a representative of two individual experiments
Lung pathology
To further investigate ERD in the immunized mice, we examined lung pathology upon challenge 
infection (Figure 3.6). Mice immunized with FI-RSV showed signs of alveolitis and infiltrates in 
both the peribronchial and perivascular areas (Figure 3.6A). The lungs of mice immunized with 
live virus on the other hand showed no signs of pathology (Figure 3.6B). Mice immunized with 
RSV virosomes showed no signs of alveolitis but did have perivascular infiltrates (Figure 3.6C) 
In contrast, the lungs of the mice who received RSV-MPLA virosomes showed no signs of lung 
pathology (Figure 3.6D) and were very similar to the lungs of mice who received live virus or 
those of non-immunized mice (Figure 3.6B,E). In addition to this, we assessed the presence of 
eosinophils in broncho-alveolar lavages (BAL) four days after challenge by May-Grunwald Giemsa 
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staining of cytospotted cells. No eosinophils were detected in BAL of mice vaccinated with RSV 
or RSV-MPLA virosomes. On the other hand, in the mice vaccinated with FI-RSV, eosinophils were 

































Figure 3.6. Lung pathology in mice after immunization and RSV infection. Mice were immunized and challenged as 
described in Figure 3.2 and the lungs were harvested, sliced and stained with H&E and assessed for pathology using light 
microscopy. . Panels represent the lungs of  A) FI-RSV, B) live virus, C) RSV virosomes, D) RSV MPLA virosomes E) buffer 
immunized mice. Black arrows point to alveolar infiltrates, grey arrows to peribronchial infiltrates and white arrows to 
perivascular infiltrates. F) Eosinophils in BAL expressed as percentage of total BAL cells. Data points represent values 
from individual mice. Statistical differences were calculated using the ANOVA test with Bonferroni correction for multi-
ple testing. *** p<0.001. The data shown are a representative of two individual experiments.
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Despite the fact that RSV has been recognized as an important vaccine target for more than 
60 years, no vaccine is registered for use in humans today. Various vaccine candidates have 
been evaluated in clinical trials but so far none of them showed the required safety and 
efficacy profiles. Generally, live attenuated virus vaccines administered intranasally are safe 
and well tolerated but it is difficult to obtain an optimal balance between immunogenicity and 
attenuation.84 Inactivated virus vaccines appear to be hard to advance to the clinic because of 
the safety concerns related to the outcome of the 1960’s FI-RSV trial. Protein subunit vaccines 
are easy to produce but are generally not very immunogenic and possibly skew towards a Th2 
immune response.84 
In this study, we evaluated the immunogenicity and protective capacity of a virosomal RSV 
vaccine adjuvanted with MPLA. Incorporation of the TLR4 ligand MPLA into the virosomal 
membrane resulted in effective human TLR4 stimulation in HEK-Blue cells in vitro and activation 
of mouse DC ex vivo as shown by the upregulation of co-stimulatory molecules. Incorporation 
of MPLA in virosomes resulted in increased RSV-specific serum IgG titers, with production of 
RSV-specific, Th1-signature, IgG2a-isotype antibodies similar to that induced by live virus 
inoculation leading to a balanced IgG1/IgG2a profile. These antibodies proved effective in virus 
neutralization. Furthermore, RSV-MPLA virosomes skewed the cellular responses towards a Th1 
profile, as shown by enhanced IFN-γ secretion, not only in ex vivo RSV-stimulated splenocytes, 
but also locally in the lungs of infected mice. Immunization with RSV-MPLA virosomes did not 
induce any detectable IgE in contrast to immunization with FI-RSV. IgE induction is a hallmark 
of a Th2-skewed allergy-like response, which is implicated in RSV infections and in FI-RSV 
induced enhanced disease.41,175,176 MPLA-adjuvanted virosomes, similar to FI-RSV, provided full 
protection against live RSV infection, but in contrast to FI-RSV, did not lead to signs of ERD, 
i.e. influx of eosinophils in the lungs or induction of lung pathology. Importantly, previous 
studies in cotton rats showed that addition of MPLA to FI-RSV reduces the induction of ERD by 
FI-RSV immunization, illustrated by a reduction in lung pathology, an increase in serum virus 
neutralization titers and a shift from a Th2 -skewed immune response to a balanced immune 
response.78,129 Our observations on the immune response induced by MPLA-adjuvanted RSV 
virosomes in mice are in line with these data and underline that MPLA-adjuvanted RSV virosomes 
hold promise as a candidate RSV vaccine. Currently, RSV-MPLA virosomes are being evaluated in 
cotton rats to optimally assess other ERD parameters, such as alveolitis, in more detail. 
Our data show that non-adjuvanted RSV virosomes stimulate human TLR4 in HEK-Blue cells and 
upregulate co-stimulatory molecules in mouse DC and that incorporated MPLA further enhances 
these effects. TLR4 activation by RSV virosomes without MPLA is likely to be caused by the RSV 
F protein. RSV F is a known TLR4 agonist that, for example, induces inflammatory cytokines like 
IL-6 in DC.42 Interestingly, despite this capacity to stimulate TLR4, RSV virosomes fail to induce 
Th1-type responses while MPLA, also a TLR4 agonist, effectively stimulates Th1-type responses. 
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This could be due to differences in the magnitude of stimulation, which is clearly higher for 
MPLA (Figure 1), but could also be caused by recruitment of different adaptor molecules 
downstream of TLR4 activation. As TLR4 uses both MyD88 and TRIF adaptor molecules, it is 
possible that MPLA competes with RSV F for TLR4 activation. This competition shifts signaling 
from RSV F-induced, MyD88-dependent, TLR4 signaling to MPLA-induced, TRIF-dependent, 
TLR4 signaling, leading to a Th1-skewed immune response induced by RSV-MPLA virosomes 
compared to non-adjuvanted RSV virosomes. 
Apart from its influence on T helper cell differentiation, TLR signaling also has a direct effect 
on IgG isotype switching.177 Antibody isotype switching is important, because different 
immunoglobulin subclasses display differences in their ability to mediate effector responses.178 
In mice, the most effective IgG isotype protecting against viral infections is IgG2a.179 As stated 
before, MPLA signals through TLR4 to induce type-I IFNs which stimulate IgG2a production 
predominantly from follicular B cells.177 Furthermore, MPLA could also directly activate TLR4 
on B cells to facilitate isotype switching, a process that is further augmented by IFNɑ and T-cell 
help.180 Previously, we incorporated TLR2 ligand Pam3CSK4 in RSV virosomes. Pam3CSK4 
inclusion also skewed towards a Th1 immune response and increased IgG2a levels compared to 
non-adjuvanted virosomes. Pam3CSK4 adjuvanted RSV virosomes did however, induce slightly 
higher IgG1 than IgG2a levels. Incorporation of MPLA in the virosomes induces similar IgG1 
and IgG2a levels. The relative increase of IgG2a levels compared to Pam3CSK4-RSV virosomes 
could be due to increased type-I IFN production induced by MPLA. Since incorporation of MPLA 
in virosomes increases IgG2a levels compared to non-adjuvanted RSV virosomes or FI-RSV, 
antibodies induced by RSV-MPLA virosomes may well be more effective in protection against 
viral infection than antibodies induced by the non-adjuvanted RSV virosomes or FI-RSV.
Production of virosomes does not include the application of cross-linking chemicals for 
inactivation of the virus. This could well be a major advantage of the use of virosomes compared 
to other approaches using whole inactivated virus. In this respect, it is important to note that one 
of the reasons why FI-RSV failed to elicit virus-neutralizing antibodies is that important epitopes 
on the virus are disrupted by formalin.80 One of the most important RSV epitopes for neutralizing 
antibodies is a specific conformational epitope making it very susceptible for alteration by 
chemical treatments, including inactivation with formalin.181 During virosome production, 
inactivation occurs through disruption of the membrane by the short-chain phospholipid 
DCPC followed by removal of the nucleocapsid. This is then followed by reconstitution of RSV 
F and G protein in the viral membrane with retention of their native conformation. Following 
this procedure, RSV virosomes lack viral RNA and thus are fully replication-incompetent.168 
Preliminary data indicate that RSV virosomes expose all of the most important known protective 
on the RSV F protein, as demonstrated by efficient binding of monoclonal antibodies directed to 
these epitopes (unpublished results).
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In conclusion, our data show the feasibility of producing RSV virosomes that have incorporated 
MPLA. MPLA improves the immunogenicity of RSV virosomes and skews immune response to 
a protective, balanced Th1/Th2-type response without priming for adverse immune reactions, 
such as eosinophil influx into the lung after infection with RSV. These data combined with the 
favorable safety profile of MPLA, and the fact that MPLA is already licensed for use in human 
vaccines, make the RSV-MPLA virosomal vaccine a suitable candidate for further evaluation in 
clinical trials.
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Animal experiments were evaluated and approved by the Committee for Animal Experimentation 
(DEC) of the University Medical Center Groningen, according to the guidelines provided by the 
Dutch Animal Protection Act (permit number DEC 5239A). Immunizations and challenges were 
conducted under isofluorane anesthesia, and every effort was made to minimize suffering.
Virus and cell culture
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV (Leiden, The Netherlands). The 
virus was grown in roller bottles on HEp-2 cells (ATCC, CL-23, Wesel, Germany) in HEp-2 medium: 
DMEM (Invitrogen, Breda, The Netherlands) supplemented with Pen/Strep, L-Glutamine, Sodium 
bicarbonate, HEPES, Sodium Pyruvate, 1X non-essential Amino Acids (all from Invitrogen) 
and 10% FBS (Lonza-Biowhittaker, Basel, Switzerland) unless stated otherwise. At 80% CPE 
(5 days post-infection) the medium was cleared by low-speed centrifugation. Aliquots of the 
supernatant were snap-frozen in liquid nitrogen, as a source of live virus for immunization and 
challenge. The remainder of the virus was pelleted by ultracentrifugation and subsequently 
purified on a sucrose gradient. Purified virus was snap-frozen in liquid nitrogen and stored at 
-80 °C in 20% sucrose in HNE buffer (5 mM Hepes, 145 mM NaCl, 1 mM EDTA, pH 7.4). 
Mouse dendritic cells (DCs) were derived from bone-marrow cultures, as described before.182 
Briefly, both tibia and femurs were flushed with Iscove’s modified DMEM (IMDM; Invitrogen,) 
supplemented with 10% FBS, pen/strep, 0.1% 𝛽-mercaptoethanol (Invitrogen). Red blood cells 
were lysed by incubating the cells with ACK buffer (0.83 % NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 
7.2) for 5 min on ice. The cells were washed with IMDM medium and incubated in IMDM medium 
supplemented with 200 ng/ml Fms-like tyrosine kinase 3 ligand (Flt3L)(R&D systems, Abingdon, 
UK). Medium was replaced after 4 days and dendritic cells were harvested 8 days after initiation 
of the culture.
HEK-Blue TLR4 and HEK-Blue Null2 cells were purchased from Invivogen (Toulouse, France) and 
maintained according to the manufacturer’s protocol. 
Vaccine production
RSV virosomes were generated as described previously.168 Briefly, purified RSV was pelleted by 
ultracentrifugation and dissolved in 100mM 1,2 dihexanoyl-sn-glycero-3-phosphocholine (DCPC) 
in HNE buffer. The nucleocapsid was removed by ultracentrifugation. Subsequently, a 2:1 molar 
mixture of egg phosphatidylcholine (PC) and egg phosphatidylethanolamine (PE) (Avanti Polar 
Lipids, Alabaster, AL, USA) in 2:1 chloroform/methanol at 850 nmol/mg protein was evaporated 
to a dry film in a glass tube. The supernatant containing the membrane lipids and proteins was 
added to the lipid mixture. For incorporation of MPLA, monophosphoryl lipid A from Salmonella 
minnesota Re 595 (Invivogen) was first dissolved in 100 mM DCPC in HNE buffer and then added 
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to the protein/lipid mixture at 1 mg MPLA/ mg virosomal protein. For the MPLA concentration 
experiment, MPLA was added in lower ratios i.e. 1:0.2, 1:0.04, 1:0.008 (mg virosomal protein to 
mg MPLA). The mixture was incubated for 15 min at 4°C, filtered through a 0.22µm filter and 
dialyzed in a sterile Slide-A-lyzer (10 kD cut-off; Thermo Scientific, Geel, Belgium) against 4 x 2 
liters of HNE pH 7.4 for 48 hours. After dialysis, virosomes were kept at 4˚C.
FI-RSV vaccine was produced according to the original protocol, which was used for the 1960’s 
FI-RSV preparation as reported in.183 FI-RSV was diluted in HNE buffer to contain 5 µg of RSV 
protein in 25 µl of vaccine.
In vitro analyses
The virosomes were analyzed by equilibrium density gradient centrifugation on 10-60% 
sucrose gradients in HNE. Gradients were spun for 60 hr in an SW 55 Ti rotor at 50000 rpm and 
samples from the gradient were analyzed for protein, phospholipid phosphate and density (by 
refractometry). Each fraction was dialyzed against HNE in a Slide-A-Lyzer MINI Dialysis Device 
(Thermo Scientific, Geel, Belgium) overnight to remove the sucrose which is toxic for HEK-
Blue cells at high concentrations. The samples were corrected for increases in volume due to 
the dialysis and 20µl volumes of the samples were used to stimulate HEK-Blue TLR4 cells (105 
cells/well) and HEK blue Null2 cells (5x104 cells per well) overnight at 37˚C in a 96 well plate 
in triplicate. To quantify alkaline phosphatase production, 20 µl of HEK-Blue cell supernatant 
was added to 180 µl Quanti-Blue (Invivogen, Toulouse, France) and incubated for 30 minutes 
at 37˚C. Absorbance was measured at 630 nm and plotted relative to the activation induced by 
100 ng/ml of TNFɑ.
Upregulation of surface markers was assessed after incubating DCs with different virosome 
preparations. DCs were incubated at 1 × 106 cells/ml at 37 °C in IMDM medium. The incubation 
was stopped after 24 hr by washing the cells twice in medium. Expression of surface markers 
was determined by staining with anti-mouse CD80-PE (12-0801-82, eBioscience, Vienna, 
Austria) anti-mouse CD86- PE (12-0862-82, eBioscience) and anti-mouse CD40-FITC (11-0402-
82, eBioscience) using standard staining protocols, followed by flow-cytometric analysis on a 
FACSCalibur flow cytometer (BD Bio- sciences, Erembodegem, Belgium).
Animal experiments
Female specified-pathogen-free BALB/c OlaHsd mice (6-8 weeks old)(Harlan, Zeist, The 
Netherlands) were used for all immunization experiments. For immunization and challenge, 
mice were anesthetized using 3-4.5% isoflurane in O2. Mice received RSV virosomes, RSV-MPLA 
virosomes or FI-RSV intramuscularly in 25 µl HNE. Each preparation contained 5 µg of protein. 
Control mice received 50 µl (1*106 TCID50) of live RSV, intranasally or 25 µl of HNE intramuscularly. 
Vaccinations were given on day 0 and day 14. On day 28 mice were challenged with 106 TCID50 
(titrated as described below) of live RSV intranasally. On time points of vaccination and challenge, 
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blood was drawn by retro-orbital puncture. Four days after challenge, mice were sacrificed and 
blood was drawn by heart puncture. Spleens were harvested for analysis of RSV-specific T cell 
cytokine responses and lungs for analysis of pathology, determination of lung cytokines and 
viral titers, respectively.
Virus titration
Virus titers were determined by titration of the tissue-culture infectious dose (TCID50). For 
challenge virus, initial dilutions of 1:5000 were made in HEp-2 medium without FBS. Serial 
twofold dilutions of these samples were made in 96-well plates in quadruplicate. 20,000 HEp-2 
cells were added to the virus dilutions and incubated for 5 days at 37°C in 5% CO2. The cells were 
then fixed with 1% paraformaldehyde in PBS for 45 min, blocked with 2% milk powder (Protifar 
plus, Nutricia, Zoetermeer, The Netherlands) in PBS for 1 hr and stained with 50µl 1:400 FITC-
labeled goat anti-RSV antibody (Meridian life science Inc, Saco, ME, USA) at 37°C overnight. The 
next day, plates were washed with PBS and analyzed under a fluorescence microscope. Wells 
were considered positive for infection if one or more fluorescent syncytium was present. Titers 
were calculated using the Reed & Muench method.
To determine virus titers in the lungs of challenged mice, the lungs were removed aseptically 
after euthanasia of the mice. Lungs were then homogenized in 1 ml of 2% FBS containing HEp-
2 medium using an automated Potter homogenizer Polytron-Aggregate® (Thomas Scientific, 
Swedesboro, NJ, USA). Next, homogenates were centrifuged at 1400 rpm for 10 min at 4°C, and 
supernatants, diluted to a 1:5 starting dilution, were used to determine viral titers using the 
TCID50 method as described above. 
In vitro neutralization assay
Volumes of 100 µl of serum were heat-inactivated for 30 min at 56°C and subsequently diluted 
with 150 µl serum-free HEp2 medium. Wells of 96-well plates were filled with 50 µl of serum free 
HEp2 medium. Fifty µl of diluted serum was applied to the first row of wells in quadruplicate 
and serial two-fold dilutions were made. Subsequently, 70 TCID50 of live RSV was added in 50 µl 
of serum free HEp2 medium and incubated at 37°C for 2 hr. After incubation, 20,000 HEp2 cells 
were added per well in 100µl of HEp2 medium with 4% FBS. After 5 days of incubation, the cells 
were washed, fixed and stained as described above for the virus titration. Neutralization titer 
was calculated with the Reed & Muench method and is indicated as the reciprocal of the dilution 
that neutralizes infection in 50% of the wells.
Immunological assays
RSV-specific antibody titers were determined as described before.168 Briefly, 96-well plates were 
coated with betapropiolactone-inactivated RSV and then blocked with 2.5% milk powder in 
coating buffer. Plates were then incubated for 90 min with two-fold serial dilutions of serum 
or broncho-alveolar lavages (BAL; see below), starting at 1:200 for serum or 1:1 for BAL. After 
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washing, plates were incubated with a 1:5000 dilution of horseradish-peroxidase-coupled goat 
anti-mouse IgG, IgG1, IgG2a, IgA, or rat anti-mouse IgE (Southern Biotech 1030-05, 1070-05, 1080-
05, 1040-05, 1130-05) for 1 hr, washed again and subsequently stained with o-Phenylenediamine 
(OPD; Sigma-Aldrich, St Louis, MO, USA). After 30 min the staining was stopped by addition of 
2 M H2SO4 and absorption was measured at 492 nm. For levels of total IgG, geometric mean 
titers (GMT) were determined. For quantification of IgG1 and IgG2a levels, a calibration curve 
was used. For this, ELISA plates were coated with goat anti-mouse-IgG (heavy and light chain, 
human absorbed; Southern Biotech, 1031-01) at 100 ng/well in coating buffer overnight at 37°C. 
After blocking with 2.5% milk powder, known concentrations of a mouse IgG1 isotype control 
(Southern Biotech, 1070-01) and mouse IgG2a isotype control (Southern Biotech, 0103-01) were 
prepared, and applied to the plates. After a 90-min incubation at 37oC, plates were washed and 
stained as described above.
For analysis of levels of IL-5 and IFN-γ in splenocyte cultures and lung homogenates (see below), 
mouse IFN-γ and mouse IL-5 high sensitivity ELISA kits (eBioscience) were used according to the 
manufacturer’s instruction. 
For the analysis of IFN-γ and IL-5 secretion in the RSV-specific recall responses of splenocytes, 
spleens were removed four days after challenge and transferred to a 15 ml tube containing 
IMDM/10% FCS. The spleens were passed through a 70-µm cell strainer (BD Biosciences, 
Heidelberg, Germany) using sterile 3-mL syringe plungers. Erythrocytes were then lysed by 
incubating with ACK buffer for 5 min on ice. The cells were washed with medium, counted and 
seeded at 2×106 cells/ml and stimulated with BPL-RSV (10 µg/mL) in IMDM/10% FCS in triplicates 
and incubated at 37oC in a 5% CO2 atmosphere for 72 hr. Supernatants were harvested and 
stored at -20oC until further analysis.
For analysis of IL-5 and IFNγ levels in RSV-infected lungs, lungs were removed from challenged 
mice and homogenized using the method as described for virus titration (see above). IL-5 and 
IFN-γ levels were then determined in supernatants of centrifuged lung homogenates.
Lung histopathology
The harvested lung lobes were inflated with 4% formalin in PBS and subsequently embedded in 
paraffin. Four µm slices were then prepared, and stained with standard hematoxylin and eosin. 
After staining, lung inflammatory parameters (peribronchiolitis, perivaculitis  and alveolitis) 
were assessed by light microscopic analysis of slides.
 Broncho-alveolar lavage cytospins
BAL were taken by rinsing the lungs of the mice with 1 ml of PBS supplemented with protease 
inhibitors using a winged shielded i.v. catheter (1.3x30mm, BD Utah) inserted, through an 
incision, in the trachea of euthanized mice. Cells in the BAL were pelleted by low-speed 
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centrifugation and resuspended in 500 μl PBS. In some cases, the remaining BAL supernatants 
were used for IgA antibody assessment in ELISA. Subsequently, cells were spotted (300 rpm 
for 5 min) onto glass slides, air dried, and fixed in 80% methanol/20% PBS (V/V) for 10 min at 
-20°C. After air-drying, slides were stained for 20 min in May-Grunwald-Giemsa stain (Merck, 
Darmstadt, Germany), diluted 1:1 in Sørensen’s phosphate buffer (0.2 M; pH 6.6). Then, slides 
were rinsed in Sørensen’s phosphate buffer, and incubated for 15 min in Giemsa stain (Merck, 
Darmstadt, Germany) diluted 1:8 in Sørensen’s phosphate buffer. After washing with tap water, 
slides were air-dried and spots were sealed using cover slides and Kaiser’s glycerol (Merck, 
Darmstadt, Germany). The presence of eosinophils in cytospot BAL cells was analyzed by light 
microscopy.
Statistical analysis
All statistical analyses were performed with Graphad Prism 5.00 for Mac OSX, (GraphPad 
Software, San Diego California USA, (www.graphpad.com). Statistical significance was assessed 
using a Mann-Whitney U test. A P value of 0.05 or lower was considered to represent a significant 
difference. 
PhD thesis_0.1.indd   64 10-10-12   11:23










PhD thesis_0.1.indd   65 10-10-12   11:23
PhD thesis_0.1.indd   66 10-10-12   11:23
Chapter
A virosomal Respiratory Syncytial Virus vaccine adjuvanted with 
MPLA provides protection against viral challenge without priming 
for enhanced disease in cotton rats
Tobias Kamphuis1, Toon Stegmann1,2 , Tjarko Meijerhof1, Jan Wilschut1, Aalzen 
de Haan1
1) Department of Medical Microbiology, Molecular Virology Section, University Medical Center 
Groningen, University of Groningen, Groningen, The Netherlands
2) Mymetics BV Leiden, The Netherlands
Submitted to Influenza and Other Respiratory Viruses
PhD thesis_0.1.indd   67 10-10-12   11:23



































Non-replicating Respiratory Syncytial Virus (RSV) vaccine candidates could potentially prime 
for enhanced respiratory disease (ERD), a Th2-mediated immune pathology, following RSV 
infection. Vaccines with built-in immune response modifiers, such as Toll-like receptor (TLR) 
ligands, may avoid such aberrant imprinting of the immune system.
Methods 
We developed reconstituted RSV envelopes (virosomes) with incorporated TLR4 ligand, 
monophosphoryl lipid A  (RSV-MPLA virosomes). Immune responses and lung pathology 
after vaccination and challenge were investigated in ERD- prone cotton rats, and compared 
to responses induced by live virus and formaldehyde-inactivated vaccine (FI-RSV), a known 
cause of ERD upon RSV challenge.
Results
Vaccination with RSV-MPLA virosomes induced higher levels of virus-neutralizing antibodies 
than FI-RSV or live virus infection and provided protection against infection. FI-RSV, but 
not RSV-MPLA virosomes, primed for increases in expression of Th2 cytokines IL-4, IL-5, IL-
13 and Th1 cytokine IL-1b, 6 h to 5 days after infection. By contrast, RSV-MPLA virosomes 
induced IFN-γ transcripts to similar levels as induced by live virus. Animals vaccinated with 
FI-RSV, but not RSV-MPLA virosomes showed alveolitis, with prominent neutrophil influx and 
peribronchiolar and perivascular infiltrates.
Conclusion
These results show that RSV-MPLA virosomes represent a safe and immunogenic vaccine 
candidate that warrants evaluation in a clinical setting.
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Respiratory Syncytial Virus (RSV) has been recognized as an important vaccine target for over 60 
years; however, there is no vaccine on the market today. A clinical trial conducted in the 1960s 
evaluated a formalin-inactivated, alum-absorbed RSV preparation (FI-RSV) as a possible vaccine 
candidate.70 Infants vaccinated with FI-RSV who subsequently acquired a natural infection, 
developed enhanced respiratory disease (ERD), especially in the youngest group of vaccinees 
who were naïve to RSV prior to vaccination, which led to the death of two of these children.67,68 In 
those two infants, severe bronchiolitis and alveolitis were observed with an influx of neutrophils 
and mononuclear cells into the lungs.68 Although the vaccine significantly increased RSV-specific 
antibody titers in 95% to 100% of vaccinees, the induced antibodies failed to neutralize the virus 
in half of the patients.72,73 Studies in mice demonstrated that impaired Toll-Like Receptor (TLR) 
signaling by the vaccine results in low antibody affinity maturation and, consequently, in the 
formation of poorly virus-neutralizing antibodies.76 Furthermore, it has been shown that FI-RSV 
induces a predominantly Th2-skewed immune response.77,166 Therefore, the objective in the 
development of non-replicating RSV vaccines is to generate a formulation that induces high 
titers of neutralizing antibodies, skews towards a Th1-type response and does not induce lung 
pathology upon natural infection.
One way to induce protective immunity without priming for immunopathology involves addition 
of a Th1-skewing adjuvant to the vaccine. The detoxified lipopolysaccharide (LPS) derivative 
monophosphoryl lipid A (MPLA) skews the immune response to a Th1-phenotype through 
activation of TLR4.169 Additionally, MPLA has an acceptable safety profile when co-administered 
with vaccine antigens in multiple clinical trials and is the only TLR ligand currently being used as 
an adjuvant in licensed human vaccines.115,128,184 Furthermore, it has been shown that addition of 
MPLA to FI-RSV alleviates the symptoms of RSV enhanced disease.78 
In a recent study in mice, we showed that reconstituted RSV viral envelopes (virosomes) 
containing viral membrane proteins and incorporated MPLA but lacking the nucleocapsid, 
represent a promising vaccine candidate.185 Immunization with these RSV-MPLA virosomes 
led to induction of high levels of neutralizing antibodies and a balanced Th1/Th2-phenotype 
compared to FI-RSV immunization. Mice immunized with RSV-MPLA virosomes cleared the virus 
after infection and showed no signs of immunopathology.
Even though mice are a valuable model to assess vaccine-induced immune responses, they are 
not permissive for RSV replication and display a different form of ERD compared to humans. 
Infiltration of eosinophils is a hallmark of FI-RSV induced ERD in mice while in the 1960s clinical 
trial, analyses of autopsy samples indicated excessive infiltrating neutrophils and only scarce 
influx of eosinophils.77,183 Cotton rats (Sigmodon Hispidus), on the other hand, are more permissive 
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for RSV than mice and also more faithfully replicate FI-RSV-induced immunopathology in 
humans.140,183 
The cotton rat was used for preclinical evaluation of the prophylactic antibody Palivizumab and 
has become the small-animal model of choice for RSV vaccine development.186 Recently, key 
cotton rat cytokine genes were sequenced enabling the analysis of Th1/Th2 cytokine profiles 
using qPCR.187 It was shown that immunization of cotton rats with FI-RSV not only induces 
increased Th2 cytokine expression, but also stimulates expression of several Th1-associated 
cytokines after live virus challenge.78 The combination of the permissiveness of the cotton rat 
for RSV, the occurrence of ERD and the new opportunity to profile Th1/Th2 cytokine responses, 
makes this animal model very suitable to study the safety and efficacy of RSV-MPLA virosomes. 
Here we show that RSV-MPLA virosomes induce a superior immune response compared to FI-
RSV or non-adjuvanted RSV virosomes, through the induction of increased virus-neutralizing 
antibody levels, a balanced Th1/Th2 response and the absence of alveolitis or influx of neutrophils 
in the lungs after challenge. These results, combined with the responses to immunization we 
observed in mice, show that RSV-MPLA virosomes represent a safe and immunogenic RSV 
vaccine candidate that warrants further evaluation in a clinical setting.
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Immunogenicity of RSV-MPLA virosomes
were produced and analyzed as described before.168 To determine the immunogenicity of RSV 
virosomes and RSV-MPLA virosomes, serum samples from immunized cotton rats, collected on 
day 21 and 49, were analyzed for RSV-specific IgG antibodies (Figure 4.1A). Immunization with 
RSV virosomes induced a significantly higher RSV-specific IgG titer in serum than immunization 
with FI-RSV or live virus. The inclusion of MPLA in the RSV virosomes significantly increased the 
antibody titer to an approximately 2-fold higher level.
To determine the virus-neutralizing capacity of the RSV-specific serum antibodies, a 
microneutralization test was performed (Figure 4.1B). Although FI-RSV induced similar levels 
of RSV-specific antibodies compared to immunization with live virus, the antibodies induced 
by FI-RSV had a significantly lower capacity to neutralize the virus (Figure 4.1B). Sera from 
rats immunized with RSV virosomes did not show increased capacity to neutralize the virus 
compared to sera from FI-RSV immunized animals. Sera from rats immunized with RSV-MPLA 
virosomes demonstrated significantly higher levels of neutralizing antibodies compared to sera 





















































Figure 1. Antibody responses to RSV vaccination. Cotton rats were immunized twice (day 1, prime and 21, boost) with 
virosomes, FI-RSV or live virus. A) On day 21 and 49, blood was drawn and RSV-specific IgG titers in serum were deter-
mined. B) Virus neutralization titer of serum on day 49. (Mann-Whitney U test *p<0.05, **p<0.01, ***p0<0.001)
Protection against RSV infection
To determine whether immunization with MPLA-adjuvanted RSV virosomes could also induce 
a protective immune response in vivo, animals were immunized and challenged with live RSV 
and lung virus titers were determined (Figure 4.2). At 6 h post-infection, RSV was recovered 
from 3 out of 5 control animals with titers of approximately 102 TCID50/gram lung. None of the 
immunized animals had detectable virus in their lungs at this time point (Figure 4.2A). At 5 days 
post challenge, increased RSV viral titers were detected in the lungs of all control animals, to 
above 104 TCID50/gram lung, indicating virus replication in these animals. In contrast, no RSV 
was detected in the lungs of the animals immunized with RSV virosomes, RSV-MPLA virosomes, 
FI-RSV or live virus (Figure 4.2B).
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Figure 4.2. In vivo virus clearance after challenge. Cotton rats were challenged with live RSV at day 49. A) 5 rats per 
group were sacrificed at 6 hours post challenge and lung virus titers were determined by TCID50. B) 7 rats per group 
were sacrificed at 5 days post challenge and lung virus titers were determined by TCID50. Values below 10 TCID50 were not 
detectable. (Mann-Whitney U test **p<0.01, ***p<0.001)
Local immune responses upon RSV infection
To analyze whether RSV-MPLA virosomes prime for immune responses associated with ERD, 
cotton rats were vaccinated and challenged as described above and cytokine gene expression 
levels in the lungs of the animals were assessed by qPCR (Figure 4.3 and 4.4). 
At 6 h after infection, cotton rats immunized with FI-RSV showed a significant increase of Th2-
associated cytokines IL-4, IL-5, IL-9 and IL-13 mRNA expression (Figure 4.3). At this time point, 
rats immunized with RSV virosomes showed increased levels of IL-5 mRNA as well. In contrast, 
animals immunized with RSV-MPLA virosomes or live virus did not show significant increases 
in expression of Th2-associated cytokines at this early time point. At 5 days post infection, IL-4, 
IL-5 and IL-13 expression remained high in animals immunized with FI-RSV. In contrast, animals 
immunized with RSV virosomes, RSV-MPLA virosomes or live virus only showed background 
mRNA levels of these cytokines. 
Animals immunized with FI-RSV also showed a significant increase in the Th1-associated cytokine 
IL-1b, but not IL-12 or IFN-γ mRNA  (Figure 4.4). Animals immunized with live virus showed early 
increases in expression levels of IL-1b, IL-12 and IFN-γ mRNA while non-immunized animals had 
increased expression levels of IL-1b and IL-12, but not IFN-γ mRNA at 6 h post infection. The 
levels of IL-12 and IFN-γ mRNA were significantly higher in animals immunized with live virus, 
than in animals immunized with RSV virosomes, but similar to levels in animals immunized with 
RSV-MPLA virosomes. At 5 days post infection all the Th1-type cytokine expression levels in the 
immunized rats had returned to background levels, i.e. levels similar to non-immunized, non-
infected animals. Non-immunized animals, however, showed increased levels of IL-12 and IFN-γ 
at 5 days post-infection. 
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Figure 4.3. Th2-type cytokine expression in the lungs of vaccinated and challenged animals. Cotton rats were vac-
cinated and challenged as in figure 2 and at 6 hrs (open bars) and 5 days (solid bars) post infection, lung cytokine ex-
pression was determined by qPCR. Values are relative quantities (RQ) compared to naïve rats (horizontal line at RQ=1). 
(Mann-Whitney U test *p<0.5, **p<0.01, ***p<0.001 comparing vaccine group to vaccine group. #p<0.5, ###P<0.001 com-
paring expression values of the vaccinated and challenged rat to expression in naïve rats.) 
Immunopathology upon RSV infection
To assess whether RSV-MPLA virosomes primed for the induction of lung pathology upon 
infection, we examined the lungs of immunized and challenged animals by means of histology. 
The lungs of non-immunized animals showed no signs of alveolitis, and the peribronchial and 
perivascular regions were also free of infiltrates (Figure 4.5A, B). In contrast, the lungs of rats 
immunized with FI-RSV showed prominent alveolitis as well as peribronchial and perivascular 
infiltrates (Figure 4.5C, 4.5D). The lungs of animals immunized with RSV virosomes also showed 
some signs of alveolitis and infiltrates in the peribronchial and perivascular regions (Figure 
4.5E, F). In contrast, rats immunized with RSV-MPLA virosomes showed no sign of alveolitis or 
infiltrates (Figure 4.5G, H) and were comparable to non-immunized animals or animals that 
received live virus immunization (Figure 4.5I, J).
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 Finally, infiltrating neutrophils in the alveoli, a hallmark of ERD in both cotton rat and humans,183 
were enumerated. The lungs of rats immunized with RSV-MPLA virosomes contained low 
numbers of infiltrates similar to those seen in non-immunized animals or animals immunized 
with live virus. Although we observed an increased number of infiltrating neutrophils in the 
lungs of the rats immunized with RSV virosomes, the numbers were significantly lower than the 




































































Figure 4.4. Th1-type cytokine expression in the lungs of vaccinated and challenged animals. As figure 4.3 but for 
Th1-type cytokines. Open bars represent relative transcription abundance at 6hrs post challenge and solid bars at 5 
days post challenge.
Figure 4.5 (Opposite page). Cotton rat lung pathology. Cotton rats were vaccinated and challenged as in figure 4.2. 
At 5 days post challenge lungs were removed, fixed in formalin under 20cm water pressure to preserve the structure of 
the lungs, embedded in paraffin and stained with H&E. A, B) No vaccine. C,D) FI-RSV. E, F) RSV virosomes. G, H, RSV-MPLA 
virosomes. I,J) Live virus. Green arrows, perivascular infiltrates. Green arrowheads, peribronchial infiltrates. Red arrows, 
alveolar infiltrates.
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Figure 4.6. Leukocytic alveolar infiltrations. Lungs were 
treated as in figure 4.5 and the numbers of neutrophils per 
mm2 were determined by light microscopy in 4 areas per 
slide and 3 animals per group. (Mann-Whitney U test *p<0.5, 
**p<0.01, ***p<0.001)
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The induction of ERD by FI-RSV in the 1960s clinical trial followed by observations that also 
other, non-adjuvanted, inactivated vaccine formulations can prime for Th2-type responses and 
ERD upon RSV infection has tempered enthusiasm for further development of these types of 
vaccines.84 Recent insights in the importance of TLR signaling in immunomodulation suggest 
that addition of TLR ligands to vaccines represents a powerful approach to steer immune 
responses towards the desired phenotype and have revived the development of inactivated RSV 
vaccines.  Here, we show that a non-replicating virosomal RSV vaccine, with incorporated MPLA, 
induces virus-neutralizing immune responses without priming for excess Th2-type responses or 
ERD in RSV–permissive and ERD-prone cotton rats. 
In cotton rats immunized with FI-RSV and subsequently challenged with live virus, we observed 
a strongly upregulated expression of Th2 cytokines including IL-4, IL-5, IL-9 and IL-13.  Studies in 
mice have shown that expression of these cytokines in lungs is implicated in allergen-induced 
asthma, rhinitis and anaphylaxis.188-191 IL-5, for example, directly activates eosinophils and is, 
therefore, an important factor in allergic reactions. IL-9 induces IL-13 expression in the lungs, 
affecting airway epithelium and contributing to signs of lung pathology.192 Furthermore, IL-4 
and IL-13 upregulate vascular cell adhesion molecule-1 (VCAM-1), which induces migration of 
eosinophils and lymphocytes. Additionally, upregulation of IL-13 induces mucus secretion in 
the lungs.193 Therefore, it appears that expression of Th2 cytokines in the lungs of cotton rats, 
immunized with FI-RSV and subsequently challenged with live virus, contributes crucially to the 
observed alveolar, perivascular and peribronchial infiltrations. 
The exact mechanism by which FI-RSV skews the immune response to a Th2 -henotype is 
unknown and most likely multifactorial. For example, antigen alteration by formalin,80 the 
presence of cell culture proteins81 and alum.82,83 have all been shown to contribute to Th2-
associated cytokine expression and ERD. RSV virosomes, on the other hand, are generated from 
untreated, purified virus, do not contain alum as an adjuvant and, therefore, do not induce 
excessive Th2 cytokine expression.
Our results show that incorporation of MPLA in the RSV virosomal membrane results in the 
induction of a balanced Th1/Th2 response. RSV-MPLA virosomes only stimulated the expression 
of the Th1-associated cytokine IFN-γ, but not of Il-1b or IL-12. In contrast, priming with live 
virus resulted in expression of all of these three Th1 cytokines after infection, reflecting a more 
Th1-skewed response than the response induced by RSV-MPLA virosomes. In a previous study 
in Th2-prone BALB/c mice, we also observed induction of a balanced Th1/Th2 response by 
RSV-MPLA virosomes.185 In the latter study, upon immunization of the animals with RSV-MPLA 
virosomes, we observed higher levels of virus-neutralizing, Th1-signature, IgG2a antibodies 
and IFN-γ expression, compared to the corresponding responses in mice immunized with FI-
RSV. However, similar to the observations made in the present study, the Th1-skewing effect 
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was more pronounced after priming with live virus than after immunization with RSV-MPLA 
virosomes. This is in agreement with the findings of Boukhvalova et al, who added MPLA to FI-
RSV and, after immunization and subsequent challenge in cotton rats, did not observe a strong 
Th1-skewed response either.78 They did, however, note a dampening of the pronounced Th2-
type response induced by FI-RSV alone. 
Comparison of the results obtained with RSV virosomes vs. RSV-MPLA virosomes demonstrates 
that MPLA is essential for complete prevention of ERD. Even though the expression of Th2 
cytokines in cotton rats immunized with non-adjuvanted RSV virosomes was much lower 
than that in FI-RSV-immunized animals, these animals did display signs of lung pathology. It 
is possible that these neutrophils were attracted through complement activation, which may 
have occurred as a result of induction of antibodies with low affinity and low neutralizing 
capacity (Figure 1), leading to the deposition of immune complexes in the lungs. This may lead 
to complement fixation, activation and chemo-attraction of neutrophils by complement factor 
fragments such as C3a, C4a and C5a.194,195 C3a may additionally induce bronchoconstriction, 
another symptom of ERD.68,196 Importantly, immune complex deposition has been demonstrated 
to play an important role in ERD in mice and immune complex-dependent C4d deposition has 
been found in lung biopsies from the children who died of ERD in the 1960s trial.74 Unfortunately, 
there are, to our knowledge, currently no reagents available to directly investigate immune 
complex formation and complement fixation in cotton rats. 
As indicated before, FI-RSV induces low-affinity antibodies that have poor virus-neutralizing 
capacity.72,76 Accordingly, our data indicate that not only FI-RSV, but also non-adjuvanted RSV 
virosomes, induce inferior neutralizing antibody levels compared to RSV-MPLA virosomes or 
live virus, pointing to a suboptimal antibody affinity maturation induced by FI-RSV or non-
adjuvanted RSV virosomes. In this respect, TLR4 activation by MPLA in RSV-MPLA virosomes or, 
for that matter, TLR3 activation by RNA in replicative virus are likely to induce proper antibody 
affinity maturation yielding antibodies more capable of virus neutralization. In the context 
of inactivated RSV vaccines, it therefore appears that proper TLR activation is essential and 
sufficient to ensure prevention of ERD upon viral challenge. 
Apart from stimulating the induction of high levels of high-affinity antibodies, TLR signaling 
also improves persistence of the antibody response.197 Previous reports183 and our data (Figure 
2) show that immunization with FI-RSV gives rise to an antibody response capable of virus 
neutralization in vivo, despite suboptimal affinity maturation of these antibodies. This is most 
likely due to the high abundance of these antibodies. However, the lack of TLR signaling upon 
immunization with FI-RSV may cause these antibodies to wane more rapidly than antibodies 
induced by RSV-MPLA virosomes. This in turn would result soon in titers below those capable 
of virus neutralization. Thus, in comparison with FI-RSV, RSV-MPLA virosomes, through their 
ability to activate TLRs, may not only induce better antibody affinity maturation, but also a 
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more sustained high level of antibodies providing protection against RSV infection for a longer 
period of time.
Taken together, our results show that RSV-MPLA virosomes induce high levels of virus-neutralizing 
antibodies, which are able to confer protection from RSV infection in cotton rats. Immunization 
with RSV-MPLA virosomes does not lead to increased expression of Th2-associated cytokines 
implicated in the induction of ERD. These data demonstrate the efficacy and safety of RSV-MPLA 
virosomes as a possible RSV vaccine candidate and warrant further evaluation in clinical trials. 
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Animal experiments were approved by the Committee for Animal Experimentation (DEC) 
of the University Medical Center Groningen, according to the Dutch Animal Protection Act 
(permit number DEC 5239D). Immunizations and challenges were conducted under isoflurane 
anesthesia, and every effort was made to minimize suffering of the animals.
Cells and virus
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV (Leiden, The Netherlands). The 
virus was grown in HEp-2 cells (ATCC, CL-23, Wesel Germany) in roller bottles in HEp-2 medium: 
DMEM (Invitrogen, Breda, The Netherlands) supplemented with Pen/Strep, L-Glutamine, Sodium 
bicarbonate, HEPES, Sodium Pyruvate, 1X Non Essential Amino Acids (all from Invitrogen, Breda, 
The Netherlands) and 2% FBS (Lonza-Biowhittaker, Basel, Switzerland) and purified on sucrose 
gradients as described before.185 
Vaccine formulations
RSV virosomes were generated as described previously.168 Briefly, the RSV membrane was 
dissolved in 100 mM 1,2 dihexanoyl-sn-glycero-3-phosphocholine (DCPC) in HNE and the 
nucleocapsid was removed by ultracentrifugation. The supernatant was applied to a dried film 
of a 2:1 mixture of egg phosphatidylcholine (PC) and egg phosphatidylethanolamine (PE) (Avanti 
Polar Lipids, Alabaster, AL, USA) at a ratio of 850 nmol lipid per mg of supernatant protein. For 
incorporation of MPLA, monophosphoryl lipid A from Salmonella minnesota Re 595 (Invivogen, 
Toulouse, France) dissolved in 100 mM DCPC in HNE was added to the protein lipid mixture 
at 1 mg MPLA per mg supernatant protein, incubated for 15 min at 4°C, filtered through a 0.1 
µm filter and dialyzed in a sterile Slide-A-lyzer (10 kD cut-off; Thermo Scientific, Geel, Belgium) 
against HNE buffer pH 7.4. After dialysis, virosomes were kept at 4°C.
FI-RSV was produced as reported before.183 FI-RSV was diluted with HNE to contain 5 µg of RSV 
protein in a 50 µl volume.
Animals and immunizations
Female outbred cotton rats (Hsd:Cotton Rat) of 4-6 weeks old were obtained from Harlan 
(Indianapolis, IN, USA). Rats received 50 µl RSV virosomes or RSV-MPLA virosomes intramuscularly 
containing 5 µg of protein. Control rats received 100 µl (106 TCID50) intranasally, 50 µl of HNE 
intramuscularly or 50 µl (5 µg viral protein) of FI-RSV intramuscularly. Vaccinations were given 
on day 0 and day 21. On day 49, rats were challenged with 106 TCID50 RSV intranasally. At the 
time of immunization and challenge, blood was drawn by retro-orbital puncture. Six hours 
or 5 days after challenge, rats were sacrificed and blood was drawn by heart puncture. Lungs 
were removed aseptically and one of the primary bronchi was ligated just below the tracheal 
bifurcation with suture wire. Approximately 20 mg of this lobe was removed and stored in 1 ml 
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of RNAlater (Qiagen, Venlo, The Netherlands) at -20°C for RNA isolation. The remainder this lobe 
was kept on ice in HEp2 medium containing 2% FBS, for virus titration. The other half of the lung 
was fixed in 4% formaldehyde in PBS under 20 cm of water pressure to preserve the structure of 
the lungs for lung histopathology analyses. Control rats used for RNA expression analyses were 
sacrificed as described above without prior challenge. 
IgG antibody ELISA
RSV-specific serum IgG titers were determined using standard protocols168 using horserad-
ish-peroxidase-coupled goat anti-mouse IgG (Southern Biotech 1030-05) which was cross reac-
tive for cotton rat IgG.
Virus titration and microneutralization assay 
Virus titers were determined by TCID50 as described previously.
185 RSV virus neutralization titers 
were determined by incubation of two-fold serially diluted cotton rat serum with 70 TCID50 
of RSV for 2 h and subsequent titration of this mixture on HEp-2 cells as described before.185 
The neutralization titer was calculated with the Reed & Muench method as the dilution that 
neutralizes infection in 50% of the wells. 
Lung histopathology
The inflated lungs were embedded in paraffin and 4 µm slices were cut. The slides were 
then stained with hematoxylin and eosin (H&E) using standard procedures. Subsequently, 
perivasculitis, peribronchiolitis and alveolitis were assessed by light-microscopy. Cellular 
infiltrates (neutrophils) in the alveoli were assessed based on morphology.
Lung RNA isolation
Lung samples stored in RNA later were transferred to tubes containing 300 µl RLT buffer (Qiagen, 
Venlo, The Netherlands) and homogenized using disposable pestles with a pestle motor 
(VWR, Amsterdam, The Netherlands). Subsequently RNA was isolated with an RNeasy mini kit 
(Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol. After isolation RNA 
concentration was determined on a Nanodrop (Thermo scientific, Wilmington, DE, USA).
cDNA synthesis and qPCR
cDNA  synthesis and qPCR were performed using the Verso cDNA synthesis kit (Acros Organics, 
Geel, Belgium) and Absolute QPCR SYBR Green Mix (Westburg, Leusden, The Netherlands) 
according to the manufacturer’s protocols. Cotton rat cytokine sequences were obtained from 
NCBI187 and used to generate primers that yield products of approximately 125 bp (table 4.1). 
PCR analyses were run on an Applied Biosystems AB7500 Real-Time PCR system (Applied 
Biosystems, Nieuwerkerk ad IJssel, The Netherlands) with the following conditions: 15 min 95°C, 
40 times 30 sec 95°C, 30 sec 60°C followed by a melt curve. Relative transcript abundance was 
calculated using the 2-ddCt method comparing Ct (cycle threshold) values from the immunized 
and challenged rats to non-immunized, non-challenged rats corrected for Ct values for the 
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housekeeping gene β-actin. 
Statistical analyses
All statistical analyses were performed with Graphad Prism 5.00 for Mac OSX, (GraphPad 
Software, San Diego California USA, www.graphpad.com). Statistical significance was assessed 





































Table 4.1. Primers for cotton rat cytokine RT-PCR
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Respiratory syncytial virus infection remains a serious health problem, not only in infants 
but also in immunocompromised adults and the elderly. An effective and safe vaccine is 
not available due to several obstacles: non-replicating RSV vaccines may prime for excess 
Th2-type responses and enhanced respiratory disease (ERD) upon natural RSV infection of 
vaccine recipients. We previously found that inclusion of the Toll-like receptor 4 (TLR4) ligand 
monophosphoryl lipid A (MPLA) in reconstituted RSV membranes (virosomes) potentiates 
vaccine-induced immunity and skews immune responses toward a Th1-phenotype, without 
priming for ERD. As mucosal immunization is an attractive approach for induction of RSV-
specific systemic and mucosal antibody responses and TLR ligands could potentiate such 
responses, we explored the efficacy and safety of RSV-MPLA virosomes administered 
intranasally (IN) to mice and cotton rats. 
In mice, we found that incorporation of MPLA in IN-administered RSV virosomes increased 
both systemic IgG and local secretory-IgA (S-IgA) antibody levels, increased Th1-type 
skewing and resulted in significantly reduced lung viral titers upon live virus challenge. 
Antibody responses and Th1/Th2-cytokine responses induced by RSV-MPLA virosomes were 
comparable to those induced by live RSV infection. By comparison, formalin-inactivated 
RSV (FI-RSV) induced serum IgG that inhibited viral shedding upon challenge, but also 
induced Th2-skewed responses. In cotton rats, similar effects of incorporation of MPLA in 
virosomes were observed with respect to induction of systemic antibodies and inhibition 
of lung viral shedding upon challenge, but mucosal sS-IgA responses were only moderately 
enhanced. Importantly, IN immunization with RSV-MPLA virosomes, like live virus infection, 
did not lead to any signs of ERD upon live virus challenge of vaccinated animals, whereas 
IM immunization with FI-RSV did induce severe lung immunopathology under otherwise 
comparable conditions. 
Taken together, these data show that mucosally administered RSV-MPLA virosomes hold 
promise for induction of safe and protective immunity against RSV.
PhD thesis_0.1.indd   86 10-10-12   11:23











Respiratory syncytial virus (RSV) infection causes viral bronchiolitis in infants and young children 
but also significant health problem in the elderly and immune-compromised individuals.1,7,8 
RSV infection at young age does not lead to life-long protection and multiple reinfections occur 
throughout life.6,7,164 Vaccination of risk groups would be an effective approach to reduce the 
burden of disease. Although RSV has been recognized as an important vaccine target, no vaccine 
is available. This is, in part, due to the fact that immunization with inactivated RSV formulations 
or purified protein preparations can prime for enhanced respiratory disease (ERD) upon natural 
infection,144 as did a formalin-inactivated RSV vaccine (FI-RSV),  evaluated in young children in 
the 1960s.68-70 Hallmarks of ERD are neutrophilic alveolar infiltrates as well as perivascular and 
peribronchial infiltration of lymphocytes.183 Immunization with FI-RSV also led to the induction 
of poorly neutralizing antibodies72,73 as a result of impaired affinity maturation, probably 
because of a lack of Toll-like Receptor (TLR) signaling by FI-RSV.76 Subsequent work in animal 
models showed that FI-RSV also induces Th2-skewed immune responses, as opposed to Th1-
type responses that are better suited to protect against viral infections.77 An approach to induce 
better neutralizing antibodies and Th1-skewed responses and to avoid priming for ERD, is to 
incorporate TLR ligands as immunomodulators in candidate non-replicating RSV vaccines.78 
RSV enters through the mucosal surface of the respiratory tract. A desirable feature of RSV 
vaccines would therefore be the capacity to induce, besides systemic antibody responses, also 
local immunity against RSV like secretory IgA antibodies (S-IgA). Mucosal immunization, through 
intranasal (IN) administration, could achieve such responses. It not only is a non-invasive and 
highly acceptable route of administration,198 in addition, it does not readily prime for enhanced 
disease, at least in animal models.199 However, as mucosal surfaces are continuously exposed 
to antigens, mucosal immune tolerance mechanisms prevent untoward immune reactions. 
Therefore, inclusion of TLR ligands in an IN-administered RSV vaccine may well represent an 
essential prerequisite for induction of robust RSV-specific mucosal as well as systemic antibody 
responses.200
A TLR ligand currently used in two registered intramuscular (IM) human vaccines is 
monophosphoryl lipid A (MPLA).127,128 We found that MPLA in RSV virosomes induces safe 
and protective immune responses in mice and cotton rats upon IM injection.185 Interestingly, 
MPLA has also been reported to have adjuvant activity when co-administered IN with different 
vaccine antigens.201,202 These findings therefore prompted further exploration of our candidate 
MPLA-adjuvanted RSV virosomal vaccine for induction of RSV-specific immunity upon IN 
administration. 
Incorporation of MPLA in RSV virosomes administered IN to mice potentiated protective RSV-
specific serum IgG and respiratory tract S-IgA antibody responses and induced Th1-skewed 
T-cell responses. Incorporation of MPLA in RSV virosomes administered IN to cotton rats 
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significantly increased virus-neutralizing serum IgG responses and protection against infection 
but only moderately stimulated mucosal S-IgA responses. In contrast to IM injection of FI-RSV, 
IN administration of RSV-MPLA virosomes did not prime for lung immunopathology upon 
challenge. These data combined show that mucosally administered RSV-MPLA virosomes hold 
promise for induction of protective immunity without priming for enhanced disease. 
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To determine the adjuvant effect of MPLA in IN-administered RSV virosomes, we immunized 
mice with RSV virosomes or RSV-MPLA virosomes. RSV-naïve mice and mice immunized with 
FI-RSV or live virus, served as controls. RSV-MPLA virosomes, but not virosomes without MPLA, 
induced RSV-specific serum IgG, although levels were significantly lower than those induced by 
IM injection with FI-RSV or live RSV infection (Figure 5.1A). One of six mice receiving a second IN 
immunization with RSV virosomes developed detectable RSV-specific serum IgG antibodies. In 
contrast, all mice that received a second IN immunization with RSV-MPLA virosomes developed 
IgG antibodies, to similar levels as in mice that received a second immunization with FI-RSV or a 
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Figure 5.1. Immunogenicity and protection in mice. Mice were immunized twice (“prime” on day 0 and “boost” on 
day 14) with RSV virosomes IN, RSV-MPLA virosomes IN, FI-RSV IM, and live virus IN. Control mice received buffer IN. A) 
Fourteen days after the immunizations blood was drawn and RSV-specific IgG in serum was determined. The immu-
nized mice were challenged on day 28 with 106 TCID50 RSV and terminated 5 days later. B, C) After termination IgA titers 
were determined in lung wash and nose wash. D) RSV virus titers were determined by TCID50 on lung homogenates. 
(Mann-Whitney U test: ns not significant,*p<0.05, **p<0.01, ***p<0.001)
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For assessment of local immune responses, we analyzed lung and nose wash RSV-specific IgA 
antibodies. Mice immunized twice IN with RSV-MPLA virosomes showed significantly higher 
S-IgA levels in lungs compared to mice immunized with non-adjuvanted virosomes, FI-RSV 
or live virus infection. Both RSV-MPLA virosomes and live virus infection induced significantly 
higher nasal S-IgA compared to levels induced by non-adjuvanted virosomes and FI-RSV (Figure 
5.1B,C). 
To determine protection against infection, immunized mice were infected with live RSV. Non-
vaccinated mice or mice immunized IN with non-adjuvanted virosomes showed virus titers of 
approximately 104 TCID50 , 4 days post-infection.  On the other hand, animals immunized with 
RSV-MPLA virosomes, FI-RSV or live virus had no detectable lung virus titers (Figure 5.1D). 
Cellular immune response
To determine if the induced immune responses had Th1- or Th2-skewed phenotypes, we 
determined IFN-γ and IL-5 levels in RSV-restimulated splenocytes from immunized and 
subsequently challenged animals of all groups (Figure 5.2). IFN-γ production in splenocyte 
cultures from mice immunized with RSV-MPLA virosomes was significantly higher than that 
in cultures from mice immunized with non-adjuvanted virosomes or FI-RSV. In contrast, IL-5 
production in splenocyte cultures from mice immunized with FI-RSV was significantly higher 
than that in cultures from mice immunized with non-adjuvanted RSV virosomes, RSV-MPLA 
virosomes or live virus infection. Therefore, RSV-MPLA virosomes and live virus infection induced 






































Figure 5.2. Cellular immune response in mice. Mice were immunized, challenged and terminated as in Figure 1. After 
termination, spleens were harvested and splenocytes were restimulated in vitro with BPL-inactivated RSV for three days. 
After three days IFN-γ (A) and IL-5 (B) were determined in the supernatants. (Mann-Whitney U test:,*p<0.05, ***p<0.001).
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Immunogenicity in cotton rats
Next, we evaluated immune responses, protection and vaccine-induced immunopathology in 
the cotton rat model. Cotton rats, compared to mice, are more permissive to RSV and more 
prone to develop ERD. Similar to antibody responses in mice, low levels of RSV-specific serum 
IgG were detected in cotton rats immunized IN with non-adjuvanted RSV virosomes (Figure 
3A). However, incorporation of MPLA in the IN-administered virosomes significantly increased 
systemic IgG levels. Animals immunized once with RSV-MPLA virosomes showed significantly 
lower titers compared to those in cotton rats immunized once with FI-RSV or live virus.  However, 
serum IgG antibody levels increased after the booster immunization to similar levels as seen in 
cotton rats primed and boosted with FI-RSV or live virus (Figure 5.3A).
Next, the virus-neutralizing capacity of the sera were assessed. Sera from RSV-naïve cotton 
rats or rats immunized IN with non-adjuvanted RSV virosomes, did not have any significant 
neutralizing capacity (Figure 5.3B). RSV-MPLA virosomes induced significantly increased levels 
of neutralizing antibodies compared to RSV virosomes without MPLA. These levels were, on 
average, also higher than those induced by IM immunization with FI-RSV, although the difference 
did not reach statistical significance. Live RSV infection, however, induced significantly higher 
neutralizing antibody levels compared to those induced by RSV-MPLA virosomes, administered 
IN, or FI-RSV, injected IM.



















































Figure 5.3. Immunogenicity in cotton rats. Cotton rats were immunized with the same preparations as given to mice 
(Figure 1) on day 0 and 21. A) On day 21 and 49, blood was taken en RSV specific IgG was determined in serum. B) RSV-vi-
rus neutralizing antibodies were determined in the day 49 serum. (Mann-Whitney U test: ns not significant,*p<0.05, 
**p<0.01, ***p<0.001).
Finally, the local antibody responses were determined. Although MPLA increased nasal S-IgA 
levels, levels of S-IgA in nose and lung induced by live virus infection were significantly higher 
than those observed in the other groups (Figure 5.4)
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 Protection from RSV challenge
To determine protection against infection, immunized cotton rats were infected with live RSV. 
Significant lung virus titers were detected in RSV-naïve cotton rats and cotton rats immunized 
IN with non-adjuvanted RSV virosomes (Figure 5.5). Five out of seven cotton rats immunized 
IN with RSV-MPLA virosomes showed no lung virus titers, while two cotton rats had detectable 
virus titers, but at levels that were significantly lower compared to those in animals immunized 
IN with non-adjuvanted RSV virosomes. All animals immunized with FI-RSV or live virus infection 












































Figure 5.4. Mucosal immune response in cotton rats. Cotton rats were immunized as in Figure 5.3 and challenged 
with 106 TCID50 live RSV on day 49. Five days after challenge, the rats were sacrificed and lung and nose washes were 




























Figure 5.5. Protection in cotton rats. Cotton rats were 
immunized, challenged and sacrificed as in Figure 5.4. Af-
ter termination, the lungs were removed and RSV titers in 
lungs were determined by TCID50. (Mann-Whitney U test: ns 
not significant,*p<0.05, **p<0.01, ***p<0.001)
Figure 5.6. (Opposite page) Lung pathology in cotton rats. Cotton rats were immunized, challenged and sacrificed 
as in Figure 5.4. After termination, one lung lobe was fixated with 4% formalin under 20 cm water pressure to retain the 
structure of the lung. After fixation, the lungs were embedded in paraffin and 4 µm slices were cut and stained with H&E. 
The lungs were evaluated by light microscopy. Groups: A,B) No vaccine, C,D) FI-RSV, E,F) RSV virosomes, G,H) RSV-MP-
LA virosomes, I,J) Live virus. Red arrows, alveolar infiltrates, green arrows, perivascular infiltrates, green arrowheads, 
peribronchial infiltrates.
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To evaluate the safety of IN administration of RSV virosomes and RSV-MPLA virosomes, we 
harvested the lungs of immunized and challenged cotton rats and assessed lung pathology 
by light microscopy. Lungs from cotton rats immunized IM with FI-RSV showed clear signs of 
ERD, with perivascular and peribronchial infiltration and alveolitis with influx of predominantly 
neutrophils (Figure 5.6 C,D). The lungs of non-immunized animals (Figure 5.6 A,B), animals 
immunized IN with RSV virosomes (Figure 5.6 E,F), RSV-MPLA virosomes (Figure 5.6 G,H) or live 
virus (Figure 5.6 I,J), however, did not show signs of ERD. 
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Intranasal administration represents an attractive route of administration for vaccines, including 
RSV vaccines. Effective induction of immune responses with non-replicating vaccine antigens 
through this route usually requires the use of adjuvants.203 The adjuvant MPLA has an acceptable 
safety profile in humans and is currently being used in a number of licensed vaccines.115,174 It 
does not only have immunomodulatory properties for induction of safe Th1-skewed responses 
against RSV,78,185 but also has been reported to have mucosal immunoadjuvant properties.201,202 
However, MPLA has not been tested before for its capacity to potentiate immune responses to 
a non-replicating RSV vaccine, such as RSV virosomes, upon IN administration. Here, we show 
that RSV virosomes with incorporated MPLA have the capacity to induce protective immune 
responses upon IN administration to mice and cotton rats, without priming for ERD. 
IN administration of RSV-MPLA virosomes effectively induces serum IgG antibody responses and 
Th1-skewed immune responses, similar to RSV-MPLA virosomes administered by IM injection.185 
This is line with previous findings by others who compared the immunoadjuvant activity of 
MPLA co-administered IN or parenterally with antigen.204 The adjuvant effect of MPLA is likely 
caused by the direct interaction of MPLA with TLR4 on dendritic cells (DC) that are abundantly 
present in draining lymph nodes, nasal or bronchus-associated lymphoid tissue, or even directly 
lining the respiratory tract. The activation leads to secretion of IL-12 and type 1 IFN, which skew 
T cell responses toward a Th1-phenotype.205 Similar to DC, B cells may be directly activated 
through TLR4 signaling which, together with aid of the induced T cell response, stimulates 
antibody responses.180 Although many cell types in the respiratory mucosa express TLR4, the 
receptor for MPLA, the expression of the co-receptors CD14 and MD2, which are crucial for the 
initiation of TLR4-mediated cell signaling, are expressed at a lower level compared to their 
expression on, for instance, DC.206 This reduced expression of CD14 and MD2 on the mucosal 
cell surfaces, e.g. epithelial cells, may reduce their susceptibility to endotoxins but possibly also 
to stimulatory effects of vaccine adjuvants such as MPLA.207 This could explain the lower levels 
of RSV-neutralizing antibodies induced by IN immunization compared to IM immunization.185 
Other TLRs, such as TLR2 and TLR5, do not require these adaptor molecules and are also 
abundantly expressed on cells in the mucosal surfaces206 and ligands for these receptors have 
been reported to have strong mucosal immunoadjuvant properties too.208,209 How the mucosal 
immunoadjuvant activity of MPLA, co-administered in RSV virosomes, compares with that of 
other virosome-incorporated TLR ligands, such as a TLR2 ligand,168 remains to be investigated 
further. 
Mucosal immunization can induce local S-IgA antibodies. More robust local S-IgA was induced 
by RSV infection in cotton rats, particularly when compared to responses induced by IN 
immunization with virosomes. In mice, differences in levels of S-IgA induced by infection or 
IN immunization were less pronounced. This difference may be related to the much higher 
permissiveness of the cotton rat for RSV infection than that of mice,141 leading to higher levels 
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of viral replication and stronger local immune activation and, consequently, to higher S-IgA 
responses. Because FI-RSV also induces serum IgA (unpublished results), IgA found in washes 
of cotton rats or mice immunized with FI-RSV may originate from serum and translocate to 
the mucosa by transudation (in case of monomeric IgA) or through transcytosis mediated by 
the polymeric immunoglobulin receptor (pIgR; in case of polymeric IgA).210 Interestingly, TLR4 
signaling upregulates expression of pIgR responsible for polymeric IgA transcytosis.210,211 Clearly, 
RSV-specific serum IgG alone, for example induced by IM injection of RSV-MPLA virosomes, 
inhibits virus shedding in the lung. In this respect, we previously observed that lung viral titers 
negatively correlate with RSV-specific serum IgG levels,200 pointing to (sufficient levels of) serum 
IgG, as an important mediator of protection of the lungs. The upper respiratory tract, however, 
may not benefit so much from serum IgG for protection against infection, as transudation of 
antibody to this site is less efficient.212 Rather, local S-IgA antibody may be more important for 
protection against viral infection at this site, as has previously been reported for influenza.213 
Further studies should clarify if S-IgA protects the upper respiratory tract by specifically 
analyzing nasal virus shedding in cotton rats immunized IN. 
Together our data show that RSV-MPLA virosomes have the capacity to induce protective 
immunity upon IN administration to mice and cotton rats, without priming for enhanced disease. 
IN administration forms an attractive alternative to IM injection, as it is a non-invasive route of 
administration. Clearly, to potentiate RSV virosome-induced immune responses through this 
route, adjuvants are needed, which could be MPLA or possibly other TLR ligands with mucosal 
immunoadjuvant properties.  
PhD thesis_0.1.indd   96 10-10-12   11:23












Animal experiments were approved by the Committee for Animal Experimentation (DEC) of the 
University Medical Center Groningen, according to the guidelines provided by the Dutch Animal 
Protection Act (permit number DEC 5239A and 5239D). Immunizations and challenges were 
conducted under isoflurane anesthesia and every effort was made to minimize suffering of the 
animals.
Virus 
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV (Leiden, The Netherlands). 
The virus was grown in HEp-2 cells (ATCC, CL-23, Wesel, Germany) and purified as described 
before.185 
Vaccine formulations
RSV virosomes were generated as described previously.168 Briefly, RSV membranes were 
dissolved in 100 mM 1,2 dihexanoyl-sn-glycero-3-phosphocholine (DCPC) in HNE (5 mM Hepes, 
145 mM NaCl, 1 mM EDTA, pH 7.4) and the nucleocapsid was removed by ultracentrifugation. The 
supernatant was applied to a dried film of a 2:1 mixture of egg phosphatidylcholine (PC) and egg 
phosphatidylethanolamine (PE) (Avanti Polar Lipids, Alabaster, AL, USA) at a ratio of 850 nmol 
lipid per mg of supernatant protein. For incorporation of MPLA, monophosphoryl lipid A from 
Salmonella minnesota Re 595 (Invivogen, Toulouse, France) dissolved in 100 mM DCPC in HNE 
was added to the protein lipid mixture at 1 mg MPLA per mg supernatant protein, incubated for 
15 min at 4˚C, filtered through a 0.1 µm filter and dialyzed in a sterile Slide-A-lyzer (10 kD cut-off; 
Thermo Scientific, Geel, Belgium) against HNE. After dialysis, virosomes were kept at 4˚C. FI-RSV 
was produced as reported before.183 
Mouse immunization and challenge experiments
Female BALB/c OlaHsd mice (6-8 weeks old) were purchased from Harlan (Zeist, The 
Netherlands). For immunization and challenge, mice were anesthetized using isoflurane. Mice 
received RSV(-MPLA) virosomes (5 µg viral protein) IN in 50 µl HNE. Control mice received 25 µl 
of FI-RSV (5 µg viral protein) IM, 50 µl (106 TCID50) of live RSV IN or 50 µl of HNE IN. Vaccinations 
were given on day 0 and day 14. On day 28 mice were challenged with 106 TCID50 of live RSV IN. 
On time points of vaccination and challenge, blood was drawn by retro-orbital puncture. Four 
days after challenge, mice were sacrificed and blood was sampled. Nose washes and broncho-
alveolar lavages were done by incising the trachea and flushing of 1 ml PBS with protease 
inhibitors (Roche, Mannheim, Germany). Spleens were harvested for analysis of RSV-specific T 
cell cytokine responses and lungs for analysis of viral titers.
Cotton rat immunization and challenge experiments
Female outbred cotton rats (Hsd:Cotton Rat) of 4-6 weeks old were obtained from Harlan 
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(Indianapolis, IN, USA). Rats received RSV(-MPLA) virosomes IN (5 µg viral protein). Control rats 
received 100 µl live virus (106 TCID50) IN, 100 µl of HNE IN or 50 µl (5 µg viral protein) of FI-RSV IM. 
Vaccinations were given on day 0 and day 21. On day 49, rats were challenged with 106 TCID50 
RSV IN. At the time of immunization and challenge, blood was drawn by retro-orbital puncture. 
Five days after challenge, rats were sacrificed and blood was sampled. Lung and nose washes 
were performed using similar techniques as in mice.  Subsequently, the lungs were removed 
aseptically and one of the primary bronchi was ligated just below the tracheal bifurcation with 
suture wire. Half of the lung was kept on ice in HEp-2 medium containing 2% FBS, for virus 
titration. The other half of the lung was fixed in 4% formaldehyde in PBS under 20 cm of water 
pressure to preserve the structure of the lungs for lung histopathology analyses. 
Immunological assays 
RSV-specific antibody titers were determined as described before.168 Briefly, 96-well plates were 
coated with betapropiolactone-inactivated RSV and blocked with 2.5% milk powder in coating 
buffer. Plates were incubated for 90 min with two-fold serial dilutions of serum or broncho-
alveolar lavages, starting at dilutions of 1:200 for serum or 1:1 for BAL or nose washes. After 
washing, plates were incubated with a 1:5000 dilution of horseradish-peroxidase-coupled 
goat anti-mouse IgG, or IgA which bind to both mouse and cotton rat IgG and IgA, respectively 
(Southern Biotech 1030-05, 1040-05) for 1 h and subsequently stained with o-Phenylenediamine 
(OPD; Sigma-Aldrich, St Louis, MO, USA). After 30 min the staining was stopped by addition of 2 
M H2SO4 and absorption was measured at 492 nm. 
IFN-γ and IL-5 secretion in RSV-stimulated splenocyte cultures were assessed as described 
before.185 
Virus titration and microneutralization assay 
Virus titers were determined by TCID50 as described previously.
185 For determination of RSV 
virus neutralization titers, serum was decomplemented by heat inactivation for 30 min at 56˚C. 
Neutralization titers were determined by incubation of two-fold serially diluted decomplemented 
serum with 70 TCID50 of RSV for 2 h and subsequent titration of this mixture on HEp-2 cells as 
described before.185 The neutralization titer was calculated with the Reed & Muench method as 
the dilution that neutralizes infection in 50% of the wells. 
Histopathology
The inflated cotton rat lungs were embedded in paraffin and 4 µm slices were cut. The slides 
were stained with hematoxylin and eosin (H&E) using standard procedures. Subsequently, 
perivasculitis, peribronchiolitis and alveolitis were assessed by light-microscopy. 
Statistical analysis
Statistical analyses were performed with Graphad Prism 5.00 for Mac OSX, (GraphPad Software, 
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San Diego California USA, www.graphpad.com) using a Mann-Whitney U test. P values of 0.05 or 
lower were considered to represent significant differences. 
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Each year, respiratory syncytial virus (RSV) infection is responsible for 180,000 hospitalizations 
and 14,000 deaths among the elderly in the USA alone, causing a disease burden similar to 
that of influenza in this population. Vaccination could significantly lower morbidity and 
mortality due to RSV among the elderly. Here, we investigated if a virosomal RSV vaccine 
has the capacity to induce protective immune responses upon intramuscular (IM) injection 
in aged cotton rats and studied if adjuvantation of virosomes with monophosphoryl lipid A 
(MPLA) further stimulates antibody responses. Furthermore, we studied the induction and 
waning of serum antibody responses induced by a priming infection early in life and the 
capacity of virosomal RSV vaccine to boost these antibodies in aged cotton rats. 
Intramuscular (IM) injection of RSV virosomes induced protective RSV-specific serum IgG 
antibody responses in aged cotton rats. Immunization with RSV-MPLA virosomes further 
enhanced serum IgG levels compared to non-adjuvanted virosomes, without priming for 
enhanced lung pathology. RSV-specific serum antibodies, induced by infection early in life, 
waned significantly upon aging, but protective levels of specific antibody were still present 
at old age. RSV-specific serum antibody levels, however, increased after IM injection of RSV 
virosomes, irrespective of whether the virosomes were adjuvanted with MPLA or not. RSV-
specific secretory IgA (S-IgA) in the the respiratory tract of primed and aged cotton rats 
increased after intranasal (IN) immunization, but not after IM immunization, with virosomal 
RSV vaccine, and incorporation of MPLA in the virosomes boosted this response. 
Taken together, these data show that RSV-MPLA virosomes are immunogenic in an aged 
immune system and are able to boost preexisting immunity against RSV. 
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Respiratory syncytial virus (RSV) is the major cause of viral bronchiolitis in children and also 
a significant problem in the elderly. By the age of two, nearly all children have been infected 
with RSV at least once.5 RSV infection does not lead to life-long protection and multiple 
reinfections occur throughout life. Previous studies pointed to RSV-specific serum IgG, but also 
mucosal secretory IgA (S-IgA), as protective effector mechanisms in RSV infection of adults.214 In 
healthy adults with insufficient immunity, reinfections may lead to mild disease with common 
cold-like symptoms.6 At older age, however, the immune system weakens and RSV infections 
can induce severe disease.65,164 In the elderly, RSV is responsible for approximately 180,000 
hospitalizations and 14,000 deaths each year in the USA alone.7 Compared to influenza, RSV 
contributes to a similar extent to severe lower respiratory infections in the elderly.7 Treatment 
of elderly suffering from RSV is mainly supportive and consist of administration of fluids and in 
some cases bronchodilatators.65 A vaccine against RSV, however, could significantly reduce the 
burden of disease in the elderly. 
We previously showed that reconstituted RSV membranes, adjuvanted with the Toll-Like 
Receptor 4 (TLR4) ligand monophosphoryl lipid A (MPLA) represent a promising vaccine 
candidate. Studies in mice and cotton rats showed that RSV-MPLA virosomes induce high levels 
of serum RSV-specific, virus-neutralizing, antibodies and a balanced Th1/Th2 response.185 
Immunization of mice or cotton rats with RSV-MPLA virosomes does not prime for lung pathology 
(i.e. enhanced respiratory disease68,77,183) upon natural infection in contrast to immunization 
with formalin-inactivated RSV (FI-RSV). It is not known whether the RSV virosomal vaccine has 
the capacity to potentiate immune responses in an aged immune system and, if MPLA has the 
capacity to boost responses under these conditions.
A suitable animal model to study the efficacy of RSV vaccines is the cotton rat (Sigmodon 
hispidus). Cotton rats are more permissive than mice for RSV and show signs enhanced disease 
lung pathology similar to that seen in humans.141,183,186 However, RSV protection studies in aged 
cotton, as a model for the elderly, are scarce. One previous study showed that nine-month-
old cotton rats have a more prolonged RSV infection compared to young cotton rats.215 This 
coincides with a delay in cytokine expression patterns in the lungs of infected cotton rats.216 
These data indicate that aged cotton rats indeed show signs of compromised antiviral immunity 
and would be a suitable model to study immune responses induced by RSV vaccines, including 
(MPLA-adjuvanted) RSV virosomes. 
Here, we investigated the efficacy and safety of an RSV virosomal vaccine in old cotton rats 
that were either naïve to RSV or primed for RSV-specific immunity by infection early in life, 
similar to the general situation in humans. We show that intramuscular (IM) injection of RSV 
virosomes induce protective antibody responses in aged cotton rats and that incorporation 
of MPLA in the virosomes significantly boosts these responses without priming for enhanced 
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lung pathology. Immunity to RSV induced by infection early in life, as demonstrated by RSV-
specific serum antibodies, waned significantly but protective antibody levels were still detected 
at old age. Levels of RSV-specific serum antibodies could, however, be boosted by IM injection 
of RSV virosomes, whether or not adjuvanted with MPLA. Finally, levels of respiratory tract 
RSV-specific secretory IgA (S-IgA), a correlate of protection against RSV in the elderly, could be 
boosted by intranasal (IN) administration of RSV virosomes to primed and aged cotton rats and 
incorporation of MPLA in the virosomes boosted this response. These data together suggest 
that RSV-MPLA virosomes have the capacity to boost protective RSV-specific immune responses 
in an aged immune system. Therefore, RSV-MPLA virosomes represent a promising vaccine 
candidate RSV vaccine for the elderly.
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RSV-MPLA virosomes in RSV-naïve old cotton rats
To determine whether RSV virosomes or RSV-MPLA virosomes are immunogenic in cotton rats 
with an aged immune system, aged (i.e. 8-months-old) cotton rats were immunized twice 
intramuscular (IM), three weeks apart, with RSV virosomes or RSV-MPLA virosomes. As controls, 
we included cotton rats that received no immunization or were immunized with FI-RSV by IM 
injection. We then analyzed levels of RSV-specific serum IgG, virus-neutralization capacities of 
sera obtained from the immunized cotton rats and protection against infection. Immunization 
with RSV virosomes in aged cotton rats gave rise to RSV-specific serum IgG with a geometric 
mean titer (GMT) of 2.7 (Figure 6.1A). Incorporation of MPLA in the virosomes significantly 
enhanced the levels of RSV-specific serum IgG. These levels were comparable to those induced 
by FI-RSV. A second immunization further stimulated IgG responses in the group vaccinated with 
RSV virosomes, but the levels were lower than those induced by two immunizations with RSV-












































































Figure 6.1. Immunogenicity and protection induced by 
vaccine in RSV-naïve old cotton rats. Cotton rats were im-
munized twice, once at 37 and once at 40 weeks old with 
RSV virosomes, RSV-MPLA virosomes, FI-RSV or live virus. 
Control mice were not vaccinated and received buffer. A) 
Fourteen days after the immunizations blood was drawn 
and RSV-specific IgG in serum was determined (white bar:14 
days after 1st immunization, black bar 14 days after second 
immunization). B) Serum virus-neutralization titers were 
determined after the first (black squares) and after the sec-
ond immunization (white squares) by microneutralization 
assay. C) The immunized cotton rats were challenged on 
week 44 with 106 TCID50 RSV and terminated 5 days lat-
er. After termination, RSV virus titers were determined by 
TCID50 on lung homogenates (Mann-Whitney U test: ns not 
significant,*p<0.05, **p<0.01, ***p<0.001)
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Antiviral antibody titers in the sera were also analyzed in an in vitro micro-neutralization assay 
(Figure 6.1B). A single immunization with RSV virosomes, RSV-MPLA virosomes or FI-RSV induced 
detectable neutralizing antibody titers only in a fraction of animals (Fig 6.1B). After a second 
immunization, the number of animals with detectable neutralizing antibody titers increased 
in the groups that received RSV virosomes, but not in the group that received FI-RSV. However, 
all animals in the RSV-MPLA-immunized group then developed neutralizing antibodies (Figure 
6.1B).
The aged and immunized cotton rats were challenged with live RSV, 49 days after the first 
immunization, to analyze the protection afforded by vaccination. After five days, the animals 
were sacrificed and virus titers were measured in the lungs (Figure 6.1C). The lungs from non-
immunized animals all had virus titers of, on average, 4.39 log TCID50. Cotton rats that received 
FI-RSV, RSV virosomes or RSV-MPLA virosomes did not have detectable lung virus titers (Figure 
6.1C). 
Enhanced respiratory disease
To determine the safety of RSV and RSV-MPLA virosomes with respect to immunopathology upon 
RSV infection following vaccination, we performed histopathological analyses on the lungs of 
immunized and challenged aged cotton rats. We compared the lungs from animals immunized 
with RSV virosomes and RSV-MPLA virosomes to the lungs of animals immunized with FI-RSV, 
which is known to prime for enhanced lung pathology.140 The lungs from non-immunized 
aged cotton rats that were infected with RSV showed no signs of lung pathology: there were 
no alveolar infiltrates and no infiltration in the peribronchial and perivascular regions (Figure 
6.2A). In contrast, aged cotton rats immunized with FI-RSV showed severe lung inflammation 
with peribronchial and perivascular infiltrates upon infection (Figure 6.2B). High numbers 
of neutrophils were also visible in the alveoli close to the bronchi. The lungs of the animals 
immunized with RSV virosomes showed some infiltrates in the peribronchial regions but no 
perivasculitis or alveolitis, as observed in animals immunized with FI-RSV. The lungs of aged 
cotton rats immunized with RSV-MPLA virosomes were similar to the lungs from non-immune 
animals and showed no signs of immunopathology upon infection (Figure 6.2D). 
RSV virosomes in aged cotton rats infected with RSV early in life
The above data indicate that RSV-naïve aged cotton rats have an intact immune response, and 
are susceptible priming for enhanced disease like young cotton rats (Chapter 4). Practically all 
humans are exposed to RSV during childhood, and develop anti-RSV antibodies that remain 
present throughout life. To mimic this process, 27 day-old cotton rats were infected with RSV 
and, immunized with RSV virosomes 8 months later with or without MPLA as an adjuvant. 
Inoculation of live RSV to the young cotton rats induced an infection in all animals, as evidenced 
by the presence of RSV-specific serum IgG in all animals, 4 weeks after infection (Figure 6.3A). 
The levels of RSV-specific serum IgG were significantly decreased after 8 months, but still 
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detectable in all animals (Figure 6.3A). At that time, the animals received a single IM injection 
with RSV virosomes or RSV-MPLA virosomes. A control group was not immunized. Three weeks 
after immunization, we observed significant increases in RSV-specific serum IgG levels with 
respect to pre-immunization levels (Figure 6.3B). RSV-specific serum IgG was not different for 
animals immunized with virosomes with or without adjuvant (Figure 6.3B). We also observed a 
significant increase in virus-neutralizing capacity of sera from the animals that were immunized 
with RSV virosomes (Figure 6.3C). The virus-neutralizing capacity of sera from RSV-MPLA-
immunized animals also increased, but the enhancement did not reach a statistically significant 
difference, probably due to a higher base-line neutralizing titer in pre-immunization sera from 
animals that received RSV-MPLA virosomes (Figure 6.3C). 
Three weeks after immunization, the animals were challenged and five days later, RSV titers 
were determined in the lungs of the animals. RSV virus was not detected in the lungs from any 
group (Figure 6.3D). Therefore, RSV infection in young cotton rats induces immunity capable of 
protection against infection at 9-10 months. 
Induction of S-IgA by intranasal immunization in old seropositive cotton rats
As mucosal S-IgA has also been linked with protection against RSV in the elderly,214 we 
determined if local intranasal administration of RSV virosomes or RSV-MPLA virosomes could 
250 µm





Figure 6.2. Lung pathology after immunization and challenge in old cotton rats. The cotton rats were immunized 
challenged and terminated as in figure 6.1 with A) buffer, B) FI-RSV, C) RSV virosomes and D) RSV-MPLA virosomes. The 
lungs were inflated and fixed with 4% formaldehyde and slices were stained with H&E. Lung pathology presenting as 
alveolitis and perivascular and peribronchial infiltrations was determined by light microscopy. Red arrows, alveolar 
infiltrates, green arrows, perivascular infiltrates, green arrowheads, peribronchial infiltrates.
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boost mucosal S-IgA responses in primed and aged cotton rats. To this end, two groups of RSV-
primed and aged cotton rats were immunized IN with RSV virosomes or RSV-MPLA virosomes 
and compared to groups that received the vaccine IM. Four weeks after immunization, lung and 
nasal washes as well as serum samples were taken to determine RSV-specific antibodies (Figure 
6.4). IN immunization with RSV virosomes or RSV-MPLA virosomes resulted in significantly 
higher levels of S-IgA in lung and nasal washes when compared to those in washes from cotton 
rats that received the vaccine IM (Figure 6.4A and B). Incorporation of MPLA in IN-administered 
virosomes significantly boosted lung S-IgA levels, but not nasal S-IgA levels (Figure 6.4A and 
B). IN immunization with RSV virosomes, adjuvanted or not, did however not stimulate RSV-

























































































Figure 6.3. Immunogenicity and protection in previously infected, old cotton rats. Cotton rats were infected with 
RSV at the age of 27 days. A) Four and 34 weeks after infection blood was drawn to determine RSV-specific serum IgG 
in 14 and all the animals respectively. At 37 weeks, the cotton rats were immunized with RSV virosomes or RSV-MPLA 
virosomes. Control cotton rat received buffer. B, C) Three weeks after immunization blood was drawn for RSV-specific 
serum IgG and virus neutralization determinations before (white bars) and after (black bars) immunization. The cotton 
rats were challenged with 106 TCID50 RSV. D) Five days after challenge the cotton rats were terminated and RSV virus 
titers were determined in lung homogenates. (Mann-Whitney U test: ns not significant,*p<0.05, **p<0.01, ***p<0.001)
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Figure 6.4. Mucosal IgA response in seropositive rats immunized with RSV virosomes and RSV-MPLA virosomes. 
The cotton rats were infected and aged as in figure 4. Subsequently the cotton rats were immunized with RSV virosomes 
and RSV-MPLA virosomes either intramuscularly (white bars) or intranasally (black bars). Control animals received buf-
fer (grey bars). Three weeks after immunization the cotton rats were challenged and terminated. After termination, A) 
lung  and B) nose washes were taken for RSV-specific IgA determination.
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An efficacious RSV vaccine could significantly decrease morbidity and mortality in the elderly. 
Immunosenescence in the elderly causes them to gradually become more susceptible to 
infections and, at the same time, less responsive to vaccinations.217,218 Here we show that RSV 
virosomes and RSV virosomes adjuvanted with MPLA are efficacious and safe in boosting RSV-
specific immunity in aged cotton rats. 
The adjuvant effect of the TLR4 ligand MPLA on vaccine-induced immune responses in RSV-
naive aged cotton rats is similar to the effect seen in young cotton rats (Chapter 4). This means 
that TLR4-mediated signaling is still intact in aged cotton rats. The available knowledge of TLR 
expression and function in the aged immune system is mainly derived from studies in mice 
which have shown decreased expression219 or decreased function of several TLR, including 
TLR4.220,221 One study in elderly people did show reduced a cytokine response to TLR1/2 ligands, 
but not to TLR4 ligands.222 Therefore, differences may exist in the responses to different TLR 
ligands in aged immune systems from different species. An intact response to the TLR4 ligand 
MPLA in aged cotton rats, as shown in this study, but also in elderly people (17), suggests that 
MPLA is suitable as an adjuvant in RSV vaccines for the elderly. 
Cotton rats that experienced an RSV infection early in life did not become susceptible for RSV at 
old age. We did observe a decline in serum IgG levels upon aging, however, this reduction was 
smaller than the decline reported in humans after infection59 and the reduced levels if IgG were 
still able to afford protection. Co-evolution of RSV and the human immune system produced 
RSV strains capable of evading the human immune response to leave a previously infected 
person susceptible for subsequent infection. This is often referred to as ‘incomplete’ immunity 
induced by natural infection. Two possible mechanisms by which RSV inhibits the formation 
of effective immunity could involved inhibition of induction of type-1 IFN11,12 or skewing the 
immune response to infection to a Th2-phenotype.41 It is not clear if similar mechanisms are 
operational in RSV infection of cotton rats. Previous studies in cotton rats have shown, however, 
that RSV infection does not lead to a Th2-skewed response.141 Also, cotton rats primed early 
in life were still protected against infection at old age (Figure 6.3), which argues against the 
presence of an efficient immune evading mechanism of RSV in cotton rats.
In primed and aged cotton rats, a similar increase in RSV-specific serum IgG was seen after 
IM immunization with RSV virosomes or RSV-MPLA virosomes. MPLA, although effective in 
aged cotton rats (Figure 6.1 and 6.4), does not seem to further boost serum IgG responses. An 
explanation for this may be the relatively high antibody levels in aged cotton rats induced by 
the infection early in life. Although these levels declined upon aging, they remained sufficiently 
high to provide protection. It is known that pre-existing antigen-specific antibodies negatively 
influence activation of B cells with the same antigen specificity, thereby avoiding unnecessary 
excess antibody production. This mechanism is also operational after influenza vaccination. For 
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example, vaccination with a similar strain as that used in the preceding years reduces further 
increases in antibody levels to that strain.223 It is therefore likely that an enhancing effect of 
MPLA on serum antibody levels can only be observed when levels have sufficiently waned. RSV-
MPLA virosomes administered IN to primed and aged cotton rats induce significant increases 
in respiratory tract S-IgA. A study in elderly people has shown that the levels of mucosal S-IgA 
correlated with protection against RSV infection.214 Induction of S-IgA by vaccination is most 
efficiently induced by mucosal vaccination, e.g. IN immunization.224 As the function of the nasal-
associated lymphoid tissue remains relatively intact during aging, mucosal vaccination through 
the intranasal route seems attractive in, for example, approaches to induce (mucosal) immunity 
to RSV in the elderly.225 In this respect, TLR ligands show promise as adjuvants in mucosal 
vaccines for the elderly.225 In line with this, we found that the TLR4 ligand MPLA has the capacity 
to boost lung S-IgA responses upon IN immunization of aged cotton rats (Figure 6.4).
Taken together our data indicate that RSV virosomes adjuvanted with MPLA have the capacity to 
induce and boost RSV-specific protective immune responses in an aged immune system. These 
data warrant further exploration of MPLA-adjuvanted RSV virosomes as a candidate vaccine for 
risk groups such as the elderly.
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Animal experiments were approved by the Committee for Animal Experimentation (DEC) 
of the University Medical Center Groningen, according to the Dutch Animal Protection Act 
(permit number DEC 5266E). Immunizations and challenges were conducted under isoflurane 
anesthesia, and every effort was made to minimize suffering of the animals.
Cells and virus
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV (Leiden, The Netherlands). The 
virus was grown in Vero cells (ATCC, CL-81, Wesel Germany) :in SMF-4 Megavir (Thermo scientific, 
Etten-leur, The Netherlands), supplemented with L-glutamine, and penicilline/streptomycin 
(Invitrogen, Breda, Netherlands). After 5 days of infection the cell debris was cleared by low-
speed centrifugation, the virus was concentrated and frozen in liquid nitrogen and stored at 
-80˚C to be used for live virus immunizations, challenge and microneutralization assays. 
Vaccine formulations
RSV virosomes were generated as described previously.168 Briefly, the RSV membrane was 
dissolved in 100 mM 1,2 dihexanoyl-sn-glycero-3-phosphocholine (DCPC) in HNE and the 
nucleocapsid was removed by ultracentrifugation. The supernatant was applied to a dried 
film of a 2:1 mixture of egg phosphatidylcholine (PC) and egg phosphatidylethanolamine 
(PE) (Avanti Polar Lipids, Alabaster, AL, USA) at a ratio of 850 nmol lipid per mg of supernatant 
protein. For incorporation of MPLA, monophosphoryl lipid A from Salmonella minnesota Re 595 
(Invivogen, Toulouse, France), was converted to 3-O-desacyl monophosphoryl lipid A by alkaline 
hydrolysis,226 dissolved in 100 mM DCPC in HNE, and added to the protein/lipid mixture at 1 mg 
MPLA per mg supernatant protein, incubated for 15 min at 4˚C, filtered through a 0.1 µm filter 
and dialyzed in a sterile Slide-A-lyzer (10 kD cut-off; Thermo Scientific, Geel, Belgium) against 
HNE buffer pH 7.4. After dialysis, virosomes were kept at 4˚C.
FI-RSV was produced as reported before.183 FI-RSV was diluted with HNE to contain 5 µg of RSV 
protein in a 50 µl volume.
Animals and immunizations
Female outbred cotton rats (Hsd:Cotton Rat) of 18 to 21 days old were obtained from Harlan 
(Indianapolis, IN, USA). One group of animals was housed conventionally for 34 weeks before 
immunization. Another group of animals received an infection with 106 TCID50 live RSV and was 
housed in individually ventilated cages (IVC). The infected animals showed no signs of illness 
after infection. Blood was sampled at 4 weeks post infection to determine the RSV-specific IgG 
response. In a number of animals, aging was associated with development of disease symptoms 
including damaged eyes, abscess or tumor formation or group B Streptococcus infection 
of the uterus. Animals with more severe symptoms were terminated and excluded from the 
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experiment. RSV infection at a young age did not correlate with the onset of the symptoms. 
Cotton rats that were not infected at a young age were immunized at the age of 37 weeks 
(priming immunization) and 40 weeks (boosting immunization) with RSV virosomes or RSV-MPLA 
virosomes intramuscularly (50 µl). Virosome preparations contained 5 µg of viral protein. Control 
rats received 50 µl of HNE intramuscularly or 50 µl (diluted to contain 5 µg viral protein) of FI-RSV 
intramuscularly. At week 44, cotton rats were challenged with 106 TCID50 RSV intranasally. Cotton 
rats that received a primo infection were immunized once, at the age of 37 weeks with virosomes 
as described above. For the infected cotton rats, we also induced intranasal immunization with 
virosomes (100 µl). At 41 weeks, the cotton rats were challenged as described above.
At the time of immunization and challenge, blood was drawn by retro-orbital puncture. Five 
days after challenge, the cotton rats were sacrificed and blood was drawn by heart puncture. The 
cotton rats were resected and a small incision was made in the trachea. From this incision, nose 
washes and broncho-alveolar lavages were performed with 1 ml of PBS with protease inhibitors 
(Roche, Mannheim, Germany). Lungs were removed aseptically and one of the primary bronchi 
was ligated just below the tracheal bifurcation with suture wire. One half of each lung was kept 
on ice in HEp2 medium containing 2% FBS, for virus titration. The other half of each lung was 
fixed in 4% formaldehyde in PBS at 20 cm of water pressure to preserve the structure of the 
lungs for lung histopathological analyses. 
IgG antibody ELISA
RSV-specific antibody titers were determined as described before.168 Briefly, 96-well plates 
were coated with betapropiolactone-inactivated RSV and blocked with 2.5% milk powder in 
coating buffer. Plates were then incubated for 90 min with two-fold serial dilutions of serum, 
BAL or nose washes, starting at dilutions of 1:200 for serum or 1:1 for BAL or nose washes. After 
washing, plates were incubated with a 1:5000 dilution of horseradish-peroxidase-coupled 
goat anti-mouse IgG, or IgA which are cross reactive with cotton rat IgG and IgA, respectively 
(Southern Biotech 1030-05, 1040-05) for 1 h and subsequently stained with o-Phenylenediamine 
(OPD; Sigma-Aldrich, St Louis, MO, USA). After 30 min the staining was stopped by addition of 2 
M H2SO4 and absorption was measured at 492 nm. 
Virus titration and microneutralization assay 
Virus titers were determined by TCID50 as described previously.
185 For determination of RSV 
virus neutralization titers, serum was decomplemented by heat inactivation for 30 min at 56˚C. 
Neutralization titers were determined by incubation of two-fold serially diluted decomplemented 
serum with 70 TCID50 of RSV for 2 h and subsequent titration of this mixture on HEp-2 cells as 
described before.185 The neutralization titer was calculated with the Reed & Muench method as 
the dilution that neutralizes infection in 50% of the wells. 
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The inflated lungs were embedded in paraffin and 4 µm slices were cut. The slides were 
then stained with hematoxylin and eosin (H&E) using standard procedures. Subsequently, 
perivasculitis, peribronchiolitis and alveolitis were assessed by light-microscopy.
Statistical analyses
All statistical analyses were performed with Graphad Prism 5.00 for Mac OSX, (GraphPad 
Software, San Diego California USA; www.graphpad.com). Statistical significance was assessed 
using a Mann-Whitney U test. P values of 0.05 or lower were considered to represent significant 
differences. 
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Even though RSV infection remains a serious threat to newborns and the elderly, no vaccine 
against RSV is available today. Here, we set out to develop a safe and efficacious, inactivated 
RSV vaccine based on “virosomes”, reconstituted RSV envelopes containing the viral membrane 
glycoproteins but lacking the nucleocapsid, with built-in lipophilic Toll-like receptor (TLR) ligands 
as adjuvants. First, we developed a procedure for production of RSV virosomes from purified 
virus. During reconstitution we incorporated the TLR2 ligand Pam3CSK4 or the TLR4 ligand MPLA 
as immunomodulating adjuvants. Immunogenicity and safety of these these preparations were 
evaluated in mice and cotton rats. Additionally, the ability of RSV-MPLA virosomes to induce 
a protective immune response after intranasal administration was examined and finally, the 
immunogenicity of RSV-MPLA virosomes in an aged immune system was determined. 
RSV virosomes
In Chapter 2 we showed that it is feasible to generate virosomes directly from purified RSV. 
In mice, RSV virosomes induced higher levels of IgG1 compared to IgG2 and did not stimulate 
production of IFN-γ in splenocytes, suggesting that this preparation skews immune responses 
to a Th2-phenotype. The addition of the TLR2 ligand Pam3CSK4 however, increased both IgG2a 
and IFN-γ levels, demonstrating the ability of virosome-incorporated TLR ligands to skew the 
immune response to a more favorable, balanced Th1/Th2-phenotype. In a previous study, 
adjuvanted RSV virosomes were produced by inserting purified RSV F protein into influenza 
virosomes mixed with E. coli heat-labile enterotoxin (HLT), as an adjuvant. These virosomes 
however, induced a Th2-skewed immune response in mice, as was indicated by the induction 
of approximately 20-fold higher levels of IgG1 compared to IgG2.148 Lipophilic TLR ligands, such 
as for example Pam3CSK4, may be better suited for use in RSV virosomal vaccines, not only 
because they skew responses to a favorable Th1-phenotype, but also because they allow tight 
association with the virosomal membranes. This association of antigen and adjuvant results 
in activation of only those antigen-presenting cells, that take up and process the antigen. This 
reduces undesirable activation of bystander cells by adjuvant only. The addition of TLR ligands 
to an RSV vaccine does not only lead to a more balanced Th1/Th2 response but additionally leads 
to the induction of antibodies with higher neutralizing capacity, possibly through improved 
antibody affinity maturation. In the early FI-RSV clinical trials, the induced antibodies failed to 
neutralize the virus upon infection;72 this later on appeared to have been due to deficient TLR 
signaling by FI-RSV.76 Inclusion of Pam3CSK4 into the RSV virosomal vaccine therefore improves 
both its safety and its efficacy to induce neutralizing antibodies. 
RSV-MPLA virosomes
Monophosphoryl lipid A (MPLA) is a TLR4 ligand that is already in use in vaccines licensed for use 
in humans and has an acceptable safety record. MPLA, like Pam3CSK4, is lipophilic which would 
allow incorporation in virosomal membranes. However, MPLA possesses superior Th1-skewing 
properties compared to Pam3CSK4. This prompted us to explore the use of MPLA as an adjuvant 
in RSV virosomes. In Chapter 3, we determined the immunoactivating properties of RSV-MPLA 
PhD thesis_0.1.indd   118 10-10-12   11:23










virosomes in vitro and in vivo. Using TLR4-expressing cell lines with NFκB reporter genes, we 
showed that RSV virosomes have TLR4-activating capacity, and that this capacity is enhanced 
by the incorporation of MPLA into the virosomal membrane. Although RSV-F in RSV virosomes 
activates TLR4 (Chapter 3), and has been shown to induce inflammatory cytokines such as for 
instance IL-6,42 immunization with RSV virosomes without MPLA does not lead to a Th1-skewed 
immune response (Chapter 3). This could be due to the magnitude of TLR4 activation by RSV 
virosomes, which is clearly lower compared to that of RSV-MPLA virosomes. Alternatively, MPLA 
may signal through a different TLR4-adaptor molecule than the one used by RSV-F.205 MPLA 
mediated TLR4-signaling occurs through adaptor molecule TRIF,169 while signaling mediated 
by RSV-F most likely occurs through MyD88. Signaling through TRIF increases the induction 
of type-I IFN.169 High levels of type-I IFN induced by MPLA lead to Th1-polarization.38and also 
contribute to IgG class switching and antibody affinity maturation,177,180 which both contribute 
to stronger and safer immunity to RSV. Possibly, MPLA in RSV virosomes competes with RSV-F for 
binding to TLR4. This could result in diminished RSV-F-induced MyD88 mediated TLR signaling 
and to lower production of inflammatory cytokines in favor of higher type-I IFN levels induced 
by MPLA.
In addition to experiments in mice, we examined the safety and protective capacity of RSV-
MPLA immunizations in cotton rats (Chapter 4). Cotton rats were used because they are 
more permissive for RSV infections than mice and closely replicate human enhanced disease 
parameters that were found in the FI-RSV clinical trial.140,144 Local Th2-cytokine expression levels 
and lung pathology consisting mainly of neutrophilic infiltrates were measured as indicators 
of ERD. In contrast to immunization with FI-RSV, neither immunization with RSV virosomes nor 
RSV-MPLA virosomes gave rise to an increase in Th2-cytokine expression in the lungs of the 
animals after challenge. There were however, significantly more neutrophilic infiltrates in the 
lungs of cotton rats that received RSV virosomes compared to those that received RSV-MPLA 
virosomes. These infiltrates may have been attracted as a consequence of the induction of 
poorly neutralizing antibodies by RSV virosome immunizations. Poorly neutralizing antibodies 
can form immune complexes in the lungs which can bind to and activate complement factors 
attracting neutrophils.227 Complement factor C3a has also been found in the lungs of the children 
who died in the 1960s FI-RSV trial indicating that complement activation by immune complexes 
could have contributed to the induction of ERD.74 The incorporation of MPLA in RSV virosomes 
does not only induce a balanced Th1/Th2 response but, importantly, also is likely to enhance 
antibody affinity maturation,76 leading to the induction of highly neutralizing antibodies without 
formation of immune complexes and induction of ERD.
Alternative routes of vaccine administration
Intranasal (IN) administration is an acceptable route of vaccination and could, in addition to 
systemic immunity, also induce local immune responses, including production of secretory IgA 
(S-IgA). As the main port of entry of RSV is the mucosa of the respiratory tract, an RSV vaccine 
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would benefit from induction of a mucosal immune response. In Chapter 5, we therefore set 
out to determine the immunogenicity and protective capacity of intranasally administered RSV-
MPLA virosomes. In mice, intranasally administered RSV virosomes induced high systemic and 
mucosal antibody responses, similar to immunizations with live virus. In cotton rats, however, 
IN vaccination appeared less potent in inducing mucosal antibody responses, particularly 
when compared to responses induced by immunization with live virus. However, cotton rats 
are more permissive for RSV than mice.141 Therefore, the local immune activation and the 
resulting antibody response induced by infection could be much stronger in cotton rats than 
in mice which could explain the relative differences between the immune response induced by 
RSV-MPLA virosomes and live virus infection seen in mice versus cotton rats. Interestingly, some 
LPS-derived TLR4 ligands have been shown to be species-specific in their capacity to activate 
TLR4.228 Such a species-specific activation probably does not play a role in the different efficacy 
of MPLA to enhance mucosal antibody responses in mice versus responses in cotton rats: MPLA 
effectively stimulated serum antibody responses in both species (Chapter 5) and is effective in 
humans too. 
In mice, MPLA demonstrated a clear mucosal adjuvant effect, as seen by increased S-IgA 
responses. Interestingly, expression of the polymeric IgG receptor (pIgR), a receptor responsible 
for transcytosis of polymeric S-IgA, is enhanced by TLR ligands through activation of MyD88.210,211 
Although MPLA could increase expression of pIgR and thereby boost transcytosis of polymeric 
IgA, this may be only a transient effect that would wane rapidly after vaccination. Therefore, the 
mucosal adjuvant activity of MPLA may rather be due to local activation of antigen presenting 
cells and B cells leading to an enhanced local SIgA antibody response. In adult humans, mucosal 
IgA levels also have been shown to correlate with protection against infection.214 Therefore, 
induction of these responses would further improve vaccine-mediated RSV-specific immunity. 
RSV vaccination in the elderly
The elderly are at significant risk of severe RSV infections.143 It is known that aging reduces 
immunocompetence, and therefore it is of interest to study the immunogenicity of RSV 
virosomes, as well as the immunoadjuvant activity of MPLA in an aged immune system. In 
Chapter 6 we showed that RSV-MPLA virosomes have the capacity to induce protective RSV-
specific immunity in aged cotton rats. The adjuvant effect of MPLA was similar to that seen in 
young cotton rats, indicating that TLR4 signaling in aged cotton rats is still effective. In mice, 
the TLR4 signaling capacity decreases with age,220,221 however, in humans it remains active upon 
aging222 like in aged cotton rats. 
In humans, RSV infection early in life does not lead to lifelong protection. There is however 
detectable humoral immunity against RSV in elderly people.229 To assess if RSV-MPLA virosomes 
can boost antibody responses in a situation of pre-existing RSV-specific immunity, we infected 
cotton rats early in life and immunized them with virosomes at old age. However, live RSV-
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primed cotton rats did not become susceptible to RSV infection upon aging. This means that 
infection of cotton rats with RSV induces an effective and durable immunity and that in this 
respect, the situation is different from that in humans. In humans, RSV employs immune evasive 
mechanisms such as inhibition of type-I IFN induction by NS proteins11,12 and direction of the 
immune response to a Th2-phenotype.41 These mechanisms may have developed during the 
long co-evolution of RSV and its natural host, i.e. humans, and may not be (fully) operational 
in cotton rats. Further research is necessary to evaluate if RSV-primed and aged cotton rats 
represent a good model to study the potential of a virosomal RSV vaccine, or other vaccine 
candidates, to boost immunity in an aged immune system. Perhaps, to more closely mimic 
the situation in humans, priming of RSV immunity in young cotton rats could be done by RSV 
infection that is confined to nasal cavity only, as opposed to a total respiratory tract infection 
used in our previous experiments. 
Concluding remarks
Taken together, the data presented in this thesis demonstrate that RSV virosomes with built-
in MPLA as an immunomodulating adjuvant, represent a promising candidate RSV vaccine. 
We have shown that RSV-MLA virosomes are immunogenic in mice and cotton rats inducing a 
balanced Th1/Th2 response and high levels of RSV-neutralizing antibodies. Safety aspects of a 
candidate RSV vaccine are equally important to immunogenicity. Immunization with RSV-MPLA 
virosomes does not lead to increases in Th2-type cytokines or increased pulmonary infiltrates in 
cotton rats upon subsequent exposure of the animals to live virus. Furthermore, it is likely that 
RSV-MPLA virosomes will be able to boost immune responses in previously RSV infected elderly 
people. Whether or not the robust immunogenicity will indeed translate into a reduction of RSV-
related morbidity and mortality in humans will have to be assessed in clinical trials.
Two very different risk-groups can greatly benefit from an RSV vaccine: infants and the elderly. 
The immune responses in these two populations differ significantly and induction of adequate 
responses will probably require different vaccine approaches.163 Because TLR signaling in 
infants takes up to six months to develop,230,231 RSV-MPLA virosomes could be less suitable for 
immunization of this population. It is generally assumed that infants will benefit most from live 
attenuated, intranasally administered vaccines as these prime the immune system similarly to 
infection with live virus and do not give rise to ERD.232 Immune responses induced by a good live 
attenuated vaccine could be robust and durable. These young infants however are also most 
susceptible to infectious RSV; therefore a live attenuated vaccine that reverts to wild type could 
induce significant disease in this risk-group.84 A perhaps more safe alternative to the vaccination 
of infants would be maternal vaccination. In this approach, pregnant women are immunized and 
the induced RSV-specific antibodies transfer through the placenta to the unborn child.233 Also, 
antibodies in breast milk are transferred to the newborns after birth.233 Non-replicating (subunit) 
RSV vaccines, including RSV-MPLA virosomes, would be highly suitable for this approach.  
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For the elderly, an adjuvanted virosomal vaccine could be of great benefit. Incorporated TLR 
ligands as adjuvants have the capacity to increase the immunogenicity of the vaccine in the 
setting of an aged and less responsive immune system. If TLR ligands are needed to prevent 
priming for ERD in the elderly remains to be seen. Most likely, the elderly have been primed 
by RSV infection earlier in life and studies in mice have shown that earlier priming with live 
virus inhibits priming for ERD by vaccination.234 Therefore, ERD may not be readily induced by 
immunization of the elderly with non-replicating RSV vaccines. Previous clinical trials evaluating 
subunit vaccines in adults have shown that these vaccines increase levels of neutralizing 
antibodies and reduce the overall incidence of all RSV infections.235 However, no significant 
decrease in lower respiratory tract infection was observed.235 This could point to the inability 
of these vaccines to induce cellular immune responses, important in protection of the lungs 
against RSV infection. In this respect, MPLA has been shown to enhance cellular responses in 
other vaccines174,236 and this ligand probably also could improve cellular responses against RSV. 
Furthermore, TLR signaling by MPLA could not only improve overall immunogenicity of RSV 
virosomes but also lead to the induction of a longer lasting immune response compared to that 
induced by RSV vaccines without TLR adjuvant.197 Whether or not RSV-MPLA virosomes indeed 
have the capacity to induce a more durable immune response in humans and also induce 
cellular immune responses will need to be investigated further.
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Infectie met  het respiratoir syncytieel virus (RSV) is de voornaamste oorzaak van virale 
bronchiolitis (longsteking) bij jonge kinderen. Daarnaast is RSV-infectie ook verantwoordelijk 
voor een groot deel van de lagere-luchtweginfecties bij ouderen en mensen met een verzwakt 
immuunsysteem. RSV wordt al sinds de ontdekking van het virus in de jaren ‘50 van de vorige 
eeuw gezien als een belangrijk doel voor vaccinatie, maar tot op heden is er nog geen RSV-vaccin 
op de markt. De oorzaken hiervan lopen uiteen van het ontbreken van een goed diermodel 
om experimentele vaccins in te testen, en de onvolledige bescherming die een infectie met 
levend RSV met zich meebrengt, tot de dramatische uitkomst van een klinische studie met een 
formaline-geïnactiveerd RSV-vaccin in de jaren ‘60 van de vorige eeuw.
RSV komt het lichaam binnen via de luchtwegen. Dat kan gebeuren door contact met een 
geïnfecteerd persoon of door contact met gecontamineerde oppervlakken van bijvoorbeeld 
speelgoed. Eenmaal in de luchtpijp en de bronchiën infecteert RSV het epitheel en kan daar 
vervolgens repliceren. RSV verspreidt zich binnen een individu door het vrijkomen van infectieus 
virus uit geïnfecteerde epitheelcellen, dat weer nieuwe cellen infecteert, maar ook door het 
fuseren van geïnfecteerde cellen met nog niet geïnfecteerde cellen. Dit fusieproces wordt 
teweeg gebracht  door het virale fusie-eiwit dat op de membraan van geïnfecteerde cellen tot 
expressie wordt gebracht en leidt tot het ontstaan van grote klompen gefuseerde cellen, ook wel 
syncytia genoemd. De virale infectie en het ontstaan van syncytia worden gedetecteerd door 
het immuunsysteem dat vervolgens het virus uitschakelt en de geïnfecteerde cellen opruimt. 
In de meeste gevallen duurt de ziekte niet lang en verdwijnen de symptomen na ongeveer een 
week. In ergere gevallen kan het virus zich verspreiden naar de lagere luchtwegen en hier een 
longontsteking veroorzaken. Bij mensen met een verzwakt immuunsysteem kan dit de dood tot 
gevolg hebben.
Na het succes van het geïnactiveerde poliovaccin in de jaren ‘50 en later, is er ook een poging 
gedaan om een formaline-geïnactiveerd RSV-vaccin (FI-RSV) te maken. Halverwege de jaren ‘60 
is dit vaccin getest in een drietal klinische studies bij jonge kinderen. Het FI-RSV leek aanvankelijk 
goed te werken: het induceerde een afweerreactie met vorming van RSV-specifieke antistoffen. 
Deze antistoffen zouden bescherming moeten bieden tegen infectie met RSV. Echter,  toen een 
aantal van de gevaccineerde kinderen een RSV-infectie doormaakten, bleken zij vatbaarder te 
zijn geworden voor het virus dan de niet-gevaccineerde kinderen in de controlegroep. Vooral 
de jongste kinderen, die voor de vaccinatie nog seronegatief waren voor RSV, maakten een 
verergerde vorm van RSV-infectie door. Dit leidde tot een toename in ziekenhuisopnames, 
terwijl twee van de jongste kinderen in de gevaccineerde groep zelfs kwamen te overleiden.
De immunologie stond in de jaren ‘60 en ‘70 nog in de kinderschoenen en het heeft dan ook lang 
geduurd voordat onderzoekers precies wisten waardoor FI-RSV niet in staat was de kinderen 
te beschermen tegen RSV, maar de ziekte juist verergerde. Weliswaar werd snel duidelijk dat 
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de antistoffen die aanwezig waren bij de gevaccineerde kinderen niet in staat waren het virus 
te neutraliseren. Maar pas veel later is aan het licht gekomen dat dit veroorzaakt werd door 
een inadequate vorm van zogenaamde “affiniteitsmaturatie”; dit is het proces dat er normaliter 
voor zorgt dat antistoffen een hoge affiniteit ontwikkelen voor de antigenen waartegen ze zijn 
gericht. Dit bleek te komen doordat FI-RSV in onvoldoende mate “Toll-Like” receptoren (TLR) 
stimuleert, die betrokken zijn bij het sturen van de immunologische afweereactie en ook 
bijdragen aan affiniteitsmaturatie van antistoffen. Tevens is uit dierstudies gebleken dat FI-RSV 
een afweerreactie met een zogenaamd Th2-fenotype induceert. 
De immunologische afweereactie tegen infectieuze ziekteverwekkers kan ruwweg opgedeeld 
worden in een respons met een Th1- of een Th2-fenotype. Th2-type afweerreacties bestaan 
uit de productie van antistoffen van het subtype IgE en de activatie van onder andere 
neutrofielen en eosinofielen. Deze afweerreactie is bij uitstek geschikt voor de bescherming 
tegen extracellulaire bedreigingen zoals parasitaire en sommige bacteriële infecties. Een Th1-
respons daarentegen wordt gekenmerkt door de vorming van antistoffen die virussen kunnen 
neutraliseren en door de activatie van cytotoxische T-cellen. Een dergelijke respons is dus meer 
geschikt voor bescherming tegen virussen zoals RSV. 
Sinds de jaren ‘60 zijn er meerdere RSV-vaccinkandidaten getest in diermodellen en bij mensen, 
maar tot nu toe is er nog geen vaccin gevonden dat goed beschermt en – minstens even 
belangrijk - volkomen veilig is. Een mogelijke manier om op een veilige manier bescherming 
te bieden tegen RSV-infecties is het gebruik van RSV-virosomen. Een virosoom is als het ware 
een virusdeeltje zonder het genetische materiaal. Hierdoor ziet een virosoom er voor het 
immuunsysteem uit als het virus, maar is het niet in staat om te repliceren; een virosoom kan 
dus geen ziekte veroorzaken. Ons lab heeft eerder laten zien dat het mogelijk is om virosomen 
van influenza virus te maken door dit virus te behandelen met een soort zeep, een fosfolipide 
dat er voor zorgt dat het membraan oplost waardoor de membraaneiwitten in oplossing 
komen. Vervolgens wordt op basis van dichtheid het nucleocapside, waar het RNA van het 
virus in zit, verwijderd door ultracentrifugatie. Als het fosfolipide dan vervolgens weer wordt 
weggehaald door middel van dialyse vormt het virale membraan zich weer met daarin de virale 
membraaneiwitten. Verder is het mogelijk om, tijdens deze zogenaamde reconstitutie, lipofiele 
moleculen toe te voegen die dan ook in de virosomale membraan komen te zitten. Dit kunnen 
bijvoorbeeld TLR-liganden zijn die de afweerreactie tegen een vaccin kunnen stimuleren en 
een bepaalde kant op kunnen sturen. Momenteel zijn er al virosomen op de markt die gebruikt 
worden als vaccin tegen influenza. In deze studie hebben wij onderzocht of het mogelijk is om 
deze techniek ook toe te passen voor RSV.
Om tijdens een infectie een goede afweerreactie tot stand te laten komen moet het afweersysteem 
op meerdere manieren gestimuleerd worden. Het afweersytyeem herkent eiwitten van de 
ziekteverwekker en zal, als deze herkenning vergezeld gaat met een soort van activatiesignaal 











een afweer reactie tegen deze eiwitten tot stand brengen. Deze activatiesignalen komen meestal 
van bepaalde lichaamsvreemde moleculen. Zo kunnen de aanwezigheid van bouwstenen 
van bacteriële celwanden of de aanwezigheid van dubbelstrengs RNA, iets dat in de mens in 
princiepe niet voorkomt, de afweerreactie tegen een infectie versterken. Deze acitvatiesignalen 
worden herkent door speciale receptoren op cellen van het immuunsyteem. In tegenstelling tot 
een infectie zal een vaccin dat bestaat uit bijvoorbeeld alleen een gezuiverd viraal eiwit deze 
activatiesignalen ontberen. Doordat echter bekent is welke signalen verantwoordelijk zijn voor 
het activeren van een bepaalde afweerreactie kunnen we dit soort signalen toevoegen aan een 
vaccin. Een stof die toe wordt gevoegd aan een vaccin wordt ook wel een adjuvant genoemd. 
Het inbouwen van een TLR ligand in onze RSV virosomen is een voorbeeld van het gebruik van 
een dergelijk adjuvant dat de afweerreactie kan versterken en bijsturen.
In hoofdstuk 2 laten we zien dat het inderdaad mogelijk is om virosomen te maken van 
gezuiverd RSV. Deze virosomen hebben we vervolgens gekarakteriseerd door middel van 
elektronenmicroscopie en eiwit-gelelectroforese. Met deze technieken hebben we ook laten 
zien dat het TLR2-ligand Pam3CSK4 is geassocieerd met de virosomen. Vervolgens hebben 
we muizen geïmmuniseerd met de virosomen en de humorale (antistoffen) en cellulaire 
(T-lymfocyten)  immuunrespons gemeten. Hieruit bleek dat de RSV/Pam3CSK4-virosomen 
inderdaad een gebalanceerde Th1/Th2-immuun respons opwekken. De geïmmuniseerde muizen 
werden vervolgens geïnfecteerd met levend RSV en na vijf dagen bleek dat de geïmmuniseerde 
muizen in staat waren het virus uit te schakelen in tegenstelling tot de niet-geïmmuniseerde 
muizen. Om de veiligheid van het vaccin te controleren is er vervolgens een vaccinatie- en 
infectie-experiment gedaan in katoenratten. De katoenrat is vatbaarder voor RSV dan de muis 
en de reactie van katoenratten op het FI-RSV, dat in de jaren ‘60 tot verergerde ziekte leidde bij 
mensen, lijkt op de reactie die ook bij mensen wordt waargenomen. In dit experiment bleek 
dat immunisatie van katoenrattenmet FI-RSV, zoals verwacht, leidde tot verergerde ziekte in de 
longen na infectie. De katoenratten die geïmmuniseerd waren met RSV/Pam3CSK4-virosomen 
lieten daarentegen geen tekenen zien van verergerde longpathologie. Het lijkt er dus op dat 
RSV/Pam3CSK4-virosomen een geschikte RSV-vaccinkandidaat vormen.
Naast de TLR2-ligand Pam3CSK4 zijn er ook andere TLR-liganden die gekozen kunnen worden 
om in RSV-virosomen te verwerken. Het TLR4-ligand MPLA wordt al gebruikt in een aantal 
vaccins die op de markt zijn. MPLA heeft als potentieel voordeel ten opzichte van Pam3CSK4 dat 
het, doordat het via een andere route werkt dan Pam3CSK4, effectiever is in het opwekken van 
een Th1-type respons. Aangezien MPLA ook een lipofiel molecuul is hebben we geprobeerd om 
MPLA in virosomen in te bouwen. 
In hoofdstuk 3 laten we zien dat het mogelijk is om MPLA in virosomen in te bouwen en dat 
deze virosomen ook daadwerkelijk activatie van TLR4 in cellen bewerkstelligen. Verder laten we 
zien dat immunisatie van muizen met RSV/MPLA-virosomen leidt tot een gebalanceerde Th1/
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Th2-immuunrespons en dat de antistoffen die geïnduceerd worden door de immunisatie goed 
in staat zijn RSV te neutraliseren. Om het effect van MPLA in virosomen op het voorkomen van 
verergerde ziekte te beoordelen, hebben we in hoofdstuk 4 dit vaccin ook getest in katoenratten. 
RSV/MPLA-virosomen bleken in staat om de katoenratten te beschermen tegen RSV-infectie 
en, in tegenstelling tot immunisatie met FI-RSV, ging dit niet gepaard met de expressie van 
Th2-geassocieerde cytokines. RSV-virosomen zonder MPLA induceerden ook geen verhoogde 
expressieniveaus van deze cytokines, maar immunisatie van katoenratten met virosomen zonder 
adjuvant leidde toch tot symptomen van verergerde ziekte zoals de influx van neutrofielen in de 
long. Het adjuvant versterkt niet alleen de versterkt niet alleen de afweerreactie, maar stuurt 
deze ook in een veiligere richting en is daarom onontbeerlijk voor het goed functioneren van 
een virosomaal RSV-vaccin.
Een groot probleem van vaccinatie is dat er voor de toediening van de meeste vaccins naalden 
nodig zijn. Dit verhoogt de drempel voor mensen om een vaccin te nemen. Bovendien is er 
geschoold personeel nodig om een vaccin via een injectie toe te dienen. Een RSV-vaccin dat op 
een andere manier toegediend zou kunnen worden, bijvoorbeel via een nesusspray, zou daarom 
zeer welkom zijn. Daarnaast zou een RSV-vaccin erbij gebaat zijn als het lokale bescherming in 
de neus en luchtwegen zou bieden aangezien RSV via de luchtwegen zijn gastheer binnenkomt. 
Om te testen of RSV/MPLA-virosomen ook goed beschermen als ze intranasaal worden gegeven, 
hebben we in hoofdstuk 5 een aantal experimenten gedaan in muizen en katoenratten waar 
we dit aspect hebben geëvalueerd. Uit deze experimenten bleek dat RSV-virosomen zonder 
adjuvant nagenoeg geen immuunrespons opwekken als ze intranasaal worden toegediend. Dit 
verandert echter door het inbouwen van een adjuvant, al is de bescherming die wordt verkregen 
met intranasaal toegediende virosomen minder robuust dan na een intramusculaire injectie 
van RSV/MPLA-virosomen. 
Er is een wezenlijk verschil tussen het vaccineren van dieren die nog nooit een RSV-infectie 
hebben doorgemaakt en het vaccineren van oudere mensen die gedurende hun leven al 
meerdere keren in aanraking zijn gekomen met RSV. Om dichter bij deze situatie in de buurt te 
komen hebben we in hoofdstuk 6 geprobeerd een model op te zetten waarbij katoenratten op 
jonge leeftijd worden geïnfecteerd met RSV en vervolgens ouder worden. Na negen maanden 
hebben we onderzocht of de katoenratten, net als oudere mensen, weer vatbaar worden voor 
het virus, of de bestaande afweerreactie gestimuleerd kan worden met RSV-virosomen en of 
hiervoor een adjuvant nodig is. In tegenstelling tot oudere mensen waar de immuniteit tegen 
RSV op een gegeven moment niet meer in staat is te beschermen tegen RSV-infectie, bleken de 
katoenratten negen maanden na de primaire infectie nog steeds beschermd te zijn. Ondanks 
dat in katoenratten de aanwezige immuunrespons niet genoeg bleek af te nemen om ze weer 
vatbaar te laten worden voor het virus, konden we wel zien dat de antistofniveaus afnamen in de 
tijd en dat deze door immunisatie met RSV- of RSV/MPLA-virosomen weer gestimuleerd konden 
worden. Verder bleek dat in oudere katoenratten de lokale afweer gestimuleerd kon worden 











door intranasale toediening van het vaccin. Hierbij werd ook duidelijk dat RSV/MPLA-virosomen 
een grotere toename van lokale antistoffen induceren dan RSV-virosomen zonder adjuvant. 
Verder is uit de literatuur bekend dat het immuunsysteem van oudere mensen nog goed in staat 
is om adequaat op TLR4-liganden te reageren. Daarom zouden RSV/MPLA-virosomen een goed 
vaccin kunnen zijn om ziekte en sterfte ten gevolge van RSV-infectie bij ouderen te voorkomen. 
Of RSV/MPLA-virosomen bij mensen voor een voldoende toename in immuniteit kunnen zorgen 
en of deze immuniteit dan ook in staat is ouderen te beschermen tegen RSV zal moeten blijken 
uit klinische studies.
In dit onderzoek hebben we laten zien dat het mogelijk is omRSV-virosomen te maken en dat 
de afweerreactie die deze virosomen teweeg brengen sterk verbeterd kan worden door het 
inbouwen van de TLR-liganden Pam3CSK4 of MPLA in de virosomale membraan. De virosomen 
met TLR ligand zijn immunogeen, bieden bescherming tegen infectie in diermodellen en 
veroorzaken geen tekenen van verergerde ziekte. De positive resultaten uit deze studie geven 
aanleiding om het vaccin te testen in een klinische studie. Eerst zal hierbij worden gekeken naar of 
het vaccin goed getolereerd wordt en geen bijwerkingen veroorzaakt na injectie. Als dit allemaal 
goed veloopt zal worden onderzocht of de RSV virosomen, net als in muizen en in katoenratten 
een goede afweerreactie teweeg brengen en als laatst zal een grote studie aan moeten tonen 
of deze afweerreactie ook daadwerkelijk in staat is tegen RSV infectie te beschermen. Voordat 
het vaccin op de markt komt is er dus nog een lange weg te gaan, maar het is duidelijk dat 
vaccinatie met RSV virosomen met een TLR ligand als adjuvant een veelbelovende aanpak van 
dit belangrijke probleem is.
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Ondanks het feit dat mijn naam de enige is die op de kaft van dit boekje staat was dit proefschrift 
nooit tot stand gekomen zonder de hulp en steun van een heleboel mensen.
Als eerst wil ik Jan bedanken voor de kans die hij mij heeft gegeven om in zijn lab mijn 
promotieonderzoek uit te voeren. Na mijn stage bij Anke en Judith heb je me tot twee keer toe 
gevraagd of ik bij de Moleculaire Virologie wilde promoveren. Ik was vereerd door het aanbod en 
toen het voor mij duidelijk werd, dat ik het motiverend vind dat mijn onderzoek een min of meer 
directe toepassing kan krijgen die bijdraagt aan het welzijn van mensen, was de keus om aan een 
RSV vaccin te gaan werken snel gemaakt. Ik heb onze gesprekken altijd als stimulerend ervaren 
en vooral op het eind van het traject, toen deze gesprekken wat regelmatiger plaatsvonden, 
heeft het me erg veel geholpen. Naast de wetenschappelijke bijdrage die je geleverd hebt aan 
dit proefschrift was het ook erg prettig om iemand in de buurt te hebben die een feilloos gevoel 
heeft voor het gebruik van komma’s, koppeltekens, tussen-n-en en wat al niet meer. 
Naast Jan wil ik Aalzen bedanken voor dagelijkse “hands on” begeleiding tijdens mijn 
onderzoek. Ik denk dat we het aantal geplande afspraken om over experimenten, data en 
planningen te praten op één hand kunnen tellen. Het was echter altijd mogelijk om met een 
vraag of een set nieuwe data bij je langs te komen en deze even te bespreken. Ook zijn er 
verrassend veel beslissingen gemaakt en problemen opgelost onder het genot van een kop 
koffie in de koffiekamer of de kantine. Ik stel je pragmatische kijk op het leven en de wetenschap 
erg op prijs, ook al sluit deze soms iets te goed aan op mijn pragmatische kijk op het leven. We 
hebben ook twee keer voor een congres de sneeuw opgezocht; een keer naar Banff voor een 
Keystone meeting en naar Rotterdam voor de RSV meeting. Onder het genot van een aantal 
glazen bier hebben we elkaar daar beter leren kennen, iets dat volgens mij de werksfeer altijd 
ten goede komt. Als laatst wil ik je bedanken voor je significante immunologische bijdrage aan 
dit proefschrift. In tegenstelling tot veel andere takken van wetenschap is de immunologie alles 
behalve zwart-wit. Jouw uitgebreide immunologische kennis kwam dan ook vaak van pas als ik 
weer eens wat te kort door de bocht ging in mijn redeneringen. In het begin vond ik dit maar wat 
vervelend -zwart-wit is immers veel overzichtelijker- maar naarmate mijn onderzoek vorderde 
kwam het besef dat het afweersysteem een bondgenoot is in het bestrijden van infectieziekten 
zolang je het op de juiste manier stimuleert, in tegenstelling tot een vervelende hindernis die 
ervoor zorgt dat dingen niet zo gaan als ze moeten. 
Ik heb het altijd plezierig gevonden dat mijn onderzoek deel uitmaakte van een Top Institute 
Pharma consortium. Het idee van TI-Pharma is dat de academie en de industrie elkaar vinden. 
Dat ik dit als plezierig heb ervaren is natuurlijk voor een groot deel te danken aan de toevoeging 
die Toon heeft geleverd aan dit onderzoek. In het begin kwam je af en toe langs om de lopende 
zaken en experimenten te bespreken en was ik enorm onder de indruk van jouw kennis over 
eigenlijk alles wat met vaccins te maken had. Jouw kijk op de proeven was net even anders 











dan die van Jan, Aalzen en mijzelf en ik denk dat dit samen tot een mooi evenwicht leidde. 
De presentaties over het werk dat jullie bij Mymetics doen om de RSV virosomen verder te 
ontwikkelen en klaar te maken voor klinische studies vond ik altijd erg interessant. Hierdoor 
heb ik jouw bezoekjes aan Groningen en onze bezoekjes aan Leiden altijd als erg motiverend 
ervaren. 
De laatste persoon die ook een significante bijdrage heeft geleverd aan alle experimentele 
hoofdstukken in dit boekje is Tjarko. Jouw hulp in het CDL en in het lab met het verwerken van 
de monsters was van onschatbare waarde en daarnaast ook nog eens erg gezellig. We hebben 
samen de nodige muisexperimenten gedaan en het cotton rat model weer opgezet in Groningen. 
Vooral de cotton rats zorgden door hun “enthousiasme” voor de nodige memorabele momenten. 
Als ik terugdenk aan alle ELISA platen die jij doorverdund hebt door de jaren heen krijg ik nog 
steeds last van mijn duimen. Het was ook altijd erg prettig dat we bij elkaar in de kamer zaten. 
Als ik vragen had over DECs of dieren waren die in elk geval snel gesteld en beantwoord.
Performing experiments and writing a thesis is one thing, but evaluating the content of this 
book for its scientific merit is something else. I would like to thank Professor Willem Van 
Eden, Professor Ruth Karron and Professor Henkjan Verkade for taking the time to read the 
manuscript and for supplying their contributions to the final version.
While I’m typing in English, I might as well take the time now to thank Shafique for the 
experiments we performed together. I really admire the fact that you left your home country 
in search of a challenge and the enormous effort you put into your research. Your work on 
optimization of intranasal RSV vaccine candidates met my project and we worked together to 
see if RSV-MPLA virosomes were also suited for intranasal administration. While this did work, I 
am looking forward to your data on the RSV-MDP-Pam3CSK virosomes. 
En dan schakelen we nu weer naar het Nederlands want dat kan Julia best lezen ondanks haar 
Duitse afkomst. Ik vond het erg leerzaam en gezellig dat jij bijna een jaar bij mij stage hebt 
gelopen. Je pakte alle experimenten snel op en je werkte super netjes en overzichtelijk. Je werk 
heeft geleid tot een mooi stage en afstudeer verslag en een aantal experimenten zijn ook in dit 
boekje terecht gekomen. Naast je goede werk heb je er ook voor gezorgd dat ik zelf, toch zeker 
een jaar lang min of meer op tijd op het lab kwam. Je was er meestal wel eerder dan ik, maar 
veel scheelde het niet. 
Naast de mensen die op een concrete manier hebben bijgedragen aan de hoofdstukken 
van dit proefschrift zijn er natuurlijk nog veel meer mensen die hebben bijgedragen aan het 
prettige klimaat waarin het allemaal tot stand is gekomen. Na een aantal omzwervingen en 
kamerwisselingen besloot Jan dat de meest stabiele oplossing een kamer was met Tjarko, 
Wouter, Tjalke, Natalija en mijzelf. Vier mannen die fungeerden als regelstaven in een 
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kernreactor die regelmatig de “meltdown” van de uiterst volatiele Natalija voorkwamen. Ik 
denk dat het moeilijk is om een kamer samen te stellen met vijf mensen die minder op elkaar 
lijken maar deze diversiteit zorgde ervoor dat het altijd gezellig was. We hebben in elk geval 
veel goede gesprekken en leuke feestjes met elkaar meegemaakt. Tjalke, Wouter en Natalija zijn 
inmiddels net als ik vertrokken bij de Moleculaire Virologie en ik wens jullie dan ook veel succes 
en plezier bij jullie nieuwe werkgevers. 
Dan wil ik natuurlijk nog Paul en Natalija bedanken dat zij mij tijdens mijn verdediging bij 
willen staan. Paul, we kennen elkaar ruim 12 jaar en ik kan me ons eerste gesprek nog goed 
herinneren. Ik denk nog vaak aan hoe de wereld er nu uit had gezien als we ons hydraulisch 
geveerde barconcept verder hadden ontwikkeld. Doordat jij met het briljante idee kwam om 
het eerste weekend van augustus in 2001 te gaan zeilen hebben we nu een gezamenlijke hobby 
waar we al vele jaren plezier aan beleven. Natalija, as was mentioned by the lady who wed you 
and Koen, we got of to a rough start. You thought I was arrogant and I thought the same of you. 
You are an acquired taste and it lasted almost the full four years of our PhD, for us to really get to 
know each other. I’d like to thank you for our good scientific and non-scientific discussions and 
of course for our dinners together. I’m sorry and proud of the fact that my birthday party is the 
reason you don’t drink alcohol anymore. That will be something to remember me by.
Verder wil ik ook alle mensen die de laatste jaren bij de Moleculaire Virologie hebben gewerkt 
bedanken voor de prettige samenwerking. Ondanks de enorme groei die de afdeling de laatste 
jaren heeft doorgemaakt bleef het een prettige plek om te werken. De labuitjes, borrels en 
feestjes waren altijd een erg welkome afwisseling.
Naast het werk heb ik natuurlijk ook erg veel tijd doorgebracht met goede vrienden en kennissen. 
Voor de nodige inspannende ontspanning kon ik altijd in klimcentrum Bjoeks terecht. Ik wil dan 
ook alle mensen die ik in Bjoeks heb leren kennen bedanken voor de mooie tijd. Ik hoop dat de 
traditionele BBX naar een jaar afwezigheid in 2013 zal terugkeren als nooit tevoren.
Als ik niet aan het klimmen of aan het werken was, bevond ik mij regelmatig op het water of in 
de kroeg met vrienden van Za Zdarowja. Ik ben blij dat ik aan die twee jaar Enschede zo veel 
goede vrienden heb overgehouden en ondanks dat iedereen nu een beetje begint te settelen, 
denk ik dat de collectie prachtige avonturen die we samen mee hebben gemaakt nog wel gaat 
uitbreiden. 
De persoon die me tijdens mijn tijd in Groningen denk ik het meest heeft gezien moet toch wel 
Martine zijn. Ik kon als ik je zag altijd even over mijn werk praten en ik merkte dat ik daar veel 
aan had. Daarnaast wil ik je heel erg bedanken voor de leuke tijd die we samen hebben gehad 
en alles wat we samen gedaan hebben. Ik denk nog vaak terug aan onze tijd samen en ik weet 
zeker dat ik je nooit zal vergeten.











Als laatst wil ik nog mijn familie bedanken voor alle kansen en steun die ze me gegeven hebben. 
Ik kan gelukkig zeggen dat ik een prettige jeugd heb gehad en dit kwam zeker in de eerste plaats 
door Papa, Mama en Liselot. Pap en mam hebben me altijd alle kansen gegeven die ik nodig 
had en gesteund bij elke beslissing die ik nam. Jullie konden het in elk geval goed verbergen 
als jullie dachten dat het niet echt goed zou komen. Elke keer als ik in Almelo op bezoek kwam 
vroegen jullie hoe het ging met de vier experimentele hoofdstukken die ik voor mijn proefschrift 
nodig zou hebben. Dit zou er immers één per jaar moeten zijn. Ik bleef maar zeggen dat ik nog 
wel op schema lag en dat het zwaartepunt altijd ergens op het eind ligt. Uiteindelijk is het ook 
goed gekomen en wordt dit hoofdstuk ook weer afgesloten. Ik ben helaas niet dichter bij komen 
wonen, maar Den Haag is ook niet de andere kant van de wereld en ik hoop dan ook dat jullie 
vaak op bezoek zullen komen. Ik ben ook trots op mijn kleine zusje Liselot die er niet zo goed 
tegen kan dat ik haar mijn kleine zusje noem. Ik ben blij dat je je draai gevonden hebt en dat je 
weer op je plekje bent in Almelo. Je hebt het goed voor elkaar en je zal altijd mijn kleine zusje 
blijven, of je dat nou leuk vindt of niet.
Al met al heb ik een boel om dankbaar voor te zijn en dit komt niet in de laatste plaats door alle 
bijzondere mensen die ik de laatste jaren heb leren kennen. Het lijkt me fantastisch om met 
jullie allemaal contact te houden. Ik zal dan ook nog regelmatig mijn hoofd laten zien in het 
noorden en het oosten van het land. Daarnaast zijn jullie natuurlijk allemaal van harte welkom 
voor een biertje, een kop koffie of een etentje in de Hofstad.
Dank jullie wel,
Tobias
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